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Factor H (FH), a complement regulatory protein comprised of 20 SCR 
domains, is able to discriminate host from pathogen cell surfaces by recognising 
glycosaminoglycans such as heparan sulphate on host cells to protect these from 
complement attack. Heparin is an analogue of HS. FH has heparin and HS binding 
sites located at SCR-6/8 and SCR-19/20. While the structure of FH is known from X-
ray solution scattering and analytical ultracentrifugation (AUC), the effects of 
heparin and HS on intact FH are not yet known. To evaluate the interactions with 
FH, solution structures of heparin fragments were determined by a combination of X-
ray solution scattering, AUC and constrained scattering modelling. These results 
revealed that heparin fragments starting from dp18 progressively show higher 
degrees of bending up to dp36, and resemble known crystal structures of heparin-
protein complexes. Similar structural studies on similar-sized HS fragments showed 
that HS fragments exhibit more bent structures than heparin. This greater bending in 
HS fragments might be due to the reduced degree of sulphation in HS molecules. To 
assess the effect of heparin and HS fragments on intact FH, FH was studied in the 
presence of a range of purified heparin and HS fragments by scattering and AUC. 
The smallest heparin fragments showed little effect on the radius of gyration RG 
values of FH. Dramatic increases in the RG values were seen with the larger heparin 
sizes, and both AUC and scattering showed that a series of large but compact 
complexes were formed. In the presence of HS, smaller increases in oligomer 
formation were observed. The heparin- and HS-induced formation of oligomers in 
FH provide a first molecular picture of how FH may interact with host cell surfaces, 
and may facilitate an improved understanding of how extracellular deposits form on 
Bruch’s membrane during the development of age-related macular degeneration. 
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(1.1) Complement overview 
Complement is a biochemical cascade of the innate immune system 
comprising of a group of serum and cell surface proteins that interact with one 
another both to opsonise pathogens and to induce a series of inflammatory responses 
that help in defence against infection. Innate immunity refers to antigen-nonspecific 
defence mechanisms that a host uses immediately or within several hours after 
exposure to an antigen. These mechanisms include physical barriers such as skin, 
chemicals in the blood, and immune system cells that attack foreign cells in the body. 
Adaptive immunity refers to antigen-specific immune response and is more complex 
than the innate immunity. In adaptive immunity the antigen first needs to be 
processed and recognized. When once an antigen has been recognized, the adaptive 
immune system creates an army of immune cells specifically designed to attack that 
antigen. Complement has three physiological activities: defending against pyogenic 
bacterial infection, bridging innate and adaptive immunity, and disposing of immune 
complexes and the products of inflammatory injury (Walport, 2001). This system can 
be activated via immunoglobulins in the bloodstream once the pathogens have been 
recognized by antibody. In the 1890s, complement was described as a heat-labile 
bactericidal activity in serum which was triggered after invading microorganisms. In 
the 1920s, advances were made when it was found that heat-labile bactericidal 
activity required the presence of four serum protein fractions. At that time, due to 
lack of protein purification methods such as gel filtration, ion exchange 
chromatography, affinity chromatography, etc, very little was known about the 
chemical characterization of the numerous components of the complement system 
until the 1960s. Today more than 35 soluble and cell bound proteins have been 
shown to be involved in the complement system. The genetics of these proteins are 
becoming well understood. Most of these complement proteins circulate in the form 
as zymogens, the inactive or nearly inactive precursor form of the enzyme that 
become activated after proteolytic cleavage.  
 
(1.2) Complement activation 
The complement system protects against pathogens in three different ways:  
(1). Complement system produces a large number of complement activated proteins 
that bind to pathogens covalently, opsonising them for their engulfment by 
phagocytes. 
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(2). The small cleavage fragments of complement proteins activate and recruit more 
phagocytes to the site of complement activation by acting as chemoattractants. 
(3). The final components in the complement pathway forms the membrane attack 
complex (MAC) that destroy and eliminate pathogens by creating holes in their cell 
membrane. 
Three pathways, namely the classical, the alternative and the lectin pathways 
of complement activation, trigger a sequence of biological reactions (Atkinson & 
Frank, 1980; Muller-Eberhard, 1988; Morgan & Harris, 1999). 
 
(1.2.1) Classical pathway  
The classical pathway of complement system was initially discovered to be 
the route for initiation of the proteolytic cascade, which leads to the destruction and 
elimination of invading pathogens. The multimolecular enzyme complex, C1, 
consists of a recognition subunit C1q and two associated serine proteases C1r and 
C1s (Arlaud et al., 1987). C1q consists of six globular head domains and six 
collagen-like arms. The C1 complex has a well defined stoichiometry: C1q is 
associated with a C1s-C1r-C1r-C1s tetramer in a Ca+2 dependent manner (Arlaud et 
al., 1987). The C1q molecule, which contains no enzymatic activity, initiates the 
activation of the classical pathway either by the binding of the globular heads of the 
hexameric molecule C1q to the Fc region of antibodies complexed with antigens or 
by direct interaction of C1q with a variety of polyanions (Figure 1.1). The 
physiological implication of the latter activation is not yet clear. This binding causes 
conformational changes in C1q, which leads to activation of the dimer of C1r, which 
in turn activates the coassociated serine protease C1s, and therefore enzymatic 
activity of C1 is derived (Law & Reid, 1995).  Activated C1s cleaves the three chain 
C4 protein at a single point in its α-chain to yield a small fragment, C4a and a large 
fragment C4b. C4b binds to the target antigens through the amide bond or ester bond. 
C4b bound to antigen in the presence of Mg++ is capable of binding with the next 
complement component C2. Activated C1s also cleaves the single chain molecule, 
C2 into a larger fragment, C2a and a smaller fragment C2b. C4b binds to C2a to 
form the C4b2a complex (the C3-convertase). The C2b fragment is not required for 
the C3-convertase activity which is mediated via the C-terminal catalytic site in C2a 
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complement protein, into the small fragment C3a and a large fragment C3b. The 
classical C5-convertase is formed from the C3-convertase by the addition of freshly 
activated C3b, which binds covalently via its reactive thioester group to a serine 
residue at position 1217 of the surface-bound C4b of C4b2a to form a C4b3b2a 
complex called the C5-convertase (Figure 1.2).  Both C4b and C3b act as co-factor 
for the catalytic component C2a within the C5-convertase (Law & Reid, 1995; 
Rother et al., 1998). It is important to mention that C4b binds to the cell surface via 
an amide bond. The C5-convertase cleaves C5 into C5b and C5a which then lead into 
the membrane attack complex (MAC) after several enzyme cascade steps. 
 
(1.2.2) Lectin pathway 
The lectin pathway resembles the classical pathway in several aspects (Figure 
1.1). Lectins are sugar binding proteins, and are able to bind to a wide range of 
microorganisms. The initiation of this pathway is based on the recognition of certain 
oligosaccharide moieties on the surface of pathogen cells via macromolecular 
complexes in the body fluids (Matsushita et al., 2000). To date, two recognition 
components of the lectin activation pathway have been described, i.e. mannan 
binding lectin (MBL) and ficolin. These components have different carbohydrate 
binding specificities. This pathway is activated by the association of MBL and ficolin 
with specific serine proteases termed MBL-associated serine protease-1 (MASP-1) 
MASP-2 and MASP-3 (Matsushita & Fujita, 1992; Fujita et al., 2004). It is important 
to note that MASP-1 and MASP-2 associate with MBL in an approximate 3:1 ratio 
(MASP-1: 65-75%; MASP-2: 25-30%), while MASP-3 is present only in trace 
amounts (Hajela et al., 2002). Like C1s in the classical pathway, MASP-2 also 
cleaves C4 and C2 into C4a/C4b and C2a/C2b respectively, which then form a 
C4b2a complex termed the C3-convertase (Kerr, 1980). Therefore, activated MASP-
2 is considered to be the main mediator of complement activation.  MASP-1 also 
cleaves C2 as efficiently as MASP-2 does, but it does not cleave C4 (Chen & Wallis, 
2004). In addition, MASP-1 also cleaves C3 at a very slow rate compared to the C3-
convertase and it has been hypothesized that this mechanism provides an initial 
source for amplification of surface deposited C3b by alternative pathway (Petersen et 
al., 2001). The role of MASP-3 in the lectin pathway is not clear (Cortesio & Jiang, 
2006). The formation of the C3-convertase from the cleavage of C4 by MASP-2 and 
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the lectin as well as the classical pathway triggers the further downstream activation 
of complement, yielding the final assembly of the bactericidal membrane attack 
complex (MAC). 
 
(1.2.3) Alternative pathway 
The activation mechanism of the alternative pathway differs from those of the 
classical in that it operates in the absence of antibodies and hence can be considered 
a component of the innate immune system (Figure 1.1). C3 is the key molecule in the 
alternative pathway, but three other proteins namely factor B (FB), factor D (FD) and 
properdin, are also required. Activation of this pathway is initiated by the 
spontaneous hydrolysis of C3 in the fluid phase. Under physiological conditions, C3 
is spontaneously hydrolyzed in plasma to C3-H2O at a low rate leading to the 
covalent deposition of a small amount of molecules onto practically all surfaces in 
contact with plasma (Pangburn et al., 1981). C3-H2O [which is functionally similar 
to C3b] initiates the alternative pathway by binding to FB, a single-chain 93 kDa 
plasma protein. Binding of the metastable complex of C3-H2O with FB renders it 
susceptible to cleavage by FD, a 26 kDa plasma serine protease. FD cleaves FB into 
two fragments Ba and Bb. Ba is released from the complex with C3-H2O while the 
Bb remained attached and forms an active enzyme of the alternative pathway, 
C3bBb, called the C3-convertase (Figure 1.1). This complex has a relatively short 
half life, but is stabilized by the plasma protein properdin, an oligomeric 
glycoprotein with a monomer mass of 53 kDa (Janeway et al., 2005; Thurman & 
Holers, 2006). Properdin increase the lifetime of the C3bBb complex three to 
fourfold. C3bBb cleaves more C3 to C3b and this leads to the amplification of the 
cascade and the efficient deposition of C3b onto target cells which binds to FB in the 
presence of Mg++ and results in the formation of more C3-convertase (Figure 1.3). 
Some of the C3b molecules bind covalently to C4b and C3b in the C3-convertase 
enzymes of the classical and alternative pathways to form the C5-convertases, 
C4b2a3b and C3b2Bb respectively (Figure 1.2). The C5-convertase then cleaves C5 
into the anaphylatoxin C5a and the larger fragment C5b. This cleavage is the only 
proteolytic event that results in the formation of MAC on the invading pathogen 





























ent pathway: C3-convertase formation. 
 
 9
(1.3) Formation of membrane attack complex (MAC)  
Although diverse mechanisms can activate complement, each activation 
pathway culminates in the formation of C5b, the first component of the membrane 
attack pathway. Once formed, C5b binds to C6 to produce a stable and soluble C5b-6 
complex to initiate formation of the membrane attack complex (Figure 1.4). The 
C5b-6 complex binds to C7 to form C5b-7 which has a transient binding site for 
membrane surfaces and becomes dissociated from C3b. This C5b-7 complex, being 
relatively hydrophobic, attaches to the surface of cell membranes without rupturing 
membrane integrity. C8 then binds to a specific recognition site of C5b in the C5b-7 
complex, which becomes more deeply incorporated in the membrane and causes the 
cell to become slightly leaky (Ramm et al.,1982). Once C8 is bound, then it directs 
the incorporation of C9 to form C5b-9.  C5b-9 has two functions: 
(i) It slowly lyses the red blood cells as well as certain nucleated cells. 
(ii) It acts as a receptor for C9 and behaves as a catalyst in C9 polymerization to 
yield the C5b-9n complex. The exact mechanism is not known but it is believed that 
the binding of C9 molecules to C5b8 transforms the C9 molecule from a globular, 
hydrophilic structure to an elongated, amphipathic structure, which inserts into and 
through the membrane. These conformational changes in C9 expose binding sites for 
additional C9 molecules to bind, unfold and insert into the target membrane (Xiong, 
2003). The addition of as many as 18 copies of C9 to the C5b8 complex forms a 
barrel-like structure called the membrane attack complex (MAC). The stability of the 
MAC (C5b-8 (9)n ), where n lies between 1 and 18, results from the association of 
the hydrophic exterior of the MAC with membrane lipids. The hydrophilic interior of 
the MAC causes changes in the permeability of the target cell membrane by allowing 
loss of water and small molecules that result in the elimination of its osmotic and 
chemical balance and ultimately leads to osmotic lysis of target cells. It has been 
deduced that MAC-mediated cell injury is principally caused by the influx of 
calcium through the MAC channels (Campbell et al., 1981). 
 
(1.4) Difference between three pathways 
Although all the three pathways of activation result in the formation of an 
unstable protease complex named the C3-convertase, their routes of activation are 
different from each other, and also different types of plasma proteins/proteins 
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pathways requires binding of antibody or the presence of a pattern recognition 
molecule to the target respectively. By contrast, the alternative pathway is initiated 
spontaneously in plasma at low level and if left uncontrolled leads to attack against 
all the particles, membranes and cells which are plasma exposed but not specifically 
protected from it (Fearon et al., 1977). The alternative pathway requires Mg++ ions 
for the assembly of the C3bBb complex, whereas the classical pathway requires both 
Mg++ ions for the assembly of C4b2a and Ca++ ions for the C1 complex. The 
alternative pathway directly activates C3 when it interacts with certain activating 
surfaces (e.g. zymosan, lipopolysaccharides) and this involves C3, factor B, factor D 
and properdin (Reid, 1986; Morgan & Harris, 1999). So, the alternative pathway 
provides a means of non-specific resistance against infection without the 
participation of antibodies (Table 1.1) and hence provides a first line of defence 
against a number of infectious agents. Although the lectin pathway is homologous to 
the classical pathway, this utilises MBL instead of C1q which interacts with repeated 
pattern of mannose and N-acetylglucosamine residues present in abundance on 
bacterial cell walls (Thiel et al., 1977).  
 
(1.5) Regulation of complement 
Uncontrolled activation of the complement cascade can inflict serious 
damage on host tissues and therefore must be tightly regulated. Regulation of 
complement system occurs at several levels of the cascade and is mediated by both 
soluble proteins in fluid phase and membrane bound proteins.  
 
(1.5.1) Regulation of classical pathway 
The activity of C1 complex is tightly regulated by a regulatory protein known 
as C1 inhibitor (C1INH) which is present at a higher concentration than C1 (Davis et 
al., 2008). C1INH is a member of the serpin family of protease inhibitors and is 
bound to most of the circulating C1 complex, thereby inactivating the C1r and C1s 
proteases (Davis et al., 2008). When the C1 complex binds to antigen-antibody 

































Classical                          Immune complexes 
                                        Apoptotic cells, certain viruses  
                                        Gram-negative bacteria, 
                                        C-reactive protein bound to ligand 
Lectin                              Microbes with terminal mannose groups 
Alternative                      Many bacteria, fungi, viruses, tumor cells 
Pathway                          Initiators 
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(1.5.2) Regulation of C3-convertase 
The C3-convertase is a proteolytic enzyme complex that drives an 
amplification cascade reaction at the heart of the complement system. The C3-
convertase is the main key to the activation and regulation of the complement 
system. The classical pathway C3-convertase consists of C4b plus C2a (C4b2a), 
while the alternative pathway C3-convertase consists of C3b plus Bb. Five human 
proteins have been identified that act to shorten the life span of the convertase 
enzyme or inhibit its assembly. The best well characterized examples in fluid phase 
are Factor H (FH) which acts as a cofactor in factor I (FI) mediated proteolysis of 
C3b into C3bi and decay accelerating activity of the alternative C3-convertase 
(C3bBb) (Jozsi & Zipfel, 2008) and C4b binding protein that dissociates the classical 
pathway C3-convertase (C4b2a) (Zipfel & Skerka, 2009). The membrane associating 
regulatory proteins are complement receptor type 1 (CR1 also known as CD35) 
(Khera & Das, 2009), CD46 (also known as membrane cofactor protein, MCP) and 
CD55 (also known as decay accelerating factor, DAF) (Spendlove et al., 2006). 
CD35 and CD55 displace a component of the C3-convertase in the classical pathway, 
while CD46 acts as a cofactor in proteolytic mediated dissociation of both the 
classical and alternative C3-convertases (Seya & Atkinson, 1989). 
 
(1.5.3) Regulation of membrane attack complex 
Complement FH related protein 1 (CFHR1), clusterin, S-proteins (also known 
as vitronectin) and CD59 are the main regulatory proteins of the membrane attack 
complex in the terminal pathway. S-proteins, clusterin and CFHR1 are the fluid 
phase inhibitory proteins of the terminal pathway (Preissner & Seiffert, 1998; 
Schwarz et al., 2008; Heinen et al., 2009), while CD59 is a membrane bound 
regulator protein that prevents the final assembly of the terminal pathway (Kimberley 

















































  15 
(2.1) Complement Factor H (FH) 
(2.1.1) Structure of FH 
          FH is a flexible single chain polypeptide glycoprotein, first identified by 
Nilson and Eberhard in 1965 and termed β1H globin. It is a major regulator of the 
alternative complement pathway and has a monomer molecular mass of 150-155 kDa 
consisting of approximately 9.3% carbohydrate which is distributed in the form of 
eight N-linked oligosaccharides at nine putative sites (Whaley & Ruddy, 1976; Sim 
& DiScipio, 1982; Perkins et al., 1991; Fenaille et al., 2007). The most recent 
sequencing by mass spectrometry showed that there are eight N-linked 
oligosaccharides (Fenaille et al., 2007). FH is composed of 20 domains, each 
consisting of approximately 60 amino acids and termed short complement regulators 
(SCRs) or complement control protein modules (Ripoche et al., 1988). These SCRs 
are joined by short linkers, each consisting of 3-8 amino acids residues. The SCRs 
contain five conserved residues including four cysteines and one tryptophan, and 
several partially conserved proline, glycine and other hydrophobic residues.  
Intact FH has not been crystallized to date due to its large size, glycosylation, 
interdomain flexibility and multiple ligand binding sites. Low resolution structural 
studies of the intact FH have increased the understanding of its overall architecture. 
The first structural studies by scattering and electron microscopy showed that FH is 
not fully extended but is partial folded with an average length of 49.5 nm (Figure 
2.1) (Perkins et al., 1991; Discipio, 1992). More detailed constrained X-ray solution 
scattering and analytical ultracentrifugation methods showed that FH is not fully 
extended in solution and had a maximum length of 40 nm compared to a theoretical 
length of 73 nm for a full extended FH molecule (Figure 2.2a) (Aslam & Perkins, 
2001). These data strongly suggest that some domains within FH are folded back 
upon themselves in solution and this is supported by later studies using the same 
techniques (Figure 2.2b) (Okemefuna, et al., 2009). The three dimensional structure 
of several SCRs have been determined showing a globular structure with up to eight 
stranded antiparallel β sheets connected with loops and turns (Perkins et al., 1988; 
Barlow et al., 1992) . To date, NMR structures for SCR-5, SCR-15/16 and SCR-1/3 
(Barlow et al., 1992; Barlow et al., 1993; Hocking et al., 2008) and crystal structures 
for SCR-1/4, SCR-6/8 and SCR-19/20 have been reported (Jokiranta et al., 2006; 
Prosser et al., 2007). For the remaining SCR domains in FH, homology models have 
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 (2.1.2) FH binding sites 
Despite the simplicity of its domain organization, FH is functionally 
complex. Early studies identified that the N-terminus of FH possess fluid phase C3b 
binding property, cofactor and decay accelerating activities (Alsenz et al., 1984, 
1985; Misasi et al., 1989; Kuhn & Zipfel, 1996). Under normal physiological 
condition, FH binds to host cell surfaces and various ligands to carry out its 
regulatory roles. These binding sites have been identified and characterized using 
different strategies based on monoclonal antibodies, enzyme digestions and deletion 
or point mutations. FH may have as many as three distinct binding sites for C3b that 
are located in SCR-1/4, in SCR-12/14 and in SCR-19/20 (Alsenz et al., 1985; 
Gordon et al., 1995; Kuhn et al., 1995; Jokiranta et al., 1996; Prodinger et al., 1998). 
Similarly FH has as many as three binding sites for polyanionic molecules such as 
heparin, heparan sulphate (HS) and sialic acids. These polyanionic binding sites are 
located in SCR-7, SCR-13 and SCR-19/20 (Pangburn et al., 1991; Blackmore et al., 
1996, 1998; Ram et al., 1998). A later study suggested that the binding site located in 
SCR-13 should be reassigned to SCR-9. Recently, it was suggested that FH has no 
binding sites for these polyanionic molecules in SCR-9 and in SCR-13 (Schmidt et 
al., 2008). Because of these polyanionic and C3b binding sites, FH is believed to 
recognize and prevents the alternative pathway activation on the host cell surfaces 
bearing sialic acid and HS (Meri & Pangburn, 1990).  Apart from these C3b and 
polyanionic binding sites, FH has binding sites for other ligands including C-reactive 
protein (CRP) (Okemefuna et al., 2010), adrenomedullin (Pio et al., 2001), and 
bacterial cell surface proteins and cell surface receptors (Horstmann et al., 1988; 
Hellwage et al., 1997; DiScipio et al., 1998). CRP binds to FH at SCR-7 that result 
in the inhibition of CRP-dependent alternative pathway activation induced by 
damaged tissues (Kaplan & Volanakis, 1974). A map of FH binding sites for these 
ligands is shown in Figure 2.3. Because of their potential relevance in pathology, 
these FH binding sites are considered to be of great interest. Some of these binding 
sites overlap with each other. The polyanionic binding sites overlap with C3b in 
SCR-19/20 (Hellwage et al., 2002) and with CRP in SCR-7 (Giannakis et al., 2003). 
Structural studies have shown that FH interacts with C3b, heparin and CRP through 
the cluster of positively charged amino acids residues located in SCR-7 and SCR-
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(2.1.3) Where does FH appear? 
The activation and damage potential of the complement system requires that 
it be kept under tight control. At least 12 proteins including FH are known that do 
this function. FH is produced by liver cells and is found in human plasma at 
concentrations of 0.235-0.810 mg/ml. Extrahepatic synthesis of FH also occur in a 
wide variety of cell types, such as peripheral blood lymphocytes, myoblasts, 
fibroblast, neurons, glomerular mesangial cells, neurons and glia cells (Friese et al., 
1999). The extrahepatic production of FH is interpreted as a mechanism to increase 
the local concentration of this complement regulator to protect the host cells from 
complement attack at sites of infection or inflammation. Recently FH has been also 
shown to be present in retinal blood vessels in the choroid (Klein et al., 2005). In 
addition to FH, FH like protein 1 (FHL-1), formed by an alternative transcript of the 
same gene that codes for FH, is also produced by the liver and is present in human 
plasma at concentration of 10-50 µg/ml. 
 
(2.1.4) What does FH bind to? 
          FH acts selectively on C3b and C3bBb (C3-convertase) on self versus non-self 
surfaces (Meri & Pangburn, 1990). It binds to C3b and accelerates the decay of the 
alternative pathway C3-convertase (C3bBb) by irreversible dissociation of Bb from 
C3bBb (Figure 2.4a). FH competes for binding of complement factor B (FB) to C3b 
(Farries et al., 1990). It also acts as a cofactor for factor I (FI), a serine protease, 
which cleaves C3b into iC3b, an inactive form of C3b, which can no longer take part 
in formation of the C3-convertase (Weiler et al., 1976; Whaley & Ruddy, 1976; 
Pangburn et al., 1977). In the presence of FH and FI, C3b proteolysis results in the 
cleavage of the α-chain of C3b at two sites that generates two fragments of 68 kDa 
and 43 kDa respectively (Figure 2.4b). FH also binds to polyanionic molecules such 
as sialic acid and HS on host cell surfaces. Due to this polyanionic binding property, 
FH is believed to distinguish between self and non-self surfaces. It has been reported 
that sialic acids influence the regulation of surface bound C3b by FH (Fearon, 1978). 
Sialic acids induce an increase in the affinity of FH for C3b. Since FH does not bind 
to the cells bearing sialic acids in the absence of C3b, it is likely to be a consequence 
of the simultaneous recognition of both sialic acid and bound C3b by the same FH 
molecule. The presence of multiple binding sites for both C3b and polyanions in FH 
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that inhibits CRP dependent activation pathway induced by damaged tissues (Kaplan 
& Volanakis, 1974). FH has binding sites for some plasma proteins and 
microorganisms that are of great interest because of their potential relevance in 
pathology.  
 
(2.1.5) What does FH do?        
          FH is a key regulatory protein of the complement system of innate immunity 
(Rodriguez de Cordoba et al., 2004). The most important and clearly identified 
function of FH is the regulation of enzymatic processing of the major complement 
component C3. In human serum, C3 is spontaneously converted into C3-H2O by 
hydrolysis. FB binds to C3-H2O and this leads to the formation of C3bBb (C3-
convertase) after removing a small part, Ba, from FB by FD and C3a from C3. An 
immune response occurs when C3b is attached to the pathogen surface. The C3-
convertase cleaves C3 to form more C3b that leads to the formation of the membrane 
attack complex which make a hole in the pathogen cell. On the host cell surfaces 
bearing sialic acid and heparan sulphate, FH competes for the binding of FB to C3b 
and hence prevents the formation of the C3-convertase. It also dissociates the C3bBb 
complex (the alternative pathway C3-convertase) by binding to the C3b subunit and 
displacing Bb. The interaction of FH with cell surface bound C3b decreases with 
removal of these polyanionic molecules such as on pathogenic surfaces. In fluid 
phase FH binds to and inactivates C3b in the presence of FI, a serine protease that 
cleaves C3b into C3bi, an inactive form of C3b (Rodriguez de Cordoba et al., 2004). 
Thus FH protects the host cells bearing polyanionic molecules such as sialic acid and 
HS from complement attack (Kazatchkine et al., 1997; Carreno, 1989).  
FH has been reported to have other functions in addition to decay 
acceleration and co-factor activity. Many of these are probably associated with a FH 
receptor which was initially reported on leucocytes (Lambris & Ross, 1982). These 
are specific, saturable and divalent cation dependent. The function which are thought 
to be associated with FH receptor include the release of FI from β-lymphocytes 
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(2.1.6) Role of FH in diseases 
          FH is encoded by a single gene (HF1) located on human chromosome 1q32. 
Genetic mutations in HF1 gene have been associated with two different renal 
diseases, membranoproliferative glomerulonephritus (MPGN) and atypical 
haemolytic uraemic syndrome (aHUS), and as shown recently age-related macular 
degeneration (AMD). 
 
(2.1.6.1) Membranoproliferative glomerulonephritus (MPGN)  
Lack of FH in plasma is a cause of MPGN. FH deficiency results in a 
progressive glomerulonephritus in the pig, similar to human type II 
membranoproliferative glomerulonephritus that leads to renal failure. However, 
similar to the deficient pigs, the knockout mice develop MPGN spontaneously and 
are hypersensitive for developing renal injury. Uncontrolled C3 activation in vivo is 
essential for the development of MPGN and defective regulation is explained by its 
association with deficiency, or functional inactivity of FH (Pickering et al., 2002). 
 
(2.1.6.2) Atypical haemolytic uraemic syndrome (aHUS) 
         Atypical Haemolytic uraemic syndrome (aHUS) is a kidney disease, which is 
characterized by haemolytic anaemia, thrombocytopenia, and acute renal failure. The 
last five year of studies on complement revealed that aHUS is strongly associated 
with mutations in proteins needed either for activation or regulation of alternative 
pathway of complement. These mutations have been described in genes encoding 
five complement proteins i.e FH, membrane cofactor protein/CD46 (MCP), FI, FB, 
and C3 (Richards et al., 2001, 2993; Kavanagh et al., 2005; Goicoechea de Jorge, 
2007; Fremeaux-Bacchi, 2006). Previously, aHUS has been associated with a 
reduced plasma concentration of FH (Thompson et al., 1981). Mutations in the FH1 
gene that encodes FH became the first link between complement and aHUS. The 
mutations cause amino acid substitutions in the C-terminus of FH mainly within 
domains 19-20 of FH (Caprioli et al., 2001; Dragon-Durey et al., 2004). Since aHUS 
is characterized by endothelial cell damage, microthrombosis, kidney failure and 
alternative pathway activation, it appeared that protection of these cells and kidney 
glomeruli from complement attack was impaired by the malfunction of the C-
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(2.1.6.3) Age-related macular degeneration (AMD) 
          A recent study of the human genome project revealed the role of the alternative 
pathway in age-related macular degeneration (AMD), an eye-sight threatening 
disease. AMD, the most common cause of central vision loss in the elderly 
population of western countries (Klein et al., 2004; van Leeuwen et al., 2003),  
involves the breakdown of the macula, a small yellowish spot (~ 2 mm in diameter) 
on the central retina which is composed of photoreceptor cells. AMD is characterized 
by the appearance of extracellular deposits known as drusen, a hallmark lesion of 
AMD, at the interface of Bruch’s membrane and the retinal pigment epithelium 
(Anderson et al., 2002). Clinically, drusen are divided into two main forms, soft and 
hard drusen. Soft drusen is the early indication of AMD with no visual loss, while 
hard drusen is an indication of late AMD with severe loss of central vision. Late 
AMD has two forms, dry and wet. Both these forms of AMD can be found 
bilaterally, meaning it occurs in both eyes of the same patient (de Jong, 2006). A 
variety of lipids, polysaccharides and glycosaminoglycans have been reported in 
drusen by histochemical and immunocytochemical studies (Abdelsalam et al., 1999; 
Hageman et al., 2001). To date more than 129 proteins have been identified in the 
drusen. Some of them are vitronectin (Hageman et al., 1999), amyloid A, amyloid P, 
α1-antitrypsin, α1-antichymotrypsin, apolipoprotein A1, apolipoprotein E, remnants 
of retinal pigment epithelium (RPE), complement components C3, C5, and C9, 
complement regulators, fibrinogen, Ig kappa, Ig lambda, and ubiquitin (Mullins et 
al., 2000; Crabb et al., 2002). One of these regulators is FH. A common variation in 
the FH1 gene that encodes FH has been associated with a significantly increased risk 
(50%) of AMD in human (Klein et al., 2005; Haines et al., 2005; Edwards et al., 
2005). Thus a single polymorphism in FH (Tyr402His) is strongly associated with 
many AMD cases, leading to heavy deposition of complement in drusen. This 
residue is located in SCR-7, a domain which is present in FH and factor like protein 
(FHL-1). The tyrosine residue at position (FHYY402) is considered as a protective 
variant whereas the histidine residue at this position (FHHH402) is a risk variant for 
AMD. In addition to these major roles of FH in diseases, it also plays a role in 
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(2.2) Glycosaminoglycans (GAG) 
Glycosaminoglycans are linear polyanionic polysaccharides found on the cell 
surfaces, in mast cells and extracellular matrix. Heparin and heparan sulphate (HS) 
are the most widely studied examples of this family and are biosynthesized as 
proteoglycans.  
 
(2.2.1) Biosynthesis of GAG 
Both heparin and HS are biosynthesized as proteoglycans through similar 
pathways. HS proteoglycans are expressed and secreted by most mammalian cells 
and are exclusively found on the cell surfaces and in the extracellular matrix 
(Gallagher et al., 1992). 
 The biosynthesis of GAG chains occurs in the Golgi apparatus and begins 
with the biosynthesis of tetrasaccharide linker (glucuronic acid (GlcA)-galactose 
(Gal)-galactose-xylose (Xyl)) to a serine residue in the core proteins (Salmivirta et 
al., 1996). Syndecans (an integral membrane protein) and glypicans (a GPI-anchored 
protein) are the two major core proteins that carry HS chain on the cell surfaces. In 
the extracellular matrix, especially in the basement membrane, HS chains are 
attached mainly to core proteins called perlecan and agrin. In heparin, this 
tetrasaccharide linker is attached to serglycin, a core protein, through a serine 
residue. The second step involves the transfer of N-acetylglucosamine (GlcNAc) 
residue from UDP-GlcNAc to form an α-linkage with C4 of the terminal GlcA of the 
tetrasaccharide attached to the core protein (Figure 2.5). This step is catalysed by 
GlcNAc transferase. This step appears to be the commitment step towards the 
formation of a HS/heparin chain rather than to chondroitin/dermatan sulphate. The 
elongation of the GAG chain takes place by the addition of alternative GlcA and 
GlcNAc residues from their corresponding UDP-sugar nucleotides to the non-
reducing termini of the growing chain. About 300 sugar residues are added to the 
polysaccharide chain before the chain terminates (Lindahl et al., 1986). As the chain 
elongates, it undergoes a series of modification reactions that include N-deacetylation 
and N-sulphation of GlcNAc by deacetylase/N-sulphotransferase, C-5 epimerization 
of GlcA to iduronic acid (IdoA) by C-5 epimerase (Lindahl et al., 1972), O- 
sulphation of IdoA at C-2 by an iduronosyl 2-O-sulphatranferase, and O-sulphation 
of GlcA at C-2 by gluconosyl 2-O-sulphotransferase (Bai & Esko, 1996),  O-
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(Jacobsson & Lindahl, 1980), and occasionally O-sulphation of GlcN residues at 
C-3 by 3-O-sulphotransferase (Rosenberg et al., 1997). HS/heparin possesses a high 
degree of structural variability which is the result of the incomplete nature of 
modification carried out by these biosynthetic enzymes. 
 
(2.2.2) Heparin  
(2.2.2.1) Importance of Heparin 
Heparin was discovered in 1916 and has been known for its anti-complement 
as well as its anti-coagulant activity (Rodén, 1989). The importance of heparin is due 
to its diverse biological activities. It is not only used as a natural therapeutic agent 
but also as analogue for HS which is present on the cell surfaces and in extracellular 
matrix. Direct inhibition of Clq binding to immune complexes, interaction of C1s 
with C4 and C2, and binding of C2 to C4b are examples of anti-complementary 
activity of heparin (Kazatchkine et al., 1981). Apart from these anti-complementary 
and anti-coagulant activities, heparin possesses some other biological activities such 
as release of lipoprotein lipase and hepatic lipase (Olivercrona & Bengtsson-
Olivercrona, 1989), inhibition of angiogenesis and tumor growth (Folkman et al., 
1983; Crum et al., 1985) and antiviral activity (Holondniy et al., 1991). These 
biological activities of heparin result from its interaction with proteins that play 
important roles in the regulation of many normal physiological processes (Figure 
2.6a). The most widely studied example is its interaction with antithrombin, a serine 
protease inhibitor that mediates anticoagulant activity of heparin. This anticoagulant 
activity resides in a unique pentasaccharide sequence (Figure 2.6b) with antithrombin 
binding properties. Hundreds of heparin binding proteins have been identified during 
the past several decades. Most of this research is focused on the characterization of 
heparin-protein binding because heparin-protein binding serve a model for the 
interaction of protein with highly sulphated regions of the HS chains of cell-surface 
HS proteoglycans (Sasisekharan & Venkataraman, 2000). 
Thus, heparin binds specifically to heparin/HS binding proteins including 
complement regulatory proteins, morphogens, growth factors, cytokines, chemokines 
and many other signalling molecules, and thereby plays an important role in 
fundamental biological processes (Capila & Linhart 2002). The heparin-protein 
interaction opens new approaches and strategies for therapeutic intervention at the 
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polysaccharides will assist in our understanding of biological processes in the post-
genomic era. As we better understand the nature of heparin–protein interactions, 
there will be rapid development and expansion of the field of ‘glycomics’, or the 
study of how proteins and saccharides interact with one another and their possible 
role in physiological and pathophysiological processes.   
 
(2.2.2.2) Structure of Heparin 
Heparin is a linear anionic polysaccharide consisting of uronic acid (1-4)-D-
glucosamine repeating disaccharide units (Comper et al., 1981). The uronic acid can 
be either α-L-iduronic acid (IdoA) which accounts for up to 90% or β-D-glucuronic 
acid (GlcA) which accounts for up to 10%. The repeating disaccharide unit of 
heparin typically contains three sulphate groups, on the 2-OH group of iduronic acid, 
on the NH2 group and the 6-OH group of D-glucosamine and is considered the most 
common occurring repeating disaccharide (Figure 2.7). Both uronic acids may be 2-
O-sulphated i.e Ido(2S), GlcA (2S). Similarly, the β-D-glucosamine (GlcN) may be 
either N-sulphated (GlcNS) or N-acetylated (GlcNAc), both of which may be 
sulphated at the 6-O or 3-O positions. Due to this high degree of sulphation and 
carboxylation, heparin is the most negatively charged macromolecule in nature 
(Capila & Linhardt, 2002).  The disaccharide subunits contain a variety of groups, 
including N-sulphate, O-sulphate and N-acetyl groups that display extraordinary 
structural diversity. Heparin and HS are structurally the most complex members of 
the glycosaminoglycan family of anionic polysaccharides. The complete structural 
analysis of heparin involve identification and quantification of uronic acid-(1,4)-
glucosamine disaccharide repeating units, determination of their sequence along the 
polysaccharide chain and characterization of the three dimensional structure of 
individual monosaccharide residues and polysaccharide chain. Unlike proteins, 
heparin is not known to display or fold into any particular tertiary structure (Capila & 
Linhardt, 2002). Heparin exists primarily as a helical structure where the three 
sulphate groups are clustered on one side of the chain, with a similar cluster forming 
on the other side of the chain for the next trisulphated sequence (Figure 2.8). The 
specificities of heparin with a wide range of biologically important proteins are due 
to the orientation of its sulphate and carboxyl groups in defined patterns.  
Structural studies of heparin are essential for reason of the considerable 
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pathophysiological processes. Up to now, molecular structures for heparin have been 
very much limited to its small fragments. For free heparin, solution structures by 
NMR spectroscopy are available for heparin oligosaccharides (Mulloy et al., 1993) 
and synthetic pentasaccharides dp5 (Ragazzi et al., 1990). These revealed a linear 
structure. For heparin-protein complexes, the current availability of 19 crystal 
structures (July 2009) have revealed heparin structures of sizes dp4 to dp10 
structures. These include crystal structures for acidic and basic fibroblast growth 
factors separately (Faham et al., 1996; DiGabriele et al., 1998), and the complexes of 
acidic and basic fibroblast growth factors with their receptors (Pellegrini et al., 2000; 
Schlessinger et al., 2000), thrombin (Carter et al., 2005), antithrombin and the 
complex of antithrombin–S195A and coagulation factor Xa (Jin et al., 1997; McCoy 
et al., 2003; Johnson et al., 2006; Langdown et al., 2009), foot and mouth disease 
virus (Fry et al., 1999), neurokinin 1 receptor (Lietha et al, 2001), annexins V and 
A2 (Capila et al., 2001; Shao et al., 2006), vaccinia complement protein (Ganesh et 
al., 2004), and protein C inhibitor (Li & Huntington, 2008). Many of these crystal 
structures likewise show extended heparin conformations except dp10 in the crystal 
structure of acidic fibroblast growth factor 1 (FGF1) with fibroblast growth factor 
receptor 2 (FGFR2) (PDB code: 1E0O) which revealed a kink in its structure (Figure 
2.9) (Pellegrini et al., 2000). It has been shown that the kinked oligosaccharide 
provides more favourable ionic and van der Waals contacts that were calculated from 
the interaction energies of a kinked oligosaccharide and an oligosaccharide with a 
standard helical structure (Raman et al., 2003). Fibre diffraction studies have also 
been reported for heparin oligosaccharides (Nieduszynski & Atkins, 1973; Atkins 
& Nieduszynski, 1977). At the opposite extreme of resolution, macroscopic solution 
structures for large polydisperse heparin fractions have been studied by X-ray 
solution scattering and analytical ultracentrifugation (Pavlov et al., 2003; Perez 
Sanchez et al., 2006). No structural information at a molecular level was reported for 
these larger heparin fractions. 
 
(2.2.3) Heparan sulphate 
(2.2.3.1) Heparan sulphate structure 
Structurally, heparan sulphate (HS) is closely related to heparin but with a 
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consisting of repeating unit of uronic acid and glucosamine which are linked together 
by an α-(1-4) glycosidic bond (Figure 2.10A) (Lane & Lindahl, 1989). The uronic 
acid may be either iduronic acid or glucuronic acid. Unlike heparin, HS has a lower 
ratio of iduronic acid to glucuronic acid. The glucosamines are approximately 
equally N-acetylated (GlcNAc) and N-sulphated (GlcNS). The disaccharide unit with 
N-acetyl group (GlcA-(1-4)-GlcNAc) is the major repeating unit in HS (Lyon & 
Gallagher, 1998). HS has a distinct organisation of domains that is not present in 
heparin (Turnbull & Gallagher, 1990; Gallagher, 2001; Capila & Linhardt, 2002). 
The region in HS chains that is enriched in IdoA(2S) and GlcNS are called S-
domains, while the region containing clusters of GlcA and GlcNAc residues are 
called NA-domains (Figure 2.10B). This NA-domain has not yet been found to 
directly influence protein binding; it may function as a spacer between the S-domains 
(Turnbull & Gallagher, 1990). N-sulphated disaccharide sequences largely occur in 
clusters of 2-8 repeating units that may also contain heparin-like trisulphated 
disaccharides as well as disulphated disaccharides. These S and NA-domains are 
separated by mixed sequences of N-acetylated and N-sulphated disaccharides 
(Bernfield, 1992). In these mixed sequences, the GlcNAc residues are often 
sulphated at the C-6 position. In term of interactions with various biologically active 
proteins, these mixed sequences of HS may have a significant biological function. 
The best example of such an interaction is the anti-thrombin-pentasaccharide 
interaction where these mixed sequences reside in the pentasaccharide sequence 
(Figure 2.6b). The S-domains along with these adjacent mixed sequences comprise 
the hypervariable regions that give different functional characteristics to HS from 
different cells. To date, no solution and crystal structural information is available for 
free HS in the literature. Only one crystal structure of a porcine intestinal mucosa 
derived HS tetrasaccharide complexed with heparinase II (PDB code: 3E7J, Figure 
2.11a) is available. This HS tetrasaccharide consists of two N-acetyl-D-glucosamine 
(NAG), one D-glucuronic acid (GCU) and one 4,5-dehydro-D-glucuronic acid 
(GCD) residues. The arrangement of these residues is NAG-GCU-NAG-GCD 
(Figure 2.11b).  Like heparin dp10 in a ternary complex of FGF1-FGFR2-dp10, this 
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(2.2.4) Conformation of HS/Heparin 
A three dimensional structure of HS/heparin is required to understand how 
HS/heparin carries out its normal physiological functions. The glycosidic linkage in 
the heparin chain is relatively stiff in solution. The GlcA and GlcNAc residues exist 
in the 4C1 conformation within the chain, whereas the IdoA residues oscillate 
between the chair (1C4) conformation and skew boat (2S0) conformation without 
significant conformational change in the backbone (Torri et al., 1985) (Figure 2.12). 
Because the energy barrier between the 1C4 and 2S0 conformations is not high, the 
oscillation between these two conformations is rapid. IdoA favours the 2S0 
conformation rather than the 1C4 conformation within the chain, because in the 1C4 
conformation the bulky carboxyl group is in the equatorial position whereas all other 
the substituents are in axial position (Capila & Linhardt, 2002). Similarly in the 2S0 
form, the three sulphate groups per disaccharide are clustered on one side with a 
similar arrangement on the other side for the next trisulphated disaccharide in the 
sequence (Mulloy & Forster, 2000; Hricovini et al., 2002). This cluster of sulphate 
groups is more dispersed in the 1C4 conformation (Hricovini et al., 2002). These 
clusters of sulphate groups are separated from each other by 1.7 nm. It has been 
suggested that the conformational flexibility of IdoA, where the two conformations 
orient the 2-O-sulphate and carboxyl groups in different positions, tends to increase 
the number of contacts of HS/heparin chain with the protein surface (Conrad, 1998). 
Upon binding to protein, IdoA residues can adopt any of these two conformations or 
even both. For example, the crystal structure of basic fibroblast growth factor (FGF2) 
complexed with heparin hexasaccharide showed that IdoA residue at position 3 is in 
the 1C4 conformation whereas IdoA at position 5 is in the 2S0 conformation (Faham 
et al., 1996). The sulphate group in an IdoA residue locked in any particular 
conformation is not always involved in binding with positively charged amino acid 
residues of the interacting protein. The Ido2S ring that is involved in binding with 
FGF2 adopts the 2S0 form, while the Ido2S ring that is not involved in binding adopts 
the 1C4 conformation (Hricovini et al., 2002). This clearly illustrates how similar 
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(2.2.5) HS/Heparin-protein interactions 
Heparin and HS play essential roles in the regulation of many physiological 
processes. Generally, it is believed that these GAGs perform their biological 
functions through interactions with wide a range of proteins with diverse functions 
and thereby localise, stabilise, activate or inactivate these interacting proteins 
(Linhardt & Toida, 1997). Because of these structural similarities, heparin is often 
used as an analogue for the interaction of HS with proteins. 
An understanding of these HS/heparin-protein interactions has been the 
subject of investigation for many years. Recently, X-ray crystallography and NMR 
studies have assisted our understanding of structural as well functional aspects of 
HS/heparin-protein interactions. HS has different binding specifities towards 
different proteins. Interleukin-8 (Spillmann, 1998), platelet factor 4 (Stringer & 
Gallagher, 1997) and interferon-γ (Lortat-Jacob et al., 1995) bind to HS through 
interaction of the monomer components of these proteins with S-domains separated 
by N-acetylated sequences. Similarly, HS oligosaccharide isolated from human skin 
fibroblast HS binds to basic fibroblast growth factor (bFGF, also known as FGF2) 
with high affinity. This binding site for FGF2 resides in the S-domain, which 
contains N-sulphates and iduronic acid 2-sulphates as essential residues for binding 
with FGF2 (Turnbull et al., 1992). Most of the HS binding proteins appear to interact 
with saccharide sequence of 5-15 units in single domains.  
Like HS, heparin has also different binding sites for different proteins. 
Fibroblast growth factors are the most widely studied examples of HS/heparin 
binding proteins. FGF has three principal sulphate-binding sites within FGF-sugar 
binding loop. It has been shown that acidic fibroblast growth factor (aFGF, also 
known as FGF1) interacts with 4-5 heparin monosaccharide units through 
electrostatic interactions (Spivak-Kroizman, et al., 1994), but only 5-6 
monosaccharide units are ordered in the crystal structure of heparin decasaccharide 
complexed with FGF1 (PDB code 2AXM). For the cross-linking of two molecules of 
FGF1 to form a biologically active dimer, a minimum octasaccharide is required 
(Ornitz et al., 1992). NMR and analytical ultracentrifugation studies of the 
interaction of FGF2 with heparin oligosaccharides showed that sugar as small as 
single sucrose octasulphate (SOS) residues or tetrasaccharides can induce FGF2 
dimerization (Moy et al., 1997; Herr et al., 1997). In addition to this FGF dimer 
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formation, heparin can also induce ternary complex formation with FGF and FGF 
receptor (FGFR) in 1:1:1 ratios (PDB 1FQ9).  
Most of these interactions of HS/heparin with heparin binding proteins are 
electrostatic. For example, vaccinia complement proteins (1RID), antithrombin (AT-
III) and foot-and-mouth proteins form specific salt bridges between the sulphate and 
carboxylate groups on heparin chain and the basic residues of the proteins. In 
addition to these electrostatic interactions, it has also been observed that some 
proteins interact with HS/heparin oligosaccharide though both electrostatic 
interactions as well as hydrogen bonding. FGF-FGFR-heparin (PDB code 1FQ9) and 
thrombin-heparin oligosaccharides (PDB code 1XMN) are the best examples of such 
interactions. A heparin decasaccharide forms 25 hydrogen bonds within one FGF: 
FGFR (1:1). In the thrombin-heparin oligosaccharides complex, a heparin molecule 
is sandwiched between each pair of thrombin monomers (AB-GH and CD-EF). In 
the thrombin dimer AB-GH, the AB monomer forms six ionic interactions and four 
hydrogen bonds, while the GH monomer makes only three ionic interactions.  In the 
thrombin dimer CD-EF, the CD monomer makes four ionic and two hydrogen bonds 









































(3.1) Introduction to macromolecular structure determination  
To gain an understanding of macromolecular functions at a molecular level, it 
is necessary to determine the three dimensional structure of the macromolecule in 
question. A variety of low and high resolution methods are used for macromolecular 
structures. High resolution methods include NMR and X-ray crystallography, while 
low resolution methods include electron microscopy, X-ray and neutron solution 
scattering and analytical ultracentrifugation.  
X-ray crystallography is a high resolution technique used to determine the 
three dimensional structure of macromolecules, their interactions and their 
conformational studies at atomic resolution of 0.1-0.3 nm. Basically X-rays measure 
the electron density of atoms within a crystal lattice. Fitting of the electron density 
map into an atomic model gives the molecular structure of the macromolecule. 
Because the wavelength is inversely proportional to energy, the X-ray photon (a unit 
of light and electromagnetic radiation) has high energies (~10,000 electron volts). X-
ray crystallography experiments require crystals of the molecule that contain many 
repeated copies of the molecules in an ordered lattice. An X-ray experiment for a 
single molecule is difficult due to two main practical obstacles: (1) The X-ray 
scattering for a single molecule is weak and contains a lot of noise from the 
scattering of other elements such as air and water; (2) the high energy of the X-ray 
photons would damage the single molecule before a useful diffraction pattern is 
obtained. The molecules in a crystal form reduce molecule damage. Because the X-
ray diffraction pattern is obtained from the scattering of all the molecules in the 
crystal lattice, each individual molecule receives a smaller dose of X-rays. For 
example if the crystal of a macromolecule contains 1010 molecules and about 1010  
photons are required to produce a diffraction pattern, then each individual molecule 
will diffract only one photon. When crystals of the sample are exposed to a 
monochromatic and collimated beam of X-rays, electrons in the molecule scatter the 
beam and an image of the spatial distribution of the molecule’s electrons is obtained 
that provides a full picture of the molecule as well as the atomic coordinates of the 
molecule. These coordinates are obtained by the superimposition of the experimental 
electronic density contours on a stick drawing representing the underlying molecular 
structure. Computer software is used to construct the stick drawing in which the 
positions of individual atoms are manipulated until they fit well with the 




coordinates is called fitting the map. The accuracy of the model is checked by 
calculating the diffraction pattern of the model and compared with the observed 
diffraction. The reliability factor (RF) is then calculated from the model that provides 
the objective measure of how well the model agrees with the observed data. 
Nuclear magnetic resonance (NMR) is also a high resolution technique used 
to determine three dimensional structures of macromolecules in solution at atomic 
level and to investigate the dynamic features and intermolecular interactions of the 
macromolecules (Ferentz & Wagner, 2000; Kay, 1998; Wüthrich, 1986, 1995; 
Zuiderweg, 2002). Although NMR-derived three dimensional structures are of 
slightly lower resolution than crystallography, NMR offers an advantage over 
crystallography because the NMR data are recorded in solution under near 
physiological condition. The NMR experiment is based on the atomic nuclei that 
possess a spin property. The nuclei with non-zero quantum number such as 1H and 
13C result in an NMR signal. The nuclei are oriented randomly in the absence of a 
magnetic field. When an external magnetic field is applied, the magnetic nuclei 
within the macromolecule adopt either an alpha spin or beta spin state. In an alpha 
spin state, the magnetic nuclei are oriented parallel to the magnetic field and have 
lower energy than in the absence of the external magnetic field. In contrast, the beta 
states in which the magnetic nuclei orientations oppose the external field are higher 
in energy than in the absence of the external field. When the nucleus of the molecule 
is irradiated with electromagnetic radiation, a nucleus with a low energy orientation 
can be induced to "transit" to an orientation with a higher energy. The absorption of 
energy during this transition is the basis of the NMR method. This absorption energy 
differs according to the chemical environment of different nuclei in the same 
molecule due to variations in the electron distribution within the molecule. NMR is 
used to study proteins in solution up to a size limit of ~ 35 kDa. Structural studies of 
large proteins and protein complexes are a challenge for NMR and the development 
of NMR techniques for the investigation of these larger molecular sizes is of 
considerable interest, for example for large proteins that cannot be crystallized, or of 
dynamics and molecular interactions in large complexes. 
Electron microscopy is a low resolution method that operates on the same 
basic principle as a light microscope, but uses an electron beam instead of light. 
Light microscopy uses a magnifying glass lenses to focus a light beam emitted from 




lenses to focus an electron beam on a very thin sample. This intense beam of 
electrons travels through the sample and creates a projection of the macromolecules 
on a fluorescent screen, a photographic film or a light sensitive sensor such as a 
charge-coupled device (CCD) camera. If many projections of different views of the 
molecule become available, they are computationally combined to approximate the 
three dimensional structure. Using TEM, structural information can also be deduced 
by obtaining the electron diffraction pattern of a sample. In recent years, different 
TEM techniques have yielded high resolution structures (Gonen et al., 2004, 2005). 
Disadvantages of this technique include radiation damage, sample preparation 
difficulties and requirements of extensive computational image processing.  
 
(3.2) Analytical ultracentrifugation 
          Analytical ultracentrifugation (AUC) is a versatile, powerful and accurate 
technique for characterizing the solution state behaviour of macromolecules. Under a 
sufficient centrifugal force, molecules with different sizes and shapes move with 
different velocities and hence exhibit different sedimentation coefficient values (s). 
Many molecules have sedimentation coefficients “s” between 1 and 100 x 10-13 
seconds. The Svedberg unit (S) is defined as 10-13 second. In a high centrifugal field, 
the molecules start sedimenting towards the bottom of the cell, resulting in a 
decrease in the concentration at the meniscus and an increase in concentration at the 
bottom. This is called a sedimentation velocity experiment.  When a weak centrifugal 
field is applied, the process of sedimentation is opposed by the process of diffusion. 
After an appropriate time, equilibrium is obtained between these two opposing forces 
and no further changes occur with time. This is called sedimentation equilibrium. 
When AUC is coupled with appropriate data analysis methodologies, it can be used 
to determine sample purity, characterizing the assembly and disassembly mechanism 
of bimolecular complexes, determining subunit stoichiometries, detecting and 
characterising macromolecular conformational changes, and measuring equilibrium 
constants and thermodynamic parameters for self- and hetero-associating systems 
(Cole & Hansen, 1999; Harding & Winzor, 2001). This method is applicable to 
molecules with molecular weights ranging from several hundreds up to many 
millions of daltons. No other method is capable for providing such a wide range of 
information. In contrast to many biophysical techniques such as electron microscopy 




information on macromolecules in solution under near physiological conditions. 
Analytical ultracentrifugation is not only applicable to proteins, nucleic acids and 
carbohydrates but to any molecule whose absorbance or refractive index differs from 
that of the solvent.   
 
(3.2.1) Instrumentation 
Historically, analytical ultracentrifugation (AUC) was a central technique in 
the development of biochemistry and molecular biology. It was first developed in the 
1920s by Svedberg (Svedberg & Pedersen, 1940). During the last eight decades, 
more advances have been made in relation to the technical implementation of 
analytical ultracentrifuges (Schachman, 1959), the theoretical foundation of 
ultracentrifugation in the thermodynamics and physical chemistry of macromolecules 
(Tanford, 1961), the mathematical analysis of ultracentrifugation experiments 
(Fujita, 1975), and the application of AUC to the study of proteins (Cole et al., 
2008). 
Beckman-Coulter Instruments has introduced two analytical ultracentrifuges, 
the XL-A and the XL-I. The XL-A has only UV and visible absorption optics for the 
detection of biopolymers (Figure 3.1) (Giebeler, 1992), while the XL-I has integrated 
both absorbance and Rayleigh interference optics (Furst, 1997). The absorbance 
optical system uses a high intensity xenon flash lamp and a scanning monochromator 
that detects the macromolecules at wavelengths ranging between 190 and 800 nm 
(Figure 3.1). The xenon flash lamp moves radially along the length of the sector to 
scan different positions of the solute. A slit below the sample moves to allow the 
light through to the cells. Thus AUC can be used for wavelength scans at a fixed 
position in the cell, as well as for radial scans at a fixed wavelength. The absorbance 
optics gives good results for macromolecules with a strong chromophore. For 
example it detects proteins/peptides by measuring the absorbance in the far UV (230 
nm due to amide bond or 280 nm due to aromatic amino acid residues). Proteins at 
concentrations as low as 10-15 µg/ml can be characterized with good signal to noise 
ratio (Cole et al., 2008). Similarly, nucleic acid can also be studied in the same 
concentration by measuring the absorbance at 260 nm. The beauty of this technique 
is that it can be applicable to samples containing two or more components with 
different absorption spectra i.e. proteins and nucleic acids. In such a case, data can be 

























The Rayleigh interference optical system is based on the refraction of light as 
it moves from one medium to another medium. When two beams of light from the 
same source are passed through different media, they refract to different extents. An 
interference fringe pattern is produced by superposition of the emergent beams of 
light from the two media. This optical system detects all biological macromolecules 
lacking intense chromophores through their changes in refractive index. Interference 
optics is useful for both sedimentation velocity and sedimentation equilibrium experi
ments. 
 
(3.2.2) Experimental applications 
An analytical ultracentrifuge can be used to perform two different types of 
experiments, namely sedimentation velocity and sedimentation equilibrium. Both 
sedimentation velocity and sedimentation equilibrium measurements provide 
complementary information, and it is often useful to apply both techniques to a given 
problem. For proteins and nucleic acids to be analysed, sample concentrations 
ranging from 10 µg/ml to 5 mg/ml are required. It requires only a small volume of 
the sample, i.e. 420 µl for sedimentation velocity experiments, 110 µl for standard 3-
mm column sedimentation equilibrium experiments and 15 µl for short column 
equilibrium experiments. The ideal ionic strength of a buffer for proteins should be 
137 mM to correspond to physiological blood buffer. Before sample analysis, the 
sample should be equilibrated with the buffer by using dialysis bags of a specific 
molecular weight cut off or size exclusion gel filtration, after which the equilibrated 
buffer should be put in the reference cell sector. 
 
(3.2.2.1) Sedimentation velocity 
(3.2.2.1.1) Brief overview 
  Sedimentation velocity observes the separation of macromolecules due to 
their different rates of migration in the centrifugal field. Sedimentation velocity is a 
hydrodynamic technique which is sensitive to both the mass and shape of the 
macromolecules.  
Sedimentation velocity cells consist of a double-sector centrepiece with a 
height of 12 mm and are cylindrical in shape (Figure 3.2).  One sector is used for the 
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is filled slightly more than the sample sector so that the reference meniscus does not 
obscure the sample meniscus. 
When a high centrifugal force is applied, the solute molecules start moving 
from the meniscus towards the bottom of the centrifuge cell in a sedimentation 
velocity experiment. A series of scans are recorded at regular interval to determine 
the rate of movement and broadening of the boundary as a function of time. The 
centrifugal force on the solute is partly counterbalanced by the buoyant force of the 
displaced solvent. The net sedimentation behaviour of macromolecules in a 
centrifugal field is described by the Svedberg equation:  
 
(Eq. 3.1)   ( ) NfMrvs ρνω −== 12  
 
This Svedberg equation indicates that the rate of sedimentation, v, is dependent on 
several factors, the strength of the centrifugal field, ω2r (where ω is angular velocity, 
r is the radial distance from the centre of rotation); the molecular mass, M; the 
molecular size and shape; the density of the solvent, ρ; the partial specific volume of 
the solute, ν . The frictional coefficient, f, is directly related to macromolecular size 
and shape. As the sedimentation coefficient, s, is dependent on shape of the 
macromolecules, therefore globular proteins have higher “s” values than elongated 
ones (Perkins et al., 2005).      
A moving boundary is formed when the solute molecules start sedimenting 
from the meniscus towards the bottom of the centrifuge cell (Figure 3.2). Because the 
moving boundary sediments and diffuses with time, it begins to spread as the 
experiment progresses. The combination of sedimentation and diffusion in the cell is 
described in terms of the flow, J 
 
(Eq. 3.2)   J = sω2rc – D (dc/dr) 
 
Where s is the sedimentation coefficient, D is the diffusion coefficient, c is the solute 
concentration and dc/dr is the solute concentration gradient. From this theoretical 
overview it can be seen that sedimentation velocity experiments can used to 




Before applying a centrifugal force, the concentration of macromolecules is 
uniform throughout the centrifuge cell and dc/dr = 0. After the application of a 
sufficient centrifugal force, the boundary forms and moves towards the bottom of the 
cell at rates proportional to the sedimentation coefficients of the components in the 
sample. The boundary spreads due to diffusion as the experiment progresses. 
Sedimentation velocity experiments are usually conducted at very high rotor speed to 
minimize the effects of diffusion and to enhance the hydrodynamic separation. If a 
low rotor speed is applied, or if small molecules are studied, diffusion effects will 
become dominant and the concentration distributions will exhibit broad features that 
lead to an equilibrium state in which the sedimentation is effectively balanced by 
diffusion throughout the entire solution column. 
 
(3.2.2.1.2) Data analysis methods 
         For the analysis of the sedimenting components in a sample, several methods 
have been developed. These methods include the integral sedimentation coefficient 
distribution G(s) (van Holde & Weischet, 1978), the dc/dt method for calculating a 
differential apparent sedimentation coefficient distribution g(s*) (Stafford, 1992), 
and the sedimentation coefficient distributions c(s) (Scott & Schuck, 2005).  
The G(s) method is an integral sedimentation coefficient distribution method 
used for qualitative analyses of sedimentation velocity experiments. This method is 
implemented in ULTRASCAN and SEDFIT software. In the G(s) method the first 
step is to divide the boundary of each scan into 20 to 50 horizontal divisions that are 
evenly spaced between the baseline and the plateau. Extrapolating the apparent s 
calculated at each boundary division to infinite time, the actual s is obtained at each 
boundary division (Figure 3.3a). The drawback of this method is that it requires a 
subset of experimental scans that exhibit clear solution and solvent plateaus, hence 
permitting boundary divisions. This is not always used for the analyses of peptides 
and small proteins. 
The dc/dt approach is the differential sedimentation velocity data analysis 
method used for calculating differential apparent sedimentation coefficient 
distribution g(s*). The g(s*) are obtained by first subtracting pairs of scans to 
generate a set of ∆c/∆t data and then the differences are normalized to subtract any 
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g(s*) versus s* (Figure 3.3b). The g(s*) distributions closely resemble 
chromatographs and can be examined visually to determine whether the sample 
contains a single species (single sharp peak) or many species (multiple peaks). The 
g(s*) method can be computed with DCDT+ developed by J. Philo 
(http://www.jphilo.mailway.com/dcdt+.htm). The main advantage of the g(s*) 
method is simplicity and the elimination of time-independent baseline components 
resulting in an increase in the signal to noise ratio. The main disadvantages are the 
limitations in the number of scans to avoid distortion of the peak shape, and the 
effect of diffusion in causing broadening of the peaks that can hide sample 
heterogeneity. The g(s*) distributions can be fitted to a Gaussian function for single 
homogenous species or a tightly associated complex.  The curve from the Gaussian 
function gives two important results. The centre of the peak gives ‘s20,w’ while the 
width of the peak gives the molecular weight M (Cole & Hansen, 1999; Perkins et 
al., 2005; Scott & Schuck, 2005).       
The c(s) analysis is also a differential sedimentation coefficient distribution 
method used for calculating the sedimentation coefficient of each species in the 
sample by a direct boundary fit approach according to the Lamm equation (Lamm, 
1929). This method is computed using SEDFIT software (Dam & Schuck, 2004; 
Schuck, 2000). In this method, first, the program creates a grid of sedimentation 
coefficients values covering the expected range of interest. After creating the grid, 
the program produces a scaling relationship between sedimentation coefficients and 
diffusion coefficients by assuming a constant shape and an equal frictional ratio 
(f/fO), for all species. The program then simulates the sedimentation boundaries for 
each point using the Lamm equation. The data are then finally fitted to a sum of these 
Lamm solutions using a procedure termed least-squares fitting procedure to define 
the concentration of each species in the grid. The resulting distribution functions 
obtained in this method are spiky. A regularization procedure is used to produce a 
smoother distribution function from this spiky distribution. This methods provides an 
estimated f/fO value, an estimated molar mass distribution c(M), information on the 
shape of the macromolecules from the size distribution c(s), the residual of the fit (i.e 
the magnitude of deviation of the model from the data points) and the residual 
bitmap in order to assess if the c(s) model adequately describes the data (Dam & 
Schuck 2004, Figure 3.3c). Because the c(s) distribution plot is obtained from 




parameters (i.e. boundary fits, r.m.s.d. values, and residuals bitmaps) to obtain a 
model that adequately describes the experimental data. Generally, the c(s) analysis 
gives an accurate result only for dilute monodisperse samples or non-interacting 
protein mixtures.  
The main advantage of the c(s) method over the dc/dt method is that there is 
no restriction and limitation on the number of scans that can be included in the 
analysis. The other major advantages of this method are the excellent resolution, high 
sensitivity and deconvolution of diffusional peak broadening from the c(s) 
distribution. For an interacting mixture of two macromolecules, it is sometimes 
difficult to obtain accurate sedimentation coefficient values for each species in the 
sample due to reaction boundaries. Reaction boundaries correspond to the co-
sedimentation of both free and complexed species if the chemical equilibrium rate 
between these species is comparable with the sedimentation rate (Dam & Schuck, 
2005). 
 
(3.2.2.2) Sedimentation equilibrium 
(3.2.2.2.1) Brief overview 
         Sedimentation equilibrium experiments are performed at lower rotor 
speeds than sedimentation velocity experiments. When solute molecules are 
subjected to a low centrifugal field, the molecules begin to sediment towards the 
bottom of the cell. The movement of these sedimenting solute molecules are 
significantly opposed by the process of diffusion (Figure 3.4a). Both the two 
opposing process balance each other after appropriate period of time and eventually 
an equilibrium concentration distribution of macromolecules is obtained throughout 
the cell (Figure 3.4b).  
 For an ideal noninteracting single component system, the equilibrium 
distribution obtained is an exponential function of the buoyant mass of the 
macromolecule, M(1 – v¯ρ) as described by the equation: 
 
(Eq. 3.3)  c(r) = c(a) exp[M((1 – v¯ρ)ω2(r2 – a2)/2RT 
   
Where c(r) is the sample concentration at a radial position r, c(a) is the sample 
concentration at the meniscus, a is the radial distance of the meniscus, M is the 





























































solvent density, ω is the angular velocity and R and T represent the gas constant and 
absolute temperature, respectively. The measurement of molecular mass for an ideal 
single component system is made by the linearization of the above equation; the 
logarithm of c(r) plotted against r2 yields a slope of M(1– v¯ρ)/2RT. If the 
macromolecular equilibrium is more complex or if the solution is thermodynamically 
nonideal, these factors will also influence the concentration gradient formed in a 
sedimentation equilibrium experiment. In each of these cases the above equation has 
been modified to account for these situations (Cantor & Schimmel, 1980; van Holde, 
1975). If the oligomeric species are in reversible equilibrium, the stoichiometries, 
equilibrium constants and the thermodynamic parameters (∆H, ∆S) that define the 
interactions can be obtained. 
 
(3.2.2.2.2) Data analysis 
      Generally, two main approaches are used for analysis of sedimentation 
equilibrium data, namely the model-independent and model-dependent approaches. 
The model-independent approach is most useful at the initial stages of sample 
analysis to determine sample behavior. This approach is also useful for comparative 
analysis of samples that are too complex to be fitted directly by model-dependent 
methods. In the model-independent method, ln c is plotted versus r2 (Cantor & 
Schimmel, 1980; Ralston, 1993). According to the equation  
 
(Eq. 3.4)  c(r) = c(a) exp[M((1 – v¯ρ)ω2(r2 – a2)/2RT 
 
the slope of the line is directly proportional to M. The slope of the ln c versus r2 plot 
will be linear if the sample is ideal and monodisperse with respect to M. The 
complexity of the sample can be determined by performing non-global nonlinear 
least-squares of a single sedimentation equilibrium c(r) gradient.  
       In contrast, the model-dependent analysis approach involve direct fitting of the 
sedimentation equilibrium concentration gradients to mathematical functions 
describing various physical models, such as a single ideal species, a monomer self-
associating system, or an A + B     C hetero-associating system. The direct fitting 
method is used for detailed quantitative analysis of sedimentation equilibrium data.  
This approach provides the best-fit values and the associated statistical uncertainties 




association constants. This provides a basis to discriminate among alternative 
physical models (Johnson and Straume, 1994, Johnson and Faunt, 1992).  
 
(3.3) X-ray solution scattering  
          Solution X-ray scattering is a low resolution structural technique that provides 
structural information on the size, shape, and interactions of biological 
macromolecules and other polymer or detergent systems in random orientations in 
solution (Perkins et al., 2008; Doniach, 2001; Svergun and Koch, 2003; Koch et al., 
2003). It has been used to determine the structure of proteins, nucleic acids, 
polysaccharides and their complexes in solution under near physiological conditions 
without the need to crystallize the molecules. The major advantage of this technique 
is its capability to provide structural information on partially or completely 
disordered systems. Although the other structural determination technique such as X-
ray crystallography and NMR produce high resolution atomic models, they have 
experimental requirements that limit their application to large scale structural studies: 
X-ray crystallography requires crystals of good diffraction quality, while NMR is 
limited to only small soluble proteins. In contrast, the solution scattering technique 
offers the possibility of varying chemical and physical conditions in solution and of 
exploring structural transitions that are difficult to induce and study by X-ray 
crystallography and NMR. This technique is applicable to molecules with molecular 
weight ranging from a few kilodaltons to several million daltons.  
 
(3.3.1) X-ray solution scattering and instrumentation 
Synchrotron radiation is produced by moving electrons that follow a curved 
path and are accelerated to speeds close to the speed of light. First, the electrons 
produced by a triode electron gun are accelerated to a 2000 MeV in a linear 
accelerator. Electrons are transmitted to a circular accelerator called a booster 
synchrotron (Figure 3.5a). In the booster synchrotron, the electrons are accelerated to 
a high energy level of 6.0 GeV using a radio frequency system. Electrons are then 
finally injected into a storage ring having a circumference of 844.4 m which includes 
both straight and curved sections. Electrons within the storage ring are forced by 
bending magnets, undulator magnets and focusing magnets to circulate at relativistic 
speeds (Figure 3.5b). The bending magnets deflect the electrons from their straight 















































which force the electrons to follow an undulating, or wavy trajectory.  The beams of 
radiation emitted from different bends overlap and interfere to produce even more 
intense X-ray beams than that produced by bending magnets. The focussing magnets 
are fixed in the straight section of the storage ring and are used to focus the beam of 
electron to keep it small and well defined. In summary, these circulating electrons 
emit white light comprised of all wavelengths including X-rays tangentially from the 
storage ring. Because the lifetime of the electron is of the order 12-14 hours, storage 
ring refills are performed several times a day.  
Small angle X-ray solution scattering experiments are performed at Grenoble, 
France, using beamline ID02A. The ID02 instrument takes a white beam of X-rays 
from the storage ring, which is then focussed and monochromated before reaching 
the sample. The maximum photon flux at the sample position is of the order 3 x 1013 
photons/second/100 mA. The ID02 camera consists of a source, optical system, 
cryogenic (liquid nitrogen) cooled Si-111 channel-cut monochromator, a focusing 
toroidal mirror, collimation and guard slits, a sample cell and a detector. A cryogenic 
(liquid nitrogen) cooled Si-111 channel-cut monochromator reduces the background 
radiation from the storage ring and the collimation and guard slits are set to define 
the maximum size of the beam stop and the minimum observable scattering. In order 
to reduce the radiation damage, fresh sample is exposed to the beam continuously 
during data collection through a 1.75 mm wide quartz capillary controlled by a 
mechanically-operated syringe. X-ray scattering measurements depend upon the 
sample-detector distance of 0.5 to 8 m, which is adjusted in order to get the desired Q 
range (Perkins et al., 2008). The detector is based on an image-intensified CCD 
device. Scattered X-ray photons fall upon on a phosphorus surface and they are then 
converted into visible photons by an image intensifier device. Measurements of 
incident and transmitted main beam intensities are important and are obtained using a 
diode device placed on the beam stop to protect the detector from the main beam at 
zero scattering angle. The detector is connected with a computer for data 
accumulation which in turn is connected to a work station for data storage and 
processing. Online data reduction using automated software is used to convert the 2D 
diffraction pattern into a 1D data curve for visual inspection to avoid radiation 
damage. The CCD takes up to 10 frames per second of 1024 x 1024 pixels 




camera is shown in Figure 3.6. The second camera experimental hutch 2 (EH2) is 
used in this thesis.  
 
(3.3.2) Basic principles 
          The basic principle of small angle solution scattering is to diffract X-ray 
photons elastically from molecules in solution and to record the scattering intensity 
as a function of the scattering angle. When a sample is irradiated with a highly 
collimated, monochromated beam of X-rays, a two dimensional circularly symmetric 
pattern is recorded on a two dimensional area detector placed behind the sample. The 
radially averaged intensities I(Q) are measured as a function of scattering vector Q 
 
(Eq. 3.5)    Q = 4π sin θ/λ 
 
where 2θ = scattering angle and λ = wavelength. Scattering views structures in 
random orientation to a low structural resolution of about 2-4 nm from data obtained 
in reciprocal space in a Q range between 0.05 and 2 nm-1 (Figure 3.7). In order to get 
absolute scattering intensities, several important corrections are applied to the data: 
(1) subtraction of CCD dark current and readout noise, (2) corrections of the spatial 
distortion induced by image intensifier, and (3) normalization of raw intensities to 
absolute values. The later step can be done by Lupolen, a calibrated standard 
scatterer with an absolute scattering intensities in the maximum which is independent 
of photon energy (Kratky et al., 1966). 
 
(3.3.3) Data analyses 
Once the scattering curve I(Q) is corrected, the data is analysed by two 
methods, i.e. Guinier analysis and distance distribution function P(r), that gives 
complementary information.  
 
(3.3.3.1) Guinier analysis 
Guinier method gives the radius of gyration, RG, which measures the degree 
of overall structural elongation in solution and the cross-sectional structure, RXS, 
which measures bending in the macromolecules being studied at low Q range (in the 


















































ins et al., 2
out of the
. The undu
s uses a cry
ce a focuse





































































dimension) (Glatter and  Kratky, 1982; Guinier, 1939 ). The Guinier plot is obtained 
by plotting I(Q) vs Q2: 
 
(Eq. 3.6)   ln I(Q) = ln I(0) - RG2 Q2/3 
 
where I(0) is the intensity at zero scattering angle. The radius of gyration RG, a 
measure of the structural elongation of the macromolecule, is obtained from the slope 
of the line if the internal inhomogeneity of scattering densities is neglected. The RG is 
defined as the root-mean square distance of all the scattering centres in the 
macromolecules from its centre of gravity. The RG is used to determine the 
anisotropy ratio, RG/RO, where RO is the RG of a sphere of equal volume to the 
macromolecule. The anisotropy ratio obtained for globular proteins by X-ray 
scattering is approximately 1.28 (Perkins, 1988). The intensity at zero scattering 
angle I(0) is proportional to Mr2 and this relationship can be used to calculate 
molecular weight and oligomeric state of macromolecule by dividing I(0) by its 
concentration: I(0)/c where  c is the sample concentration. 
When the structure of the macromolecule is elongated, the radius of gyration 
of the cross-sectional structure RXS and the cross-sectional intensity at zero angle 
[I(Q).Q]Q-->0, (Hjelm, 1985), at  intermediate Q values (between Q values of 0.3 to 
1.0 nm-1, depending on the macromolecular dimension), are obtained from the 
equation below:  
 
(Eq. 3.7)  ln [I(Q).Q] = ln [I(Q).Q]Q--> 0  - R2XS Q2/2 
 
where RXS is the cross sectional radius of gyration which measures the shorter axes of 
an elongated molecule. The maximum length of the macromolecule, L, can be 
calculated from the Guinier parameters using the equation below: 
 
(Eq. 3.8)       L = √12(RG2 - RXS2) 
 
(3.3.3.2) Distance distribution function P(r) 
The distance distribution function P(r) curve calculated from the full 
scattering curve provides the radius of gyration RG value and maximum length of the 




(between Q of 0.05 and 2 nm-1) is applied to yield the distance pair-distribution 
function P(r) which represent the structure in real space with units of nm. This is 
carried out according to the following equation: 
 
                                                           ∝   
(Eq. 3.9)  P(r) =  1/ 2π2 ∫ I (Q) Qr sin(Qr)d(Q) 
                                                           0 
 
Where P(r) corresponds to the distribution of distances r between any two volume 
elements within macromolecule. GNOM software is used to transform the scattering 
data indirectly in real space which yields scattering curve P(r) (Semenyuk and 
Svedgun, 1991). 
This corresponds to the summation of all the distances r between the atoms 
within the macromolecule. The point at which P(r) approaches zero gives the 
maximum length L of the macromolecule (Figure 3.8). P(r) also gives an alternative 
calculation of the RG and I(0) values from the full scattering curve I(Q) that should 
agree with those from Guinier analyses. The maximum length L can be imprecise 
because of the lower intensity at larger r values. The maxima M in the P(r) curve are 
the most frequently occurring distances between pairs of atoms within 
macromolecules. This provides information on the shape and oligomeric state of 
macromolecules. For example if the r value at M is half of the length of the monomer 
macromolecule, the macromolecule is spherical. Because P(r) can be calculated 
easily from the crystallographic atomic coordinates, it is also useful for comparing 
the solution structure and the crystal structure or for examining the validity of a 
model.  
Figure 3.9a-d shows P(r) functions for a monomer, and various homodimer 
arrangements of this monomer with a decreasing cross-section towards the ends. A 
parallel arrangement of the dimer gives a maximum dimension in a similar range to 
that of the monomer (Figure 3.9a), whereas a linear arrangement gives a maximum 
dimension almost twice of the monomer dimension (Figure 3.9b). The two 
rectangular arrangements of the dimer namely T-type (Figure 3.9c) and L-type 
(Figure 3.9d) lie between these two arrangements. The P(r) distribution maximum is 
located more at larger r values for L-type than for T-type dimer arrangements 
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dimer formation. This hump at larger r values is larger for L-type structures than T-
type (Figure 3.9c,d). 
 
(3.4) Biomolecular modelling 
Constrained scattering modelling is the generation of randomised structural 
models that best accounts for the observed scattering curve and calculated 
experimental parameters after filtering out the poor fit models. Since the X-ray 
solution scattering is a low resolution technique (2-4 nm), constrained scattering 
modelling is used to give medium resolution structure of the macromolecules with an 
improved precision of 0.5 - 1 nm compared to the use of no modelling. These models 
are generated based on the available atomic coordinates that represent the position of 
each atom in the three dimensional structure of the macromolecules determined by 
X-ray crystallography or NMR. If crystal or NMR structures are not available, 
homology models can be used to generate the models. Homology modelling is the 
creation of atomic-level models based on known sequences and atomic structures of 
homologous domains that best represents the three dimensional structure of the target 
domain. Homology modelling can be performed by a widely used modelling 
software procedure called MODELLER (Sali & Blundell, 1993). Constrained 
scattering modelling is able to rule out poor-fit structures and validate the scattering 
data by determining a family of best-fit structures that show best curve fitting with 
the experimental curve. Because the best fit structures are based on the observed 
scattering data, they can provide experimentally-derived structural and functional 
information on the macromolecule (Perkins et al., 2008). 
 
(3.4.1) Analysis of protein/glycoprotein composition 
Before starting solution scattering modelling, it is essential to extract 
information from the amino acid and monosaccharide composition of the 
protein/glycoprotein using the program SLUV (Perkins, 1986). This program gives 
the partial specific volume, estimated molecular mass and molecular volume (both 
hydrated and unhydrated). This program also gives the extinction coefficient (at a 
wavelength of 280 nm) that calculated from the tryptophan, tyrosine and cysteine 
content of the protein (Perkins, 1986). The extinction coefficient can be used for 





(3.4.2) Creating atomic models 
The first step is to find high resolution atomic coordinates of the 
macromolecule determined by X-ray crystallography or NMR. For proteins, over 
65,000 crystal and NMR atomic structures are available in the PDB. If these 
structures are suitable for the protein or protein domains being studied, these are used 
as the basis for the models created by an automatic modelling procedure. If the actual 
high resolution structures are not available in the PDB, these individual domains are 
then modelled based on the known structures of homologous domains. If high 
resolution atomic co-ordinates for the macromolecules being studied (other than 
proteins) such as polysaccharides are not available for the whole macromolecule, the 
small oligosaccharide fragments can be joined to make a fully extended molecule. 
The extended molecule can then be used to as a template to generate randomized 
conformers. 
After the construction of an initial atomic structure of the macromolecule, a 
set of 2000-10,000 molecular models is generated in randomised conformations. For 
proteins possessing fixed domains, each peptide between the fixed domains 
designated as linker is generated in an extended starting conformation using 
INSIGHT II 98.0 molecular graphic software (Accelrys, San Diego, CA, USA). For 
each of these linkers, a library of 5000 randomised linker conformations is generated 
using the same software. For proteins containing putative glycosylation sites, 
available three dimensional structures of N- and O-linked oligosaccharide chains are 
positioned properly at the glycosylation sites on the protein in the starting model. In 
order to obtain a wide range of conformations, the peptide structures are subjected to 
molecular dynamics for 300 iterations at 773K. An automated modelling procedure 
is then used to select linkers randomly from the linker library in order to join the 
domains to generate a series of complete molecular models. Typically, 2,000-10,000 
trial-and-error models for the intact macromolecule are generated in one search.  
For the polysaccharide being studied, conformational models in totals of 
5,000-80,000 are created from the linear model by changing the phi (Φ) and psi (Ψ) 
angles of the glycosidic bonds. This was achieved using Discovery Studio (Accelrys, 
San Diego, CA, USA).  The Φ and Ψ angles were randomised to take values in a 
maximum range of -45° or 45° from their starting values using the TorsionKick 
function in a PERL script that was modified from the ExtractAngle.pl script provided 




San Diego, CA, USA). For example, for the heparin fragment dp36, where dp stands 
for degree of polymerisation, a total of 18 Φ and Ψ angles for IdoA-GlcNS and 17 Φ 
and Ψ angles for GlcNS-IdoA were modified in this way. In order to remove the 
steric overlap clashes between the atoms, minimization was carried out using a 
constant force field known as “Dreiding” provided with Discovery Studio. Dreiding 
is useful in predicting structures for molecules where there are little or no 
experimental data, by providing accurate geometries and reasonably accurate 
conformational barrier for various organic, biological and main-group inorganic 
molecules.  
 The force field refers to the functional form of the potential energy 
expression and the entire set of parameters used to describe the potential energy of 
the molecule (Ermer, 1976). Because in molecular modelling the energetic penalties 
are associated with the deviation of bonds and angles away from the reference or 
equilibrium values, the force field is used to describe the energy changes as bonds 
are rotated with respect to bonded and non-bonded interactions. The Dreiding force 
field uses general force constant and geometry parameters that are based on simple 
hybridisation rules rather than on individual force constants and geometric 
parameters that depend on the particular combination of atoms involved in the bond, 
angle, or torsion terms (Mayo et al., 1990). A concept that is more common to most 
force fields is that of an atom type which contains information about its hybridisation 
state and sometime the local environment. Atoms with the same atom type are 
treated identically in the molecular mechanics force field. The atom types in the 
Dreiding force field are denoted by five characters:   
●   The first two characters represent the elemental symbol (for example C_ for 
carbon, Sn for tin), where the elements with one letter have an underscore. 
●   The third character represents hybridization state or geometry (for example 1 = 
linear (sp1), 2 = trigonal (sp2), 3 = tetrahedral (sp3) and R = an sp2 involved in a 
resonance. 
●    The fourth character represents the number of implicit hydrogen (for example 
C_R2 is a resonant carbon with two implicit hydrogens, and C_32 is tetrahedral atom 
with two implicit hydrogens atoms. 
●    The fifth character indicates other special characteristic such as oxidation state. 
For an arbitrary geometry of a molecule, the potential energy is expressed by 




depend on specific bonds of the structure whereas the non-bonded interactions 
depend on the distance between the atoms. The total potential energy is given as: 
 
(Eq. 3.10)    E  = Eval   +  Enb  
 
In the Dreiding force field, the potential energy (Eval) of valence interactions consists 
of the following terms: 
 
(Eq. 3.11)    Eval  =  EB  +  EA  +  ET  +  EI 
 
Where EB, EA, ET and EI are the bond energies for bond stretching, angle bending, 
torsion (dihedral) angle and the inversion respectively. 
The potential energy of non-bonded interactions consists of the following terms: 
 
(Eq. 3.12)    Enb  =  Evwd  +  EQ  +  Ehb 
 
Where Evwd, EQ and Ehb are the bond energies for van der waals interactions, 
electrostatic interactions and hydrogen bonds. The Dreiding force field provides 
several functional forms for each of these energy terms which are explained in detail 
elsewhere (Mayo et al., 1990). Because randomised models created by TorsionKick 
function showed large deviation from the standard values (which was shown visually 
by steric overlap clashes between the atoms), the Dreiding force field was used to 
bring these deviated values to the accepted global energy values.  
 
 (3.4.3) Sphere modelling 
After making molecular models, the next step is to calculate the scattering 
curve of all the models and fit to the experimental curve. First the atomic coordinates 
of models are converted into small sphere models consisting of small non-
overlapping spheres of uniform density of the same total volume as the original 
atomic volume (Figure 3.10c). This conversion is performed by placing the atomic 
coordinates within a three dimensional grid of cubes. The size of the cubes and the 
number of atoms that each cube contains is defined by the user and are tested 
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close to the unhydrated volume of the macromolecule as possible. The unhydrated 
volume is calculated from the macromolecular composition using SLUV program 
(Perkins, 1986). Typically, the cube side length of 0.5 to 0.6 nm is used to produce 
an unhydrated sphere model. Once a grid size has been determined, it is kept 
constant in the automated curve fitting searches. 
Because neutron experiments in 2H2O buffer do not detect the hydration shell, 
the unhydrated sphere models are directly used to calculate scattering curve. No 
neutron data was used in this thesis. In X-ray scattering experiment, the hydration 
shell is readily detected and therefore the unhydrated sphere models are hydrated 
before scattering curve calculation. The hydration shell is based on the usual 
assumption of 0.3g H2O/g of glycoprotein and corresponds approximately to the 
mass of a monolayer of water molecules surrounding the macromolecule (Perkins, 
2001). Spheres corresponding to this monolayer of water molecules are added evenly 
over the surface of the unhydrated sphere model to achieve the desired hydration 
volume (Figure 3.10d). The hydration shell can be seen clearly by overlaying the 
unhydrated and hydrated sphere models.  
 
(3.4.4) Debye scattering curve calculation 
The X-ray scattering curve I(Q) is calculated using the Debye equation as 
adapted to spheres and assuming a uniform scattering density for the spheres: 
(Perkins & Weiss, 1983), 
 
where g(Q) is the squared form factor for the sphere of radius r, n is the number of 
spheres filling the body, Aj is the number of distances rj for that value of j, rj is the 
distance between the spheres, and m is the number of different distances rj. Briefly 
the Debye equation is amended to consider the spheres of the model rather than the 
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atoms in the molecule. The g(Q) function is therefore determined by calculating the 
distances r from each sphere to the remaining spheres and summing the results 
(Equation 3.14). A single density scattering curve calculation is applicable to 
proteins and glycoproteins with low carbohydrate content, provided that the 
comparisons between the experimental data sets are consistent for the X-ray curves. 
If  the carbohydrate content of a glycoprotein is high, differences in the scattering 
densities of the protein and the carbohydrate moieties may give rise to systematic 
deviation in X-ray curves. For such glycoproteins, models can be made using two-
density sphere models. This is not related to the work presented in this thesis, as no 
scattering models were generated for such glycoproteins. 
 
(3.4.5) Identification of best fit models 
After scattering curve calculation, the last step is the identification of best-fit 
models and removal of unsatisfactory models. To do this, all these models are 
subjected to the following four filter parameters: 
1. The automatic modelling procedure can produce models that possess unreasonable 
steric overlaps between domains or subunits. All those models having steric overlaps 
are readily detected by the grid transformation which will give too few spheres if 
significant overlap occurs. So all those models having less that 95% of the expected 
total spheres are removed, while models having at least 95% of the expected total of 
spheres are selected and subjected to the next filter parameter. 
2. The radius of gyration, RG and cross sectional radius of gyration, RXS values are 
determined from the calculated scattering curves using the same Q ranges as used for 
experimental Guinier fits. All the models having RG and RXS values of at least 95% of 
the experimental data are selected for the next filter parameter.  
3. The remaining good models are then filtered using a goodness-of-fit R-factor. An 
R-factor is calculated for a quantitative comparison of each model scattering curve 
I(Q)cal against experimental scattering data I(0)exp over the whole Q range, where 
I(Q)cal is set as 1000 (Figure 3.10d). The R-factor is given by the equation:  
 
(Eq. 3.15)             R =  
Σ | I(Q)exp – I(Q)cal |     x 100%        
                                                 





The R-factor is the goodness of fit between the calculated and experimental curves 
and is analogous to that used for the refinement of crystallographic models (Beavil et 
al., 1995). A good fit is considered to have an R-factor less than 10%. All these 
filtering parameters were carried out in a large spreadsheet with the geometrical steps 
used to define each model, the number of spheres in it, the RG and RXS values, and the 
R-factor values.  
 
(3.4.6) Calculation of hydrodynamic properties  
Sedimentation coefficient values monitor the degree of elongation of the 
macromolecule which is analogous to RG. The calculation of s020,w values for the best 
fit models corroborate the outcome of the scattering data. Two approaches are used 
to calculate the s020,w values. The first approach is to convert the atomic co-ordinates 
into small spheres and to subsequently add a hydration shell. So this is the same 
hydrated sphere model that is used for X-ray scattering fit. These hydrated sphere 
models are then subjected to HYDRO software program to calculate the s020,w values 
(Garcia de la Torre et al., 1994). The second approach is to subject the atomic co-
ordinates directly into HYDROPRO software program (Garcia de la Torre, 2000). 
HYDROPRO represents the macromolecule as a hollow shell with equal sized 
spheres representing the surface. In HYDROPRO, the recommended empirical value 
of 0.31 nm for atomic element radius for all the atoms represents the hydration shell 
at the macromolecular surface. Comparison of the modelled s020,w values with the 
experimental s20,w values validate the scattering models provided that the modelled 
s020,w values are within the error range of ± 0.21 S to that of experimental values 















Semi-rigid solution structures of heparin by constrained X-ray scattering 






















Heparin is a highly sulphated linear polysaccharide that is found in the 
granules of mast cells and granulated cells of organs such as the liver and intestine 
(Lane & Lindahl, 1989). Heparin is an analogue of heparan sulphate which mediates 
a wide range of biological and physiological activities through its interactions with 
proteins. These include the inhibition of blood coagulation (Lane & Lindahl, 1989), 
complement activation (Kazatchkine et al., 1981; Sharath et al., 1985), angiogenesis 
and tumor growth (Folkman et al., 1983; Crum, et al., 1985), antiviral activity 
(Holondniy et al., 1991; Shieh & Spear, 1994; Capila & Linhardt, 2002) and the 
release of lipoprotein lipase and hepatic lipase (Lane & Lindahl, 1989; Liu et al., 
1992). The breadth of heparin-protein interaction offers many potential strategies for 
therapeutic intervention at the cell-tissue-organ interface. The classical example is 
the frequent use of heparin in the clinic as an anticoagulant.   
The basic subunit of heparin is a disaccharide (dp2) of uronic acid and D-
glucosamine linked by a (1-4) glycosidic bond (Figure 4.1) (Capila & Linhardt, 
2002). The uronic acid can be either α-L-iduronic acid (IdoA) which accounts for up 
to 90% of heparin or β-D-glucuronic acid (GlcA) which accounts for up to 10% of 
heparin. The most common occurring heparin disaccharide contains three sulphate 
groups, which are located on the 2-OH group of IdoA, and on the 2-NH2 group and 
the 6-OH group of D-glucosamine. The high degree of sulphation and carboxylation 
makes heparin the most negatively charged macromolecule known in nature. Like 
heparin, heparan sulphate is a linear polysaccharide consisting of alternating uronic 
acid and α-(1-4)-D-glucosamine residues, but differs in exhibiting a reduced degree 
of sulphation (Figure 4.1). Unlike heparin, heparan sulphate is less modified and 
contains a higher proportion of N-acetylated saccharides (Gallagher & Walker, 1985; 
Hileman et al., 1998).  
Structural studies of heparin are essential because of the extensive number of 
reported heparin-protein interactions and their involvement in a broad range of 
pathophysiological processes. Up to now, molecular structures for heparin have been 
limited to small fragments (Capila & Linhardt, 2002). For free heparin, solution 
structures by NMR spectroscopy are available for heparin oligosaccharides (Mulloy 
et al., 1993) and synthetic pentasaccharides dp5 (Ragazzi et al., 1990). These 
revealed a linear structure. For heparin-protein complexes, the current availability 
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dp4 to dp10. These include crystal structures for acidic and basic fibroblast growth 
factors separately (Faham et al., 1996; DiGabriele et al., 1998), the complexes of 
acidic and basic fibroblast growth factors with their receptors (Pellegrini et al., 2000; 
Schlessinger et al., 2000), thrombin (Carter et al., 2005), antithrombin and the 
complex of antithrombin–S195A and coagulation factor Xa  (Jin et al., 1997; McCoy 
et al., 2003; Johnson et al., 2006; Langdown et al., 2009), foot and mouth disease 
virus (Fry et al., 1999) neurokinin 1 receptor (Lietha et al., 2001), annexins V and 
A2 (Capila et al., 2001; Shao et al., 2006), vaccinia complement control protein 
(Ganesh et al., 2004), and protein C inhibitor (Li & Huntington, 2008). Many of 
these crystal structures likewise show extended heparin conformations. At the 
opposite extreme of resolution, macroscopic solution structures for large 
polydisperse heparin fractions have been studied by X-ray solution scattering and 
analytical ultracentrifugation (Pavlov et al., 2003; Perez Sanchez et al., 2006). No 
structural information at a molecular level was reported for these larger heparin 
fractions. Fibre diffraction studies have also been reported for heparin 
oligosaccharides (Nieduszynski & Atkins, 1973; Atkins & Nieduszynski, 1977). 
  To extend our understanding of heparin structures, we require molecular 
structures for heparin fragments ranging from dp6 to dp36. These were obtained by 
applying small angle X-ray scattering and analytical ultracentrifugation in 
conjunction with constrained modelling as a powerful combination of three 
techniques to determine molecular structures (Perkins et al., 2008, 2009). This 
multidisciplinary approach is well-established for solution structure determinations 
of large multidomain complement and antibody proteins (Bonner et al., 2009), but is 
novel for oligosaccharides or polynucleotides. We show that heparin fragments 
starting from dp18 onwards become progressively more bent with increase in size. In 
solution, heparin structures are essentially extended and rigid, but possess enough 
flexibility in terms of bending to facilitate binding to a broad range of proteins in 
essentially preformed conformations. The results provide new insight on how heparin 
binds to proteins.  
 
(4.2) Results and discussion 
(4.2.1) Sedimentation velocity data analysis for the heparin fragments 
Six oligosaccharide fragments of heparin dp6 to dp36 were prepared in 
collaboration with Dr. Barbara Mulloy (National Institute of Biological Standards 
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and Control, Blanche Lane, South Mimms, Potters Bar, Hertfordshire, UK) (Material 
and methods: section 4.4.1). These fragments were purified through gel permeation 
chromatography using Biogel P-10 column (Figure 4.2). This elution profile shows 
that the dp6 and dp12 fractions eluted as well-resolved peaks, while the dp18, dp24, 
dp30 and dp36 fractions became less resolved with increase in size. The top fractions 
corresponding to each individual peak from Biogel P-10 column ran as single 
homogenous peak in analytical high performance size exclusion chromatography, 
which was performed as described (Mulloy et al., 1997) to determine the sizes of the 
oligosaccharide fractions (Figure 4.3).  
 Analytical ultracentrifugation (AUC) studies macromolecular structures in 
solution by following their sedimentation behaviour under a high centrifugal force 
(Cole et al., 2008). Both the shape of the six dp6-dp36 fragments at 0.5 mg/ml and 
their degree of polydispersity was analysed by AUC size distribution analyses using 
SEDFIT. Three rotor speeds were used to obtain better resolution of size distribution 
analyses of these fragments with no or minimum back diffusion effects and to check 
the speed dependence of the size distribution analyses. Using both absorbance and 
interference optics, here the size distribution analyses of these fragments at rotor 
speed of 40,000 rpm, 50,000 rpm and 60,000 rpm were performed. The absorbance 
data using rotor speed of 40,000 rpm gave a single peak with sedimentation 
coefficient s20,w values of 1.03 S for dp6, 1.38 S for dp12, 1.45 S for dp18, 1.54 S for 
dp24, 1.61 S for dp30 and 1.83 S for dp36 was observed (Figure 4.4a). The 
corresponding interference analyses at 40,000 rpm for dp6-dp36 also resulted in 
good boundary fits and single c(s) peaks with similar s20,w values of 1.22 S for dp6, 
1.60 S for dp12, 1.69 S for dp18, 1.74 S for dp24, 1.80 S for dp30 and 1.89 S for 
dp36 were obtained (Figure 4.4b).  
Using a rotor speed of 50,000 rpm, the absorbance data analyses reproducibly 
resulted in good boundary fits and revealed a single peak in each case with 
sedimentation coefficient s20,w  values of 1.01 S, 1.29 S, 1.43 S, 1.58 S, 1.62 S and 
1.77 S for dp6-dp36 in that order (Figure 4.5a). The correspondence interference data 
analyses also gave good boundary fits and single c(s) peaks with s20,w  values of 1.19 
S, 1.34 S, 1.42 S, 1.47 S, 1.60 S and 1.89 S for dp6-dp36 (Figure 4.5b). Data 
analyses at 60,000 rpm, using only interference optics, resulted in  single major c(s) 
peaks with s20,w values of 1.08 S for dp6, 1.19 S for dp12, 1.05 S for dp18, 1.19  S for 
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contaminant peak at interference s20,w  values of 1.3 S and 0.8 S for dp36 was 
observed both at 50,000 rpm and 60,000 rpm respectively. This contaminant peak 
was not observed at 40,000 rpm, indicating that this speed is comparatively lower to 
get better resolved s20,w  peaks. 
The peaks and their widths may be used to assess fragment polydispersity. In 
this regard, the interference optics showed better resolution and single narrow major 
peaks. The single peaks indicate that the six fragments are relatively homogenous in 
size. The similar peak widths from either absorbance or interference optics suggest 
that all six fragments showed narrow size distributions and are relatively 
homogenous, in agreement with the high performance size-exclusion 
chromatography described above. Although slight variation in the s20,w values of the 
absorbance and interference data were observed at different rotor speeds, the six 
averaged values (together with those for dp10 which was prepared in a similar 
manner (Fernando et al., 2007) showed a linear increase with the heparin length 
(Figure 4.7a,b). Previously, s020,w values of 1.69 S, 1.88 S, 1.99 S and 2.25 S from 
interference optics were reported for heparin fragments of approximate sizes deduced 
to be dp26, dp32, dp38 and dp46 in that order in 0.2 M NaCl (Pavlov et al., 2003; 
Perez Sanchez et al., 2006). These earlier values agree well with the more extensive 
data presented in Figure 4.7b.  
The sedimentation coefficient s020,w values of 16 heparin models 
corresponding to linear dp10 to dp40 structures were calculated using HYDROPRO 
software on the basis of the linear dp12 NMR structure (Mulloy et al., 1993). The 
HYDROPRO software program is used to calculate the s020,w values directly from the 
atomic co-ordinates (Section 3.4.6). While variability was observed in their 
calculated values, the overall dependence of the s020,w values on length is linear 
(Figure 4.7) and agrees well with experiment (Figure 4.4-4.6). By AUC, there is no 
evidence of structural bending from the s20,w values for heparin lengths of up to 18 
nm in dp36.     
 
(4.2.2) X-ray solution scattering data for heparin fragments 
           Solution scattering is a diffraction technique that studies the overall structure 
of biological macromolecules in solution (Perkins et al., 2008). In order to obtain 
more detailed structural information compared to that obtained from AUC, the  
solution structures of the six heparin fragments dp6–dp36 at 0.5 mg/ml were 
  
















































































characterised by synchrotron X-ray scattering. Experiments give the scattering curve 
I(Q) as a function of Q (where Q = 4π sin θ/λ; 2θ is the scattering angle, and λ is the 
wavelength). Guinier analyses of ln I(Q) versus Q2 at low Q values give the radius of 
gyration RG, which measures the degree of macromolecular elongation. Due to 
differences in the lengths of the heparin fragments, different Q ranges were required 
for each fragment in order to work within acceptable Q.RG ranges (Figure 4.8a). 
Thus, the Guinier fit Q range of 0.2–0.7 nm− 1 for dp6 was successively reduced in 
stages to 0.14–0.40 nm− 1 for dp36 (Figure 4.8 legend). The mean Guinier RG values 
increased from 1.33 ± 0.26 nm for dp6 to 3.12 ± 0.10 nm for dp36 (Table 4.1). The 
RG values of 16 heparin models corresponding to linear dp10–dp40 structures were 
calculated from sphere models derived from the linear dp12 NMR structure (Mulloy 
et al., 1993; Perkins and Weiss, 1983). The calculated RG values increased linearly 
with the size of heparin (Figure 4.8d). In contrast, Figure 4.8d shows that, unlike the 
linear increase in the s20,w values with size, the Guinier RG values of the six heparin 
fragments do not exhibit a linear increase with heparin size, with deviations being 
seen for dp24, dp30, and dp36. The difference from the AUC results is attributable to 
the better resolution of the X-ray scattering method. The RG values in Figure 4.8d are 
comparable with that of 3.2 nm for dp32 measured at higher concentrations between 
6 mg/ml and 20 mg/ml in 0.2 M NaCl (Pavlov et al., 2003).  
If the macromolecule is sufficiently elongated in shape, the cross-sectional 
radius of gyration RXS value monitors the degree of bend within the macromolecular 
length. Cross-sectional Guinier analyses of ln I(Q)Q versus Q2 at larger Q values 
showed the required linearity for dp18–dp36 in a Q range of 0.9–1.5 nm− 1. Fits gave 
values of 0.50 nm for dp18 up to 0.53 nm for dp36 (Figure 4.8b; Table 4.1). The dp6 
and dp12 fragments were too small for this analysis to be carried out. The small 
increase in the RXS values with heparin fragment size indicates that the fragments are 
indeed elongated but become progressively slightly more bent with increase in size. 
Combination of the RG and RXS values according to the relationship 
L2 = 12(RG2 − RXS2) for an elliptical cylinder (Glatter & Kratky, 1982) showed that 
dp18, dp24, dp30, and dp36 have approximate lengths of 7.0 nm, 9.1 nm, 9.6 nm, 
and 10.7 nm, in that order. In contrast, larger L values of 14 nm for dp26, 16 nm for 
dp32, and 20 nm for dp38 have been determined on the basis of a smaller RXS value 
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 spheres a 
 
RG (nm) b 
 
RXS (nm)    
 
R-factor  
   (%)  
 
Length  
 (nm) c 
 
s020,w (S) d 
dp6 Experimental   1.33 ± 0.26 
1.03 ± 0.03 
  3.0 1.09 ± 0.10 
dp12 Experimental   1.83 ± 0.13    
1.81 ± 0.08 
  6.0                1.35 ± 0.03 
dp18 None 5000 46-78 1.25-2.39 0.17-0.98 2.2-16.8 NA NA 
 RG, R-factor 9 54-64 2.06-2.07 0.49-0.50 2.2 7.7-8.3 1.14-1.52 
 Best fit 1 59 2.07 0.50 2.2 7.8, 7.0 1.32 
 Experimental    2.07 ± 0.05 
2.09 ± 0.09 
0.50 ± 0.01  7.4                 1.41 ± 0.04 
dp24 None 5500 46-100 1.44-3.02 0.013-1.17 1.3-18.2 NA NA 
 RG, R-factor 9 77-82 2.59-2.64 0.47-0.52 1.3-1.4 9.8-10.5 1.45-1.64 
 Best fit 1 78 2.61 0.49 1.4 10.2, 9.0 1.45 
 Experimental   2.67 ± 0.15 
2.78 ± 0.06 
0.50 ± 0.01  9.4                 1.52 ± 0.07    
dp30 None 6000 79-122 1.76-3.58 0.01-1.32 3.0-18.1 NA NA 
 RG, R-factor 9 85-100 2.79-2.96 0.46-0.57 3.1-3.4 10.2-11.8 1.49-1.86 
 Best fit 1 96 2.79 0.52 3.3 10.2, 9.6  1.86 
 Experimental   2.83 ± 0.14 
2.92 ± 0.11    
0.52 ± 0.01  10.3               1.63 ± 0.02    
dp36 None 6000 93-141 2.04-3.90 0. 10-1.46 3.5-21.7 NA NA 
 RG, R-factor 9 102-120 3.18-3.28 0.47-0.63 3.5-4.0 11.1-12.9 1.72-1.95 
 Best fit 1 102 3.18 0.53 3.5 12.6, 11.5  1.87 
 Experimental   3.12 ± 0.10 
3.52 ± 0.12   
0.53 ± 0.01  12.3              1.84 ± 0.06 
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Table 4.1 legend 
a The optimal totals of hydrated spheres are 53 for dp18, 71 for dp24, 88 for dp30 and 
106 for dp36. 
b The first experimental value is from the Guinier RG analyses and the second one is 
from the GNOM P(r) analyses. 
c The lengths L of the 9-15 best fit models were calculated using HYDROPRO. The 
length of the best-fit model length was calculated using HYDROPRO, and the 
second one was calculated from the modelled P(r) curve. The experimental L values 
are the model-independent values from the P(r) curve.  
d The averaged experimental s20,w value is reported from the absorbance (234 nm) and 
interference data sets, with the absorbance data being recorded at 40,000 and 50,000 
rpm and the interference data at 40,000, 50,000 and 60,000 rpm.  
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relationship L2 = 12(RG2 − RXS2) shows that the latter set of L values is too large to be 
consistent with the measured RG values.  
The distance distribution function P(r) curve calculated from the full I(Q) 
curve (Section 4.4) provides RG values and model-independent determinations of 
overall lengths L following an assumption of the value of the maximum dimension 
Dmax (Figure 4.8c). The mean RG values obtained from the P(r) curves increase from 
1.03 ± 0.03 nm for dp6 to 3.52 ± 0.12 nm for dp36 (Table 4.1). Comparison of the 
six pairs of mean Guinier and P(r) RG values showed good agreement to within 
0.01–0.4 nm (Table 4.1). Again, the RG values do not increase linearly with size 
(Figure 4.8d). Model-independent L values are determined from the r value where 
the P(r) curve reaches zero at large r. The experimental L values for dp6 and dp12 
were 3.0 nm and 6.0 nm, respectively, in good agreement with a length of 3.2 nm for 
an unhydrated linear dp6 model and a length of 5.9 nm for an unhydrated linear dp12 
model, provided that a hydration shell of 0.6 nm (=  2 × 0.3 nm) thickness is added 
to these model lengths (Perkins, 2001). The experimental L values for dp18, dp24, 
dp30, and dp36 were found to be 7.4 nm, 9.4 nm, 10.3 nm, and 12.3 nm, respectively 
(Figure 4.8c). These values show increasing deviation from the lengths of linear 
dp18, dp24, dp30, and dp36 models (i.e., 8.4 nm for dp18, 11.1 nm for dp24, 
13.6 nm for dp30, and 16.3 nm for dp36), showing that heparin is not linear in 
solution. These values also deviate from the L values determined above from the RG 
and RXS values, and this is attributable to the assumption of an elliptical cylinder 
shape for this L calculation. In conclusion, both the RG and the L values indicate a 
measurable degree of bending from linearity in larger heparin fragments. The P(r) 
curves also provide the most frequently occurring interatomic distance M within the 
heparin structure from the r value of the peak maximum. The maximum M1 was 
observed at r values that started at 1.05 nm for dp6 and slowly increased to 1.41 nm 
for dp36 (Figure 4.8 legend). A second subsidiary maximum M2 may be present at 
about 3.4–4.2 nm for dp24, dp30, and dp36. The appearance of this second feature 
may correspond to a regular structure that becomes more evident in longer heparin 
structures. In conclusion, the P(r) curves indicate a measurable degree of bending 





(4.2.3) Constrained modelling of the heparin fragments  
Solution structures for the four larger heparin fragments dp18, dp24, dp30, 
and dp36 were determined by constrained scattering modelling, using the linear 
models created from the NMR structure of dp12 as starting constraint. Modelling 
was not performed for dp6 or dp12 because their sizes were too small for this 
procedure and poor signal-noise ratios were obtained. In the models, the bond 
connectivity between oligosaccharide rings was maintained, while the phi (Φ) and 
psi (Ψ) angles at each glycosidic bond were varied (Figure 4.1). In initial trials, 
around 200 random models for dp30 were made manually by changing the Φ and Ψ 
angles at two positions. The R-factors and RG values were calculated for all the 
models, where the R-factor is a measure of goodness-of-fit, and the RG value was 
calculated using the same Q range used for the experimental Guinier fits (Figure 
4.8). The best dp30 model gave R-factor of 3.9 %, RG of 2.94 nm and maximum 
length L of 10.0 nm, which are in fair agreement with the experimental RG of 2.83 ± 
0.14 nm and L of 10.3 nm (Figure 4.9a). The sedimentation coefficients calculated 
from the best-fit models dp30 model gave s020,w values of 1.66 S, in good agreement 
with the experimental s20,w value of 1.63 ± 0.02 S. The linear dp30 model showed a 
worsened R-factor of 6.3 %, RG value of 3.41 nm, L value of 13.6 nm and s020,w 
values of 1.78 S (Figure 4.9b). This initial manual modelling for dp30 showed that 
the automated modelling for dp30 and other heparin fragments was possible. 
In the automated modelling procedure, the bond connectivity between the 
oligosaccharide rings was maintained, while the Φ and Ψ angles at each glycosidic 
bond was varied randomly in a range of up to ± 45o from their starting values. Trial 
calculations showed that this range of rotations was sufficient to produce a sufficient 
range of bent structures that would fit the X-ray scattering curves. In all, 5,000 
models for dp18, 5,500 models for dp24 and 6,000 models each for dp30 and dp36 
were generated.  A constant force field known as the “Dreiding minimization” 
protocol was applied to avoid steric clashes between the atoms (Section 3.4.2). X-ray 
scattering curves were calculated from these models and fitted to the experimental 
curves. The R-factors and RG values were calculated for all the models, where the R-
factor is a measure of goodness-of-fit and the RG values was calculated using the 
same Q range used for the experimental Guinier fits (Figure 4.8). The comparisons 
of Figure 4.10a–d showed that all the models (yellow circles) spanned the 
experimental RG values (broken lines), and that the best R-factor values were well  
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below the level of 5% required for excellent curve fits (Perkins et al., 2008). This 
showed that 5,000-6,000 randomised models were sufficient to determine best fit 
heparin solution structures from them. The lowest R-factors showed the best 
agreement with the experimental X-ray curves, and their RG values (red and cyan 
circles) agree well with the experimental RG values. In distinction, the linear models 
for dp18, dp24, dp30 and dp36 showed large deviations (green circles).  
For dp18, the modelling analyses show that this has a slightly bent structure 
that accounts for the X-ray and AUC data. All nine best-fit models gave the same R-
factor of 2.2% and the RG values of 2.06-2.07 nm that agree with the experimental 
RG value of 2.07 ± 0.05 nm (Figure 4.10a, Table 4.1). The best-fit dp18 models show 
a maximum length L of 7.7–8.3 nm, in good agreement with the experimental 
maximum length of 7.4 nm. In contrast, the linear dp18 model gave a worsened R-
factor of 3.3%, an RG value of 2.25 nm, and an L value of 8.4 nm. Visual agreement  
between the experimental I(Q) curve and the modelled I(Q) curve, and that between 
the experimental P(r) curve and the modelled P(r) curve were excellent (Figure 
4.11a). The calculation of sedimentation coefficients from the nine best-fit models 
gave s020,w values of 1.02 S to 1.47 S. The best-fit model gave a value of 1.29 S, 
which agrees well with the experimental s20,w value of 1.32 ± 0.04 S, this agreement 
being within the usual precision of ± 0.21 S for these calculations (Perkins et al., 
2009).  
For dp24, modelling analyses showed similar good agreements with X-ray 
and AUC, but corresponded to slightly more bent structures. For the nine best-fit 
models, the R-factor and RG values ranged from 1.3% to 1.4% and from 2.59 nm to 
2.64 nm, respectively, where the latter corresponds well with the experimental RG 
value of 2.67 ±   0.15 nm (Table 4.1). The maximum lengths of the models were 9.8–
10.5 nm, in good accord with an L value of 9.4 nm. The linear model again showed a 
worsened R-factor of 4.8%, an RG value of 2.94 nm, and an L value of 11.1 nm. The 
agreement between the experimental and the modelled I(Q) and P(r) curves was 
excellent (Figure 4.11b). The nine modelled s020,w values of 1.45–1.64 S are       
comparable with the experimental s20,w value of 1.52 ±   0.07 S, and the best-fit 
model gave a value of 1.45 S.  
For dp30, modelling analyses showed similar good agreements with X-ray 
and AUC, in which deviation from a linear structure for dp30 becomes pronounced.  
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The nine best-fit dp30 models gave R-factor values of 3.1–3.4%, RG values of 2.79–
2.96 nm, and L values of 10.2–11.8 nm. These correspond well with the 
experimental RG value of 2.83 ±   0.14 nm and an L value of 10.3 nm (Table 4.1). 
The deviations from a linear dp30 model are larger, for which the R-factor is 6.3%, 
the RG value is 3.41 nm, and the L value is 13.6 nm. The agreement between the 
experimental and the modelled I(Q) and P(r) curves was again excellent (Figure 
4.11c). The nine modelled s020,w values of 1.49-1.86 S agree well with the 
experimental s20,w value of 1.63 ± 0.02 S, with the best-fit model giving a value of 
1.86 S.  
For dp36, similar good agreements between the models and the X-ray and 
AUC data were obtained, and the deviation obtained from a linear dp36 structure 
was larger. The nine best-fit dp36 models gave R-factor values of 3.5–4.0%, RG 
values of 3.18–3.28 nm, and L values of 11.1–12.9 nm. The latter agrees well with 
the experimental RG value of 3.12 ± 0.10 nm and an L value of 12.3 nm (Table 4.1), 
even though the availability of 6000 randomised models in this case reduced the 
quality of the fits in Figure 4.10d compared to those in Figure 4.10a and b. The best-
fit models deviate from the parameters for the linear dp36 model, which have an R-
factor of 5.3%, an RG value of 3.82 nm, and an L value of 16.3 nm. The maxima M1 
and M2 become more noticeable in the P(r) curve for the best-fit model (Figure 
4.11d), and their r values agree with those seen experimentally. The nine modelled 
sedimentation coefficients calculated from the best fit dp30 models ranged between 
1.72-1.95 S, in good agreement with the observed s20,w value of 1.84 ± 0.06 S, with 
the best-fit model giving a value of 1.87 S.  
In conclusion, the best-fit models for dp18, dp24, dp30, and dp36 show 
progressively more bent structures in solution with increase in heparin size. 
Compared to the lengths of the linear models, these being the most extended ones 
possible, the four heparin fragments are reduced in length by 18%, 16%, 29%, and 
29%, in that order. This overall conclusion applies to all the best-fit models in each 
of the four structure determinations. This is illustrated by the superimposition of the 
9–15 best-fit models in each fragment (Figure 4.12), which showed that an increase  
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in bending with increase in size is common to all of them. In the case of dp30, and 
more so with dp36, the appearance of the minor peak M2 in the experimental P(r) 
curve is consistent with the appearance of more bending in the larger heparin 
fragments. In all four cases, the bent models showed s020,w values that are similar to 
those of the linear models, indicating that the AUC data are not able to distinguish 
between slightly bent and linear structures, unlike the X-ray scattering data. 
 
(4.2.4) Comparison with heparin conformations in crystal structures  
Given the current knowledge of 19 heparin-protein crystal structures (Section 
4.4), we now survey the heparin conformations in these as well as that of the NMR 
dp12 solution structure. The two major conformations of six-membered iduronate 
rings in heparin are the 1C4 chair and the 2S0 skew-boat (Mulloy & Forster, 2000). 
The two forms can interconvert with relatively little disturbance to the glycosidic 
linkages to neighbouring residues, and the polysaccharide chain need not bend as a 
consequence, although the relative positions of sulphate groups within the ring will 
alter. In terms of the glycosidic linkages, information on their conformation in 
heparin is available from analyses of their Φ and Ψ angles (Figure 1). The first 
survey of five heparin-protein crystal structures (Mulloy & Forster, 
2000) showed that the average Φ and Ψ angles were -75° and 135° (18 values for 
each) respectively for IdoA-GlcNS glycosidic bonds, whereas these were 78° and 
103° (15 values each) respectively for GlcNS-IdoA glycosidic bonds (standard 
deviations of 10o to 19o). These five structures (Faham et al., 1996; DiGabriele et al., 
1998; Fry et al., 1999) thus show similar heparin geometries. Their similarity with 
that of the NMR structure of dp12 where the Φ and Ψ angles were -55° and 135° 
respectively for IdoA-GlcNS and 108° and 83° respectively for GlcNS-IdoA 
(Mulloy et al., 1993) showed that the bound conformation is similar to that in 
solution (Table 4.2). The current availability of 19 heparin-protein crystal structures 
enabled this analysis to be extended (Figure 4.13a,b). After the removal of five pairs 
of outliers shown in Figure 4.13a,b, the average Φ and Ψ angles of IdoA-GlcNS 
glycosidic bonds were remarkably similar to previous at -79° and 132° (65 values 
each) respectively, whereas the average Φ and Ψ angles of GlcNS-IdoA glycosidic 
bonds were similar to previous at 84° and 100° (58 values each) respectively. Here, 
the standard deviations have increased to 19o to 22o. All five outliers in Figure 











Table 4.2. Summary of the Φ and Ψ angle in heparin structures 
 IdoA-GlcNS  GlcNA-IdoA  
 Φ (°) Ψ (°) Φ (°) Ψ (°) 
Five crystal 
structures (2000) a 
-75 ± 10 135 ± 13 78 ± 16 103 ± 19 
19 crystal structures 
(current study) a 
-79 ± 20 132 ± 19 84 ± 22 100 ± 19 
NMR structure -55 135 108 83 
dp18 -52 ± 21 135± 15 104 ± 27 96 ± 25 
dp24 -61 ± 17 127 ± 20  100 ± 26 78 ± 17 
dp30 -64 ± 21 136 ± 21 87± 25 82 ± 22 
dp36 -63 ± 23 129 ± 27 103 ± 22 89 ± 24 
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heparin structure. It appears likely that these terminal residues at the reducing or 
non-reducing ends have greater freedom to reorientate themselves in the crystal 
structures, and the outliers are not considered significant. Overall, it is concluded 
that heparin has a well-defined and similar extended conformation when bound to 
proteins. 
Conformational variability was observed in the extended structures of bound 
heparin. While considerations of structural resolution and carbohydrate refinement 
parameters may preclude detailed analyses, such as the existence of skew boat or 
chair ring conformations, it should be possible to infer relative IdoA and GlcNS ring 
orientations. The commonly-occurring dp5 fragment in 12 or 13 of the 19 
crystallographically-observed heparin structures were superimposed on the second, 
third and fourth rings of dp5 (bottom of Figure 4.13). The two rings flanking the 
central ring were in similar locations, as expected from Figure 4.13a,b, with only one 
instance of a 180o GlcNS ring flip (visible at the top of the central image in Figure 
4.13). The sulphate and carboxylate groups in the two flanking rings were distributed 
in a range  up to 0.5 nm, while this positional variability was reduced to less than 0.1 
nm in the case of the central ring alone. The superimpositions showed that six or 
seven structures of the 19 exhibited clear bends in an otherwise extended heparin 
structure. For example, the longest-observed crystallised heparin dp10 is found in the 
2:2 complex of fibroblast growth factor 1 and fibroblast growth factor receptor 2, in 
which dp10 links the four protein subunits together (Pelligrini et al., 2000). In the 
five IdoA-GlcNS glycosidic bonds, one Ψ angle was 78o in distinction to the average 
Ψ angle of 132o. In the four GlcNS-IdoA glycosidic bonds, two Ψ angles were 141o 
and 135o instead of the average Ψ angle of 84°. Consequently two significant bends 
were visible in the dp10 structure (Figure 4.14a). Heparin dp8 bound to vaccinia 
virus complement control protein assists the virus in its infection cycle (Ganesh et 
al., 2004) (Figure 4.14c). In the four IdoA-GlcNS glycosidic bonds, one Φ value is -
106° in distinction to the mean value of -79° and one Ψ angle was 78° in distinction 
to the average Ψ angle of 132o. In the three GlcNS-IdoA glycosidic bonds, one Ψ 
angle was 135o instead of the average Ψ angle of 84°. Sometimes, the heparin 
conformation is not the same when binding to the same protein. For example, 
the crystal structure of four thrombin molecules complexed with two dp8 molecules 
showed that the two dp8 molecules are sandwiched between two different thrombin 
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The best-fit solution structures of dp18, dp24, dp30 and dp36 (Figure 4.11) 
can now be compared with the observed heparin conformations in crystal structures. 
The average Φ and Ψ angles of the IdoA-GlcNS glycosidic bonds were very similar 
at -52° and 135° (dp18: 9 values), -61° and 127° (dp24: 12 values), -64° and 136° 
(dp30: 15 values), and -63° and 129° (dp36: 18 values) (Figure 4.13c). While their 
standard deviations are higher at 15o to 23o (Table 4.2), no outliers were present. The 
Φ angles from scattering may be slightly reduced compared to the crystal structures, 
while being more similar to the NMR structure (Table 4.2). Likewise, the average Φ 
and Ψ angles of the GlcNS-IdoA glycosidic bonds were very similar at 104° and 96° 
(dp18: 8 values), 100° and 78° (dp24: 11 values), 87° and 82° (dp30: 14 values), and 
103° and 89° (dp36: 17 values) (Figure 4.13d). No outliers were again present. The 
Φ angles from scattering may be slightly increased compared to the crystal 
structures, while being more similar to the NMR structure (Table 4.2). It is 
concluded that, despite the additional bending seen in dp36 compared to dp18, 
heparin is well-maintained in solution as a semi-rigid extended structure (Figure 
4.12). Its conformations are similar to those seen in 19 heparin-protein crystal 
structures, while the dp12 NMR structure (Figure 4.7) may be too linear to 
correspond to heparin conformations in solution.  
 
(4.3) Conclusions 
In this study, we have here determined the first molecular structures in 
solution for heparin dp18–dp36. These provide new insight into the way that heparin 
(and, by analogy, heparan sulphate) interacts with its protein ligands. We show that 
heparin is well-represented as an extended and semi-rigid structure in solution. The 
dp6 and dp12 structures by both NMR (Mulloy et al., 1993) and constrained 
scattering modelling (here) show comparatively little bending. Starting with dp18, 
the heparin fragments progressively show higher degrees of partial bending up to 
dp36, while maintaining approximately linear segments within these structures. The 
coordinate models have been deposited in the so-named Protein Data Bank at 
http://www.rcsb.org/pdb/. As far as we are aware, this study is the first successful 
application of constrained scattering modelling to oligosaccharides, with this method 
having previously been used to determine molecular structures for multidomain 
antibody and complement proteins (Perkins et al., 2008, 2009). We envisage that this 
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modelling approach can be extended to structure determinations for other 
oligosaccharides and polynucleotides. 
While solution scattering is traditionally a low-resolution method that 
generates shape envelopes, its utility to the determination of medium-resolution 
heparin solution structures is assisted by constrained modelling. Constrained 
modelling determines a three-dimensional molecular structure that best accounts for 
the observed scattering curve. It is reliable in defining the averaged extension and 
bending of the polysaccharide chains and in deriving information on flexibility. It 
cannot provide the resolution necessary to provide coordinates within the chain, even 
if averaged Φ–Ψ values are calculated from constrained modelling. Even though 
unique structure determinations are not possible due to random molecular 
orientations observed by scattering, this modelling is able to rule out structures that 
are incompatible with the scattering curves. Hence, the basic premises of constrained 
modelling are twofold: (i) by fixing parts of the structural analyses to what is already 
known about the macromolecule, scattering fits are subjected to significantly fewer 
modelling variables; and (ii) by identifying poor-fit models and rejecting these, 
good-fit models are obtained and ranked in order of their compatibility with the data. 
A related strategy resulted in the NMR solution structure of dp12 (Mulloy et al., 
1993). By NMR, the measurements of 1H–1H nuclear Overhauser enhancements for 
heparin permitted these to be tested against molecular models for heparin. Here, for 
the constrained scattering modelling of heparin, the only variables are the Φ and Ψ 
angles of each glycosidic bond. The randomised variation of these angles readily 
resulted in the V-shaped graphs of R-factor versus RG values, from which the best-fit 
models were identified at the lowest R-factor values. In fact, the quality of the dp18–
dp36 scattering curve fits is better than that obtained for other recent examples of 
multidomain proteins such as complement FH or complement receptors types 1 and 
2 (Okemefuna et al., 2009; Furtado et al., 2008; Gilbert et al., 2006). If constrained 
modelling is not employed, only a macroscopic view of heparin structures in solution 
analysed using worm-like sphere models is possible (Pavlov et al., 2003; Perez 
Sanchez et al., 2006; Ortega & Garcia de la Torre, 2007). The two approaches are 
conceptually different. In the worm-like model, flexibility is dynamic (fluctuating) 
and distributed continuously, while constrained modelling presents a family of static 
structures that fit the experimental X-ray data. 
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Our structural study of dp6–dp36 provides new insights on 19 crystal 
structures for heparin–protein complexes (Section 4.4). The crystal structures are 
notable for the observation of comparatively small heparin fragments that range in 
size from dp4 to dp10, with the most common being dp5. These sizes are sufficient 
to form well-defined heparin–protein complexes (Figure 4.14). The majority of 
contacts between the protein surface and heparin are ionic between basic amino acid 
side chains and anionic sulphate groups. The axial orientations of sulphate groups in 
heparin are repeated after every four oligosaccharide rings. Thus, dp4 possesses a 
sufficient number of at least six sulphate groups and two carboxylate groups to 
generate protein specificity for heparin. Within each dp4 fragment, two sulphate 
groups are located in similar but opposed axial orientations in GlcNS residues, while 
the third sulphate and the carboxylate group are located in opposed axial orientations 
in IdoA residues (Figure 4.7). Views of 12–13 superimposed dp3 fragments centred 
on either IdoA or GlcNS residues confirm that these axial orientations are largely 
preserved and approximately aligned with each other between IdoA and GlcNS 
residues (Figure 4.13). The current study shows that the solution structures of 
heparin in sizes of up to dp12 in size are generally linear, although not necessarily 
maintaining a regular helical repeat. Linearity may be influenced by the repulsion of 
the sulphate and carboxylate groups, which assist in this regard but are not 
mandatory (Mulloy et al., 1994). We show that, if the heparin fragments are dp18 or 
larger, bending of its linear structure becomes more pronounced, even though the 
mean Φ and Ψ angles remain unchanged (Table 4.2). In the constrained modelling, 
this bending appears as kinks in the heparin structure at a few positions. Thus, 
heparin appears as a succession of linear regions similar to dp6 or dp12 that are 
joined by semi-rigid kinks. The physical basis for the occurrence of kinks may result 
from the occasional occurrence of GlcA-GlcNAc sequences, and not IdoA–GlcNS 
sequences (Figure 4.1), but the crystal structures show that kinks also occur in other 
regions (Figure 4.14). Overall, our X-ray modelling of dp6–dp36 clarifies that large 
heparin segments in solution form extended stable and preformed conformations that 
are ideal for protein ligation, including the presence of occasional kinks in these 
solution structures.  
This study opens the way to analysing more complex heparin–protein 
interactions, including the occurrence of two heparin binding sites on the same 
protein. Can the same heparin molecule bind simultaneously to a double heparin 
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binding site, or does heparin cross-link different proteins? The heparin-binding 
regulatory chemokine macrophage inflammatory protein 1α (MIP-1α) is one case in 
point (Stringer et al., 2002). Heparin binds strongly to dimeric MIP-1α, in distinction 
to monomeric or tetrameric MIP-1α. Heparinase III digests, and molecular modelling 
suggests that two dp14 fragments joined by a flexible dp6 fragment bind to dimeric 
MIP-1α. This conclusion is explained by our modelling of dp30 and dp36, which 
indicates the existence of linear segments joined by semi-rigid kinks. 
Physiologically, multiple interactions of this type will account for the packaging of 
heparin–protein complexes within mast cell granules. The binding of heparin dp26 to 
the dimer of interferon-γ represents a different case, where the interaction does not 
necessarily involve bent heparin structures (Perez Sanchez et al., 2006). In 
distinction to these cases, crystal studies show that heparin is able to cross-link 
monomers to form complexes (e.g., the fibroblast growth factor family and their 
receptors) (Pellegrini et al., 2000; Schelessinger et al., 2000). The complement 
regulator FH, which is composed of 20 short complement regulator (SCR) domains, 
is a distinct example altogether (Khan et al., 2008). The heparin–FH interaction at 
cell surfaces protects host cells from attack by the innate immune system, directing 
this instead against pathogenic bacteria, which often lack a polyanionic 
oligosaccharide coating. Two different heparin binding sites occur at the SCR-7 and 
SCR-20 domains in FH. Up to now, it is not clear whether flexibility within FH or 
heparin could permit SCR-7 and SCR-20 to bind simultaneously to the same heparin 
oligosaccharide. Our new dp18–dp36 structures indicate that heparin has insufficient 
flexibility to facilitate the simultaneous binding of two FH sites with one heparin. It 
is more likely that FH cross-links different heparin oligosaccharides to form very 
large oligomers (Khan et al., 2008). At least two different heparin sites may have 
evolved within FH in order to enable FH to bind selectively to host cells showing an 
appropriate abundance of polyanionic surfaces, in distinction to pathogens that lack 
these FH sites. 
A further key question in relation to heparin–protein interactions is whether 
protein conformational changes occur on heparin binding. The availability of 19 
heparin–protein crystal structures partly answers this question, being mainly limited 
by the relatively small sizes of the heparin fragments. Physiologically, heparin (and 
heparan sulphate) exists as long oligosaccharides. The largest crystallographically 
observed heparin to date is a decasaccharide (Pellegrini et al., 2000). Even when a 
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heparin 14-mer was cocrystallised with a protein, the largest crystallographically 
observed heparin was as small as a pentasaccharide dp5 (Lietha et al., 2001). 
Heparin may induce conformational changes in proteins in order to alter activities. 
The best-known case is that of antithrombin, whose β-sheet structure is allosterically 
activated by heparin in a series of events in order to inhibit the coagulation factors 
IXa and Xa and thrombin (Langdown et al., 2009). In most crystal structures, 
heparin binding sites are found on surface-exposed positions (Figure 4.14d), and 
conformational changes do not appear to be required for complex formation. The 
case of FH is distinct from these two scenarios. Each SCR domain is stabilised by 
two conserved disulphide bridges at each end of its β-sheet structure and a 
hydrophobic core that includes a conserved Trp residue (Saunders et al., 2007). A 
single SCR domain will accommodate heparin dp8 without conformational change 
(Ganesh et al., 2004). However the linker conformations between SCR domains are 
variable and not easily predicted (Perkins et al., 2002). Flexibility in inter-SCR 
linker conformations has been demonstrated by the different solution and crystal 
structures of SCR-1/2 in complement receptor type 2, in which the two SCR domains 
are joined by a long eight-residue linker (Gilbert et al., 2005). If heparin binds to two 
neighbouring SCR domains, heparin will need to be at least dp18 in size to do so, 
and its binding may alter the inter-SCR conformation. An initial study of dp10 
binding to a recombinant SCR-6/8 fragment of FH showed that either a 
conformational change or oligomer formation resulted (Fernando et al., 2007). By 
this present study, the improved understanding of dp18–dp36 solution structures 
opens the way to clarifying how FH binds to heparin, including the consideration of 
heparin-induced conformational change in its domain structure (Khan et al., 2008). 
 
(4.4) Materials and methods 
(4.4.1) Purification of heparin fragments 
Oligosaccharide fragments of heparin were prepared from both from the low 
molecular weight heparin Tinzaparin (Leo Pharma, Denmark), for preliminary work, 
and from bovine lung heparin pre-digested with heparinase I provided by my 
collaborator Dr. Barbara Mulloy (National Institute of Biological Standards and 
Control, Blanche Lane, South Mimms, Potters Bar, Hertfordshire, UK). This 
digestion procedure has been previously described (Pellegrini et al., 2000; Mulloy et 
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al., 1997; Rice et al., 1985). In summary, about 80 mg of bovine lung heparin (the 
2nd International Standard Heparin) was taken up in 2 ml 20 mM phosphate buffer 
pH 7.4, and 100 µl heparinase I solution (the kind gift of Leo Pharma, Ballerup, 
Denmark, used as supplied without assay) was added. The digestion was allowed to 
proceed for 4 min at room temperature and the reaction stopped by heating in a water 
bath at 100ºC. After evaporation of the solution under reduced pressure at 50ºC, the 
digest was taken up in 1.5 ml of 2% ammonium bicarbonate, filtered through a 
syringe-mounted 0.45 micron membrane, and then applied to a preparative gel-
permeation chromatography column (100 cm × 1.6 cm, packed with Biogel P-10; 
Bio-Rad, UK). The heparin fragments were eluted using 2% ammonium bicarbonate 
at a flow rate of 0.2 ml/min and collected in 2-ml fractions. The absorbance of the 
fractions at 234 nm was measured, and the fractions corresponding to each resolved 
peak were pooled. Heparin oligosaccharides larger than dp12 were not completely 
resolved (Figure 4.2). Each fraction was evaporated under reduced pressure and 
lyophilised before assessment of its size by analytical gel-permeation 
chromatography (Mulloy et al., 1997). This was carried out using two columns (TSK 
G3000 SW-XL, 30 cm; TSK G2000 SW-XL, 30 cm; Anachem, UK) connected in 
series (Figure 4.3). The eluant was 0.1 M ammonium acetate solution at a flow rate 
of 0.5 ml/min, and heparin was detected with a refractive index detector (RI-1530; 
Jasco, UK). The chromatography system was calibrated using the First International 
Reference Reagent Low Molecular Weight Heparin for Molecular Weight 
Calibration (NIBSC 90/686). Heparin quantification was achieved by integration of 
the area under each refractive index peak and comparison with a standard curve 
prepared using known concentrations of low-molecular-weight standards. 
 
(4.4.2) Analytical ultracentrifugation of heparin fragments 
  Sedimentation velocity experiments were performed using two Beckman XL-
I analytical ultracentrifuges (Beckman Coulter, Inc., Palo Alto, CA) equipped with 
both absorbance and interference optics. Experiments with dp6–dp36 fragments were 
performed at concentrations of 0.5 mg/ml in 10 mM Hepes and 137 mM NaCl 
(pH 7.4). Buffer density (1.00480 g/ml) was measured at 20°C using an Anton-Paar 
DMA5000 density meter. A partial specific volume of 0.467 ml/g was used for 
heparin (Pavlov et al., 2003). Runs were carried out in an eight-hole AnTi50 rotor 
with standard double-sector cells with column heights of 12 mm at 20°C using 
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absorbance optics at 234 nm and interference optics. Sedimentation velocity data 
were collected at 40,000 rpm and 50,000 rpm using absorbance optics, and at 
40,000 rpm, 50,000 rpm, and 60,000 rpm using interference optics. The continuous 
c(s) analysis method was used to determine the sedimentation coefficients s20,w of 
heparin fragments using SEDFIT software (version 9.4) (Dam & Schuck, 2004; 
Schuck, 2000). The c(s) analysis directly fits the sedimentation boundaries using the 
Lamm equation, the algorithm for which assumes that all species have the same 
frictional ratio f/fo in each fit. The final SEDFIT analyses used a fixed resolution of 
200 and optimised the c(s) fit by floating the meniscus and cell bottom when 
required and by holding the f/fo value, baseline, and cell bottom fixed until the 
overall root-mean-square deviations and visual appearance of the fits were 
satisfactory (Figure 4.3, 4.4 and 4.5). The f/fo values for the heparin fragments were 
calculated to be 1.33 for dp6, 1.39 for dp12, 1.64 for dp18, 1.78 for dp24, 1.82 for 
dp30, and 1.88 for dp36, starting from the known volume of each fragment (Perkins, 
1986). 
 
(4.4.3) X-ray scattering of heparin fragments 
X-ray solution scattering of the six heparin fragments (dp6, dp12, dp18, 
dp24, dp30, and dp36) was performed on beamline ID02 at the European 
Synchrotron Radiation Facility (Grenoble, France) in two sessions with a ring energy 
of 6.0 GeV (Narayanan et al., 2001). In the first session, data were collected for the 
six fragments in 16-bunch mode using beam currents from 79 mA to 86 mA. In the 
second session, data were collected for the six fragments in four-bunch mode using 
beam currents from 30 mA to 43 mA. Data were acquired using an improved fibre 
optically coupled high-sensitivity and dynamic-range charge-coupled device detector 
(FReLoN) with a smaller beamstop. The sample-to-detector distance was 2.0 m. 
Experiments used the same heparin concentration (0.5 mg/ml) and buffers as used 
for the sedimentation velocity experiments. For each heparin fragment, samples were 
measured in a flow cell, which moved the sample continuously during beam 
exposure in 10 time frames with different exposure times of 0.1 s, 0.2 s, 0.25 s, and 
0.5 s to check for the absence of radiation damage effects. This exposure was 
optimised using on-line checks for the absence of radiation damage to show that this 
was not detectable, after which the frames for 0.5 s were averaged in order to 
maximise signal-to-noise ratios. 
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Guinier analyses give the radius of gyration RG, which characterises the 
degree of structural elongation in solution if the internal inhomogeneity of scattering 
within the macromolecules has no effect. Guinier plots at low Q values give the RG 
and the forward scattering at zero angle I(0): (Glatter & Kratky, 1982) 
 
ln I(Q) = ln I(0) - RG2 Q2/3 
 
This expression is valid in a Q.RG range of up to 1.5. If the structure is elongated 
(i.e., rod-shaped), the radius of gyration of the cross-sectional structure RXS and the 
mean cross-sectional intensity at zero angle [I(Q)Q]Q → 0 parameters are obtained 
from:  
 
ln [I(Q).Q] = ln [I(Q).Q]Q→ 0  - RXS2 Q2/2 
 
The RG and RXS analyses were performed using an interactive PERL script program 
SCTPL7 (J. T. Eaton and S. J. Perkins, unpublished software) on Silicon Graphics 
O2 Workstations. Indirect Fourier transformation of the full scattering curve I(Q) in 
reciprocal space gives the distance distribution function P(r) in real space. This 
yields the maximum dimension of the macromolecule L and its most commonly 
occurring distance vector M in real space:  
 







The transformation was carried out using GNOM software (Semenyuk & Svergun, 
1991). For dp6, the full X-ray I(Q) curves contained 506 data points in the Q range 
between 0.20 nm− 1 and 0.89 nm− 1. For dp12, 171 data points were used in the Q 
range between 0.24 nm− 1 and 1.40 nm− 1. For dp18, 571 data points were used in the 
Q range between 0.12 nm− 1 and 2.0 nm− 1. For dp24, 280 data points were used in 
the Q range between 0.08 nm− 1 and 1.0 nm− 1. For dp30, 600 data points were used 
in the Q range between 0.11 nm− 1 and 2.18 nm− 1. For dp36, 252 data points were 
used in the Q range between 0.11 nm− 1 and 1.81 nm− 1. 
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(4.4.4) Molecular modelling of heparin oligosaccharides  
To analyse the conformation of free and protein-bound heparin 
oligosaccharides available in the PDB, the glycosidic dihedral angles Φ and Ψ 
corresponding to the torsion angles O5′–C1′–O4–C4 and C1′–O4–C4–C3, 
respectively (Figure 4.1), were calculated for all the IdoA–GlcNS and GlcNS–IdoA 
disaccharides using INSIGHT II 98.0 molecular graphic software (Accelrys, San 
Diego, CA) on Silicon Graphics O2 and OCTANE Workstations. The solution NMR 
structure of free dp12 was used (PDB code 1HPN). The following 19 heparin–
protein crystal structures were identified from database searches of the PDB 
http://www.rcsb.org/pdb/, biologically active dimer of acidic fibroblast growth factor 
(PDB codes 1AXM and 2AXM), basic fibroblast growth factor (PDB codes 1BFB 
and 1BFC), complex of fibroblast growth factor 1 and fibroblast growth factor 
receptor 2 (PDB code 1E0O), complex of fibroblast growth factor 2 and fibroblast 
growth factor receptor 1 (PDB code 1FQ9), antithrombin (PDB codes 1AZX, 1EO3, 
and 3EYJ), thrombin (PDB code 1XMN), antithrombin–S195A complex with factor 
Xa (PDB code 2GD4), neurokinin 1 (PDB codes 1GMN and 1GMO), annexin V 
(PDB code 1G5N), foot-and-mouth disease virus (PDB code 1QQP), VCP (PDB 
code 1RID), annexin A2 (PDB codes 2HYU and 2HYV), and cleaved protein C 
inhibitor (PDB code 3DY0). The list is not exhaustive, and other PDB files (PDB 
codes 1NQ9, 1SR5, 1TB6, 1XT3, 1ZA4, 2BRS, and 2B5T) also correspond to 
heparin–protein crystal structures. The majority of these were not analysed for this 
study because these involve heparin disaccharides or synthetic heparin mimetics..  
Linear models of heparin dp6 to dp36 were constructed using the NMR 
structure of dp12 (Mulloy et al., 1993) in the 2S0 configuration with INSIGHT II 
98.0 software. The superimposition of four dp12 molecules was used to create a 
dp42 oligosaccharide, from which the six heparin fragments dp6–dp36 were 
obtained by removing non-required disaccharides. Here, the Φ and Ψ angles were 
− 55° and 135°, respectively, for IdoA–GlcNS, and 108° and 83°, respectively, for 
GlcNS–IdoA (Figure 4.13). Totals of 5,000 conformational models for dp18, 5,500 
for dp24 and 6,000 each for dp30 and dp36 were generated starting from these linear 
models. The Φ and Ψ angles were randomised to take values in the maximum range 
of − 45° or 45° from their starting values using the TorsionKick function in a PERL 
script that was modified from the ExtractAngle.pl script provided with Discovery 
Studio molecular graphics software (version 2.1) (Accelrys). For example, for dp36, 
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a total of 18 Φ and Ψ angles for IdoA–GlcNS and a total of 17 Φ and Ψ angles for 
GlcNS–IdoA were modified in this way.  
 
(4.4.5) Constrained scattering and sedimentation coefficient modelling  
Each heparin model was used to calculate X-ray scattering curves for 
comparison with the experimental curves using Debye sphere models (Okemefuna et 
al., 2009; Furtado et al., 2008; Gilbert et al., 2006). A cube side length of 0.513 nm, 
in combination with a cutoff of four atoms, was used to create the spheres in the 
heparin models of dp18–dp36. The hydration shell corresponding to 0.3 g/g H2O was 
created by adding spheres to the unhydrated sphere models using HYPRO (Ashton et 
al., 1997), where the optimal total of hydrated spheres is listed in Table 4.1. The X-
ray scattering curve I(Q) was calculated using the Debye equation as adapted to 
spheres and assuming a uniform scattering density for the spheres: (Perkins & Weiss, 
1983). 
 









∑ n2 + n( g(Q) = I(0)I(Q) 2-1-  
   RQ/ )QR)  QR - QR (3( = g(Q) 662cossin  
 
where g(Q) is the squared form factor for the sphere of radius r, n is the number of 
spheres filling the body, Aj is the number of distances rj for that value of j, rj is the 
distance between the spheres, and m is the number of different distances rj. Other 
details are given elsewhere (Perkins, 2001; Okemefuna et al., 2009; Furtado et al., 
2008; Gilbert et al., 2006). X-ray curves were calculated without instrumental 
corrections, as these are considered to be negligible for the pinhole optics used in 
synchrotron X-ray instruments. First, the number of spheres N in the dry and 
hydrated models after grid transformation was used to assess steric overlap between 
the heparin disaccharides, where models showing less than 95% of the optimal totals 
were discarded (Table 4.1). Next, the models were assessed by calculation of the X-
ray RG values in the same Q ranges used for the experimental Guinier fits in order to 
allow for any approximations inherent in the use of the Q.RG range of up to 1.5. 
Models that were filtered using the N and RG filters were then ranked using a 
goodness-of-fit R-factor in order to identify the best-fit nine models.  
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 Sedimentation coefficients s020,w for the best-fit scattering models were 
calculated directly from molecular structures using the HYDROPRO shell modelling 
program, with the default value of 0.31 nm for the atomic element radius for all 
atoms in order to represent the hydration shell (Garcia de la Torre, 2000).  
 
(4.4.6) Protein Data Bank accession number 
 The best-fit dp18–dp36 models have been deposited in the Protein Data Bank 















The solution structure of heparan sulphate differs from that of heparin: 






















Heparan sulphate (HS) is a highly sulphated glycosaminoglycan molecule 
and is found exclusively on the host cell surfaces and in extracellular surfaces 
(Gallagher et al., 1992; Bernfield et al., 1992). HS has key roles in biological 
recognition processes at the cell-tissue-organ interface through its interactions with a 
wide range of proteins (Conrad, 1998; Sasisekharan et al., 2000). Specific 
interactions involving HS include in cell growth and development (Perrimon et al., 
2000), cell adhesion (Scarpellini et al., 2009), inflammation and wound healing 
(Stringer and Gallagher, 1997), angiogenesis and cancer (Sasisekharan et al., 1997 
and 2002; Liu et al., 2002), viral invasion (Chen et al., 1997, Shukla et al., 1999) and 
anticoagulation (Petitou et al., 1999). The breadth of HS-protein interaction offers 
many potential strategies for therapeutic intervention at the cell-tissue-organ 
interface.  
 HS is a sulphated polysaccharide consisting of uronic acid and D-
glucosamine residues linked by α-(1-4) glycosidic bonds (Figure 5.1) (Lane and 
Lindahl, 1989; Capila & Linhardt, 2002). The uronic acid residue is either 
unmodified β-D-glucuronic acid (GlcA), alternating with N-acetylated glucosamine 
(Figure 5.1a); or α-L-iduronic acid (IdoA), often 2-O-sulphated, alternating with N-
sulphated glucosamine (GlcNS) (Figure 5.1b). In the latter, sulphation often occurs at 
C6 and rarely also at C3 (Coombe et al., 2005; Lyon & Gallagher, 1998). Unlike 
heparin, HS has a distinct domain organisation that is comprised of small S-domains 
with IdoA2S and GlcNS residues, long NA-domains with GlcA and GlcNAc 
residues, and mixed regions with residues from both S and NA-domains (Capila and 
Linhardt, 2002; Coombe et al., 2005). The S-domains and mixed domain regions are 
termed the hypervariable regions that result in different functional characteristics for 
HS from different cells (Coombe et al., 2005). 
Three-dimensional structural studies of HS are required in order to complete 
the understanding of the physiological significance of HS-protein interactions. Many 
structural studies have been carried out for heparin which is an analogue for HS but 
possesses a higher degree of sulphation, and for at least 19 heparin-protein co-crystal 
complexes. This abundance results because of the ease with which heparin is  
obtained and its strong binding to many of the cell surface proteins whose 
physiological ligand is HS. Thus an NMR structure is known for heparin (Mulloy et 
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constrained scattering modelling; these were shown to be similar in conformation to 
heparin when observed in heparin-protein crystal structures (Khan et al., 2010). In 
distinction, no molecular structures for free HS are known, and only one crystal 
structure for a dp4 HS oligosaccharide complexed with heparinase II is available 
(Shaya et al., 2010).  
Given the importance of understanding the HS solution structure, we have 
used a multidisciplinary approach to determine molecular structures for HS based on 
the combination of three methods, namely analytical ultracentrifugation, small angle 
X-ray scattering, and constrained scattering modelling (Perkins et al., 2008, 2009). 
This approach is well-established for solution structure determinations of large 
multidomain complement and antibody proteins, and was recently applied to small 
heparin oligosaccharide fragments (Khan et al., 2010; Bonner et al., 2009). Here, we 
apply this approach for the second time for oligosaccharide solution structures, this 
time for eight HS fragments ranging in sizes from dp6 to dp24, thus permitting 
detailed comparisons with heparin. The HS fragments exhibited solution structures 
that were distinct from those of the heparin fragments. In particular, their overall 
lengths are longer compared to heparin, and their structures display a greater degree 
of bending with increase in size compared to heparin. Our results are attributed to the 
difference in monosaccharide sequence between HS and heparin fragments, 
combined with a much reduced degree of sulphation in the HS fragments, which 
possessed greater structural flexibility than heparin. These results provided new 
insight on the potential binding modes of HS to proteins. 
 
(5.2) Results and discussion 
(5.2.1) Sedimentation velocity data analysis for the HS fragments 
Eight oligosaccharide fragments of HS dp6 to dp24 were prepared in 
collaboration with Dr. Barbara Mulloy (National Institute of Biological Standards 
and Control, Blanche Lane, South Mimms, Potters Bar, Hertfordshire, UK) through 
Biogel P-10 column (Section 5.4). The purification profile from the Biogel P-10 
column shows that the four smallest HS fragments dp6-dp8 were eluted as well 
resolved peaks, while the four larger fragments dp14-dp18 and dp24 were less well 
resolved (Figure 5.2). Analytical high performance size exclusion chromatography of 
the HS oligosaccharide fractions (Figure 5.3)  as described (Mulloy et al., 1997), and 
polyacrylamide gel electrophoresis (PAGE) were performed to show that all eight 
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peak fractions showed altered sizes as expected, and were relatively homogenous in 
size (Figure 5.2 inset).  
Analytical ultracentrifugation (AUC) studies macromolecular structures and 
sizes through quantitative measurements of sedimentation rates in a high centrifugal 
field (Cole et al., 2008). Sedimentation velocity experiments at three rotor speeds 
were performed for the eight HS fragments (dp6-dp18 and dp24) to determine their 
shapes and degree of polydispersity. The sedimentation coefficient distribution 
function c(s) was calculated by direct fitting of the sedimentation boundaries using 
SEDFIT software. The absorbance optics analyses for each HS fragment 
reproducibly resulted in good boundary fits that resulted in single major peaks 
(Figure 5.4a). The mean sedimentation coefficient s20,w values at three speeds ranged 
from 0.82 ± 0.05 S for dp6 to 1.26 ± 0.06 S for dp24. The corresponding interference 
optics analyses for dp6-dp24 also resulted in good boundary fits and single major 
c(s) peaks with mean s20,w values that ranged from 1.05 ± 0.04 S for dp6 to 1.35 ± 
0.04 S for dp24 (Figure 5.4b). The number of peaks and their widths assess the 
polydispersity of each HS fragment. In this regard, both the absorbance and 
interference optics showed better resolution and single narrower major peaks when 
compared with the equivalent data sets for heparin (Chapter 4: Figure 4.5). The most 
likely explanation for this appears to be variability in the sulphate content within the 
heparin fragments, causing variations in mass that resulted in a broader peak width. 
This effect would not be present in HS because of the reduced sulphation level in 
HS. The similar single peak widths from either absorbance or interference optics 
suggest that all eight HS fragments showed narrow size distributions and are 
relatively homogenous, in agreement with the chromatography results above. The 
smaller HS fragments show slightly broader peak widths than the larger ones and this 
is attributed to a higher back diffusion effect. Unlike heparin, a small decrease in the 
s20,w values of the absorbance and interference data was observed with increase of 
rotor speed; this indicated that the s20,w values depend on the rotor speed (Figure 
5.5a,b). Inspection of the boundary fits showed that the rotor-speed dependence 
resulted from a contribution from back-diffusion in the c(s) fits that was reduced with 
increase in rotor speed. 
Like heparin, the HS analyses revealed s20,w values that increased with 
increase in size of the fragments (Figure 5.5a,b). A typical molecular mass of the 
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corresponding value for heparin dp2 is 628 Da (Chapter 4: Figure 4.1a). Because of 
the differences in molecular size, the Svedberg equation predicts that the s20,w values 
of the HS fragments will be 77% of those for the equivalent sized heparin fragments. 
The mean s20,w value for HS dp24 is 1.30 ± 0.06 S (Table 5.1), which is 86 ± 8 % of 
the corresponding value for heparin dp24 of 1.52 ± 0.07 S (Chapter 4: Table 4.1). 
This is almost within error of the mass-predicted reduction in s20,w value. If real, the 
difference between the 77% and 86% values would correspond to a 10% smaller 
frictional coefficient for HS compared to heparin, i.e. HS may have a slightly more 
compact solution structure than heparin. 
The sedimentation coefficient s020,w values were calculated using 
HYDROPRO software from molecular models of HS. For this, 13 linear HS models 
(dp6 to dp30) were computed starting from the HS dp4 crystal structure seen in its 
complex with heparinise II (Shaya et al., 2010). The HYDROPRO software program 
is used to calculate s020,w values directly from atomic coordinates (Chapter 3: section 
3.4.6). Even though the increase of the s020,w values with size was predicted correctly, 
the theoretical s020,w values for HS were consistently lower than those seen 
experimentally (Figure 5.5a,b). This difference was not seen for heparin (Chapter 4: 
Figure 4.7). The lower theoretical values for HS than those seen experimentally 
indicate that the linear HS structures are more extended than the actual solution 
structures for HS. The theoretical s020,w value for HS dp24 is 1.05 S, which is 69% of 
the corresponding theoretical value of 1.52 S for a linear heparin dp24 structure. 
 
(5.2.2) X-ray solution scattering data for eight HS fragment 
Solution scattering is a diffraction technique that provides structural 
information on biological macromolecules in random orientations in solution 
(Perkins et al., 2008, 2009). In order to complement the AUC data in more detail, the 
solution structures of the same eight HS fragments dp6-dp24 at 0.5 mg/ml were 
characterized by synchrotron X-ray scattering. The scattering experiments reports the 
scattering curve I(Q) as a function of scattering angle Q. Tests for possible radiation 
damage effects  (Materials and methods) showed that these were not detectable, 
accordingly data were acquired with the longest exposure time of 1 sec in order to  
maximise signal: noise ratios. Guinier analyses of ln I(Q) vs. Q2 at low Q value gives 
the radius of gyration RG, which monitors the degree of macromolecular 
elongation. Because of the very different sizes of the HS fragments, different Q range 
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 spheres a 
 
RG (nm) b 
 
RXS (nm)    
 
R-factor  





S020,w (S) c 
dp6 None 5000 9-23 0.82-1.19 0.04-0.43 4.4-7.8 n.a  
 RG, RXS, R-factor 8 15-20 1.01-1.03 0.30-0.31 4.4-4.5 3.0-3.5 0.52-0.79 
 Best fit 1 19 1.01 0.30 4.4 3.0 0.52 
 Experimental   1.03 ± 0.08 
0.98 ± 0.05 
0.31 ± 0.06     3.0 0.82 ± 0.05 
1.05 ± 0.04 
dp8 None 5000 12-30 1.04-1.44 0.16-0.52 4.4-8.3 n.a  
 RG, RXS, R-factor 8 20-23 1.17-1.18 0.39-0.40 4.4 3.7-3.8 0.45-0.80 
 Best fit 1 20 1.18 0.39 4.4 3.7 0.77 
 Experimental   1.19 ± 0.08     
1.16 ± 0.02 
0.40 ± 0.03     3.5             0.94 ± 0.06 
1.06 ± 0.08 
dp10 None 5000 15.37 1.17-1.63 0.24-0.63 4.3-8.0 n.a  
 RG, RXS, R-factor 8 25-30 1.40-1.43 0.42-0.47 4.3-4.4 4.7-4.8 0.48-0.95 
 Best fit 1 26 1.42 0.42 4.3 4.8 0.91 
 Experimental   1.41 ± 0.07     
1.37 ± 0.04 
0.44 ± 0.04     4.5               0.95 ± 0.09 
1.09 ± 0.06 
dp12 None 5000 16-43 1.33-184 0.23-0.72 4.1-9.9 n.a n.a. 
 RG, RXS, R-factor 8 30-37 1.64-1.65 0.49-0.50 4.2 5.3-5.8 0.47-0.98 
 Best fit 1 34 1.64 0.49 4.2 5.5 0.92 
 Experimental    1.65 ± 0.09 
1.62 ± 0.03 
0.49 ± 0.04  5.5               1.08 ± 0.09 
1.16 ± 0.05 
dp14 None 8000 24-50 1.52-1.94 0.18-0.76 4.2-9.0 n.a. n.a. 
 RG, RXS, R-factor 8 35-40 1.75-1.78 0.48-0.51 4.4 6.0-6.5 0.74-1.05 
 Best fit 1 37 1.75 0.49 4.4 6.2 0.96 
 Experimental   1.76 ± 0.07 
1.82 ± 0.09 
0.51 ± 0.02  6.0               1.07 ± 0.07 
1.18 ± 0.04 
dp16 None 8000 28-54 1.57-235 0.36-0.91 6.3-19.4 n.a. n.a. 
 RG, RXS, R-factor 8 40-50 1.98-2.02 0.49-0.52 6.3-6.4 6.5-7.2 0.61-1.1 
 Best fit 1 43 1.96 0.52 6.3 6.8  1.10 
 Experimental   2.03 ± 0.07 
2.11 ± 0.11     
0.52 ± 0.01  7.0               1.10 ± 0.03 
1.24 ± 0.08 
dp18 Experimental   2.34 ± 0.03 
2.44 ± 0.11     
0.61± 0.05  8.5              1.12 ± 0.06 
1.25 ± 0.07 
dp24 Experimental   2.82 ± 0.10 
3.0 ± 0.05      
0.65 ± 0.05  10.0             1.26 ± 0.06 





Table 5.1 legend 
a The optimal totals of hydrated spheres were 16 for dp6, 21 for dp8, 26 for dp10, 31 
for dp12, 37 for dp14 and 42 for dp16. 
b The first experimental value is from the Guinier RG analyses and the second one is 
from the GNOM P(r) analyses. 
c The averaged experimental s20,w value is reported, the first value being from the 
absorbance (234 nm) data sets, and the second value from the interference data sets. 






























were required for each fragment in order to work within acceptable linear Q.RG 
ranges (Figure 5.6a). Thus the Guinier fit Q range of 0.4 to 0.8 nm-1 for dp6 was 
successively reduced in stages to that of 0.28 to 0.55 nm-1 for dp24 (Figure 5.6a). The 
mean Guinier RG values increased from 1.03 ± 0.08 nm for dp6 up to 2.82 ± 0.10 nm 
for dp24 (Table 5.1). These RG values for the eight HS fragments do not show a 
linear relationship with the size of the HS fragments, unlike the RG values calculated 
from linear models (Figure 5.7a). Thus these linear HS structural models show 
bending in solution. In comparison with heparin, the heparin RG values are smaller 
for the dp18-dp36 fragments than those seen for the HS dp18 and dp24 fragments. 
This shows that heparin has a more compact structure than that for HS. Like HS, 
heparin also showed a similar non-linear increase in the RG values of its fragments 
with increase of size (Chapter 4: Figure 4.8).  
Macromolecules that are sufficiently elongated in shape will show a cross-
sectional radius of gyration RXS value. The RXS value monitors the degree of bending 
within the macromolecular length. As for the RG analyses, different Q ranges were 
used for the RXS fits for the different HS fragments depending on the size of the HS 
fragment, all of which were larger than the Q ranges used for the RG analyses (Figure 
5.6b). In all cases, despite the worsened signal-noise ratios of the I(Q) data, linear fit 
ranges were identified in the plots of ln I(Q).Q vs. Q2. These gave experimental RXS 
values of 0.31 nm for dp6 that increased up to 0.65 nm for dp24 (Figure 5.7b; Table 
5.1). This increase in the RXS values correlated with the deviation of the RG values 
from linearity (Figure 5.7a). They were larger than the calculated RXS values from 
0.31 nm to 0.40 nm for the linear HS dp6-dp30 models, thus supporting the 
conclusion that the HS fragments become progressively more bent with increase in 
size. Combination of the RG and RXS values according to the relationship L2 = 12 (RG2 
–RXS2) for an elliptical cylinder (Glatter & Kratky, 1982) showed that HS dp6, dp8, 
dp10, dp12, dp14, dp16, dp18 and dp24 have approximate lengths of 3.4 nm, 3.9 nm, 
4.6 nm, 5.5 nm, 5.8 nm, 6.8 nm, 7.8 nm and 9.5 nm in that order. Similar lengths of 
7.0 nm, 9.1 nm, 9.6 nm and 10.7 nm were observed for the heparin dp18, dp24, dp30 
and dp36 fragments (Chapter 4: Table 4.1). In conclusion, the comparison of the 
dp18 and dp24 lengths showed that HS has a longer structure than that of heparin, in 
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The distance distribution function P(r) is calculated from the full Q range of 
the I(Q) scattering curve (Section 5.4). This provides RG values and model-
independent determinations of the overall length L following an assumption of the 
maximum dimension Dmax (Figure 5.7c). The mean RG values obtained from the P(r) 
curves increase from 0.98 ± 0.05 nm for dp6 to 3.0 ± 0.05 nm for dp24 (Table 5.1). 
These P(r) RG values are in excellent accord with the corresponding Guinier RG 
values from the low Q values and follow the same trends with size (Table 5.1; Figure 
5.7a). Model-independent L values are determined from the r value where the P(r) 
curve reaches zero at large r. These experimental L values were 3.0 nm for dp6, 3.5 
nm for dp8, 4.5 nm for dp10, 5.5 nm for dp12, 6.0 nm for dp14, 7.0 nm for dp16, 8.5 
nm for dp18 and 10.0 nm for dp24. These values show increasing deviation with size 
from the longer lengths measured for the linear HS dp6-dp24 models (i.e. 3.5 nm for 
dp6, 4.1 nm for dp8, 5.6 nm for dp10, 6.5 nm for dp12, 7.2 nm for dp14, 7.8 nm for 
dp16, 9.2 nm for dp18 and 11.2 nm for dp24), noting that a hydration shell of 
thickness 0.6 nm (= 2 × 0.3 nm) is added to these linear model lengths (Perkins, 
2001). These experimental L values from the P(r) curves are more accurate 
compared to the approximate L values calculated from the RG and RXS values that 
assumed an elliptical cylinder shape for HS, however these approximate L values 
show that the RG and RXS values are consistent with the P(r) analyses. The P(r) 
curves also provide the most frequently occurring interatomic distance M within the 
heparin structure from the r value of the peak maximum. M was observed at r values 
that started at 1.02 nm for dp6 and increased to 1.90 nm for dp24 (Figure 5.7c). In 
conclusion, these comparisons show that HS has a progressively more bent solution 
structure with increase in size. 
 
(5.2.2) Constrained modelling of six HS fragments  
The experimental X-ray RG and RXS values showed that the solution structures 
for HS are longer and more bent than those of heparin. Here, constrained scattering 
modelling was performed with HS in order to provide a molecular explanation of 
these scattering data. The linear models created from the HS dp4 crystal structure 
were the starting constraint. All eight HS fragments dp6-dp24 were subjected to 
modelling. As illustrated in the previous modelling of heparin, the linkage 





the Φ and Ψ rotational angles at each glycosidic linkage was varied randomly in a 
range of up to ± 45o from their starting values. In all, 5,000-8,000 models for each of 
the eight HS fragments were generated. For each fragment, X-ray scattering curves 
were calculated from these randomised models and fitted to the experimental curve. 
The RG, RXS and R-factor values were calculated for each modelled curve, where the 
RG and RXS values were calculated using the same Q range used for the experimental 
Guinier fits (Figure 5.6), and the R-factor is a measurement of goodness-of-fit. The 
R-factor distributions of Figures 5.8a-f and 5.9a-f showed that all the dp6-dp16 
models (yellow circles) encompassed the experimental RG and RXS values (dashed 
lines), and that the R-factor values were well below the level of 5% usually expected 
for excellent curve fits (Perkins et al., 1998). Totals of 5000 models for dp6-dp10 
and 8000 models for dp12-dp16 provided enough randomised conformers in order to 
be able to determine best fit HS solution structures. The lowest R-factors showed the 
best agreement with the experimental X-ray curves. At these minima, the best fit RG 
values (red and cyan circles) agreed well with the experimental RG values. The best 
fit RXS values also showed good agreement with the experimental RXS values (Figure 
5.9a-f). In distinction, the linear models for the dp6-dp16 HS fragments showed more 
marked deviations from the experimental RG and RXS values (green circles). Of 
interest was that this modelling procedure could not be applied to HS dp18 or dp24 
(not shown). There, no minimum R-factor could be identified in what turned out to 
be comparatively flat distributions. In addition, the curve fits showed better 
agreement for the linear models of dp18 or dp24 than the bent HS models, which was 
contrary to the analyses of Figure 5.5 and 5.7. The inability to fit the X-ray curve was 
attributed to the lack of a single well-defined solution structure for dp18 and dp24, 
unlike the cases of dp6-dp16.  
For HS dp6, the modelling analyses showed that a near-linear structure with 
slight bending accounted for the X-ray and AUC data. The eight best fit models gave 
R-factors of 4.4-4.5%, RG values of 1.01-1.03 nm, RXS values of 0.30-0.31 nm, and 
maximum lengths L of 3.0-3.5 nm. These agree well with the experimental RG value 
of 1.03 ± 0.08 nm, RXS value of 0.31 ± 0.06 nm, and the P(r) length of 3.0 nm 
(Figures 5.8a and 5.9a; Table 5.1). In distinction to these agreements, the linear dp6 
model gave a higher R-factor of 5.3 %, an RG value of 1.10 nm and a L value of 3.5 




































































































































P(r) curves was excellent (Figure 5.10a). The calculated s020,w values from the eight 
best-fit models gave 0.52 S to 0.79 S. These are lower but comparable with the 
experimental s20,w  values of 0.82 ± 0.05 S and 1.05 ± 0.04 S, given that the typical 
accuracy of the s020,w calculation is ± 0.21 S (Perkins et al., 2009). 
For HS dp8, the modelling analyses indicated slightly bent structures similar 
to those seen for dp6. The eight best fit models gave R-factors of 4.4%, RG values of 
1.17-1.18 nm, RXS values of 0.39-0.49 nm, and L values of 3.7-3.8 nm. These values 
agree well with the experimental RG value of 1.19 ± 0.08 nm, RXS value of 0.40 ± 
0.03 nm, and the P(r) length of 3.5 nm (Figures 5.8b and 5.9b; Table 5.1). In 
distinction to these agreements, the linear model again showed a higher R-factor of 
5.3 % and RG value of 1.28 nm, a lower RXS value of 0.35 nm and a larger L value of 
4.1 nm. The visual agreement of the experimental and modelled I(Q) and P(r) curves 
was excellent (Figure 5.10b). The eight calculated s020,w values of 0.45-0.80 S are 
smaller than the experimental s20,w values of 0.94 ± 0.06 S and 1.06 ± 0.08 S, 
however the best-fit model gave a calculated value of 0.77 S which is within error of 
experiment. 
For HS dp10, the modelling analyses showed good agreements with slightly 
bent structures, in which the deviation from a linear dp10 structure for dp10 was 
slightly increased. The eight best fit dp10 models gave R-factors of 4.3-4.4 %, RG 
values of 1.40-1.43 nm, RXS values of 0.42-0.47 nm, and L values of 4.7-4.8 nm. 
These correspond well with the experimental RG value of 1.41 ± 0.07 nm, RXS value 
of 0.44 ± 0.04 nm, and L value of 4.5 nm (Figures 5.8c and 5.9c; Table 5.1). The 
deviations from a linear dp10 model are larger, for which the R-factor is 4.5 %, the 
RG value is 1.46 nm, the RXS value is 0.36 nm and the L value is 5.6 nm. The visual 
agreement of the experimental and modelled I(Q) and P(r) curves was again 
excellent (Figure 5.10c). The eight modelled s020,w values of 0.48-0.95 S are similar 
to that of the experimental s20,w values of 0.95 ± 0.09 S and 1.09 ± 0.06 S, with the 
best-fit model giving a modelled value of 0.91 S. 
For HS dp12, the modelling analyses were also successful, in which the 
deviation from a linear dp12 structure was greater. The eight best fit models gave R-
factors of 4.2%, RG values of 1.64-1.65 nm, RXS values of 0.49-0.50 nm, and L values 
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RXS value of 0.49 ± 0.04 nm and L value of 5.5 nm (Figures 5.8d and 5.9d; 
Table 5.1). The linear model showed a higher R-factor of 4.6 %, a higher RG value of 
1.74 nm, a reduced RXS value of 0.34 nm and a longer L value of 6.5 nm. The visual 
agreement of the experimental and modelled I(Q) and P(r) curves was excellent 
(Figure 5.10(d)). The eight modelled s020,w values of 0.47-0.98 S are comparable with 
the experimental s20,w values of 1.08 ± 0.09 S and 1.16 ± 0.05 S, with the best-fit 
model giving a value of 0.92 S. 
For HS dp14, good agreements between the models and experimental data 
were obtained, while the deviation from a linear dp14 structure was larger. The eight 
best fit dp14 models gave R-factors of 4.4 %, RG values of 1.75-1.78 nm, RXS values 
of 0.48-0.51 nm and L values of 6.0-6.5 nm. These agree well with the experimental 
RG value of 1.76 ± 0.07 nm, RXS value of 0.51 ± 0.02 nm respectively, and L value of 
6.0 nm (Figures 5.8e and 5.9e; Table 5.1). These deviated from the linear dp14 
model which had an R-factor of 4.5 %, a higher RG value of 1.88 nm, a lower RXS 
value of 0.39 nm, and an L value of 7.2 nm. Again the visual agreement of the 
experimental and modelled I(Q) and P(r) curves was excellent (Figure 5.10e). The 
eight modelled s020,w values of 0.74-1.05 S compare well with the experimental s20,w 
value of 1.07± 0.07 S and 1.18 ± 0.04 S respectively, where the best-fit model gave a 
value of 0.96 S. 
For HS dp16, the outcome of the modelling analyses was similar to that of 
dp14. The eight best fit models gave R-factors of 6.3-6.4%, RG values of 1.92-2.02 
nm, RXS values of 0.49-0.52 nm, and L values of 6.5-7.2 nm. These agree well with 
the experimental RG value of 2.03 ± 0.07 nm, RXS value of 0.52 ± 0.01 nm, and L 
value of 7.0 nm (Figures 5.8f and 5.9f; Table 5.1) The linear model gave a poorer fit 
with an R-factor of 6.5 %, RG value of 2.12 nm, RXS value of 0.41 nm and L value of 
7.8 nm. The experimental and modelled I(Q) and P(r) curves showed excellent 
agreement (Figure 5.10f). The eight modelled s020,w values of 0.61-1.1 S are similar 
to the experimental s20,w values of 1.10 ± 0.03 S and 1.24 ± 0.08 S, with the best-fit 
model giving a value of 1.10 S. 
In conclusion, the best fit models for HS dp6 to dp16 show progressively 
more bent structures in solution with increase in HS size. This is visible from the 
superimposition of the eight best fit models for each HS fragment (Figure 5.11). In 
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glycosidic bond in HS has a similar length to that in heparin (Figure 5.12b). In HS, 
the separation between the C1-C4 atoms of GlcA-GlcNAc is 0.237 ± 0.003 nm and 
that between GlcNAc-GlcA is 0.235 ± 0.002 nm. For heparin, analyses of five crystal 
structures containing dp6 showed that very similar separations were seen between 
IdoA-GlcNS of 0.241 ± 0.004 nm and between GlcNS-IdoA of 0.243 ± 0.006 nm. 
Thus the increased length of HS in solution compared to heparin is therefore 
principally the consequence of altered Φ and Ψ angles. In terms of rotational bend, it 
is noteworthy that the crystallographic Φ and Ψ angles for smaller HS and heparin 
structures are in agreement with each other within error (Table 5.2; Figure 5.13). 
However the comparison of the Φ and Ψ angles of HS and heparin showed that these 
values differed (Figure 5.13). The mean Φ and Ψ angles for the GlcA-GlcNAc 
glycosidic linkage were -93º and 134º in HS, and are similar to the corresponding 
IdoA-GlcNS values of -61º and 132º in heparin, although the standard deviations are 
large at ±21-36º (Table 5.2). In distinction, the mean Φ and Ψ angles for the 
GlcNAc-GlcA linker were 4º and 138º in HS, which are more different from the 
corresponding values of 98º and 86º for the GlcNS-IdoA linker in heparin, although 
the standard deviations are again large (Table 5.2). The distribution of the Φ and Ψ 
values in Figure 5.13b suggests that there is more rotational variability at this second 
glycosidic bond in HS when compared with those for heparin in Figure 5.13d. In 
conclusion, when compared with the corresponding solution structure of large 
heparin fragments, large fragments of HS showed a longer and more bent structure in 
solution than those of heparin (Figure 5.12a).      
 
(5.3) Conclusions 
The size and spacing of S-domains in heparan sulphate are proposed to be as 
important to its biologically significant interactions with proteins as are the detailed 
sequences of the S-domains themselves (Kreuger et al., 2006).  Heparin, a commonly 
used model compound for heparan sulphate, consists of lengthy S-domains, made up 
largely of the repeating trisulphated disaccharide shown in Figure 5.1a, separated by 
much smaller, unsulphated NA-domains. In heparan sulphate the position is reversed, 










Table 5.2. Summary of the Φ and Ψ angle in the solution and crystal structures of 
HS and heparin  
         Φ (°)          Ψ (°)            Φ (°)           Ψ (°) 
     
 GlcA-GlcNAc GlcA-GlcNAc GlcNAc-GlcA GlcNAc-GlcA 
HS crystal structure a -90 ± 1 127 ± 4   83 ± 3 94 ± 1  
HS dp6  -101 ± 38 140 ± 19 -16 ± 27 129 ± 48 
HS dp8 -93 ± 26 121 ± 29  34 ± 55 152 ± 15 
HS dp10 -121 ± 26 126 ± 17   18 ± 41 143 ± 23 
HS dp12 -78 ± 30 114 ± 26  24 ± 35 121 ± 30 
HS dp14 -64 ± 32 149 ± 21 -12 ± 53 139 ± 42 
HS dp16 -112 ± 38 136 ± 45        -11 ± 88    143 ± 52 
Average (27 / 35 values) -93 ± 36 134 ± 32         4 ± 58    138 ± 37 
 IdoA-GlcNS IdoA-GlcNS GlcNS-IdoA GlcNS-IdoA 
19 heparin crystal 
structures a 
-79 ± 20 132 ± 19 84 ± 22 100 ± 19 
Heparin dp18 -52 ± 22 135± 15 104 ± 27 96 ± 25 
Heparin dp24 -61 ± 17 127 ± 20  100 ± 26 78 ± 17 
Heparin dp30 -64 ± 21 136 ± 21 87± 25 82 ± 22 
Heparin dp36 -63 ± 23 129 ± 27 103 ± 22 89 ± 24 
Average (50 / 54 values) -61 ± 21 132 ± 22 98 ± 25 86 ± 22 
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S-domain conformation, exemplified by heparin, has been the subject of numerous 
studies (Mulloy & Forster, 2000), the NA-domain has not. It has  
been proposed that the NA-domain repeating sequences are less flexible (Hricovini et 
al., 1997) and more flexible (Mobli et al., 2008) than the S-domains. 
By this study, we have determined molecular solution structures for small and 
medium sized HS fragments dp6 to dp16, and obtained insights into the structures of 
HS dp18 and dp24. The fragments we used were produced by extensive 
depolymerisation using heparinase I, an enzyme that cleaves only within the S-
domains (Powell et al., 2010) leaving NA-domains untouched. It is therefore likely 
that some minor degree of sulphation remains at the reducing and non-reducing end 
of our fragments, but that internal disaccharides are unsulphated. Such fragments 
bear a closer resemblance to NA-domains of intact HS than the most commonly used 
model compound for this sequence, the capsular polysaccharide from E. coli K5 
(Hricovini et al., 1997; Mobli et al., 2008). 
These comprise extended ones with flexibility around the glycosidic linkages 
between monosaccharide residues and evidence of flexibility in the larger structures. 
The structures provide novel comparative insight into the structures of HS and 
heparin, and the likely manner that these two polyanionic oligosaccharides interact 
with their protein ligands. Previously we reported that heparin dp6-dp36 exhibited a 
semi-rigid structure in solution (Chapter 4). HS and heparin both share similar 
covalent structures (Figure 5.1). The comparison of our two sets of structures for HS 
and heparin becomes essentially that between NA-domains and S-domains. The 
greater length and bending of HS compared to heparin (Figure 5.12) may be 
attributed to the difference in uronic acid residue, in which GlcNAc alternates with 
IdoA in HS, causing HS to adopt a distinct conformation from  that of fully sulphated 
heparin (Mulloy et al., 1994). The regular repeats of sulphate groups in heparin that 
are absent in HS are also expected to contribute to the relative rigidity of heparin.  
The application of constrained scattering modelling has proved to be as 
effective for the HS fragments as it was for heparin previously. Usually scattering 
fits are performed for protein structures with masses of 20-100 kDa and higher 
(Perkins et al., 2008, 2009). The HS fragments dp6-dp24 and the heparin fragments 
dp6-dp36 are an order of magnitude smaller in size with masses of 1-7 kDa and 2-11 





strength of the X-ray beam at the ESRF synchrotron and the low background levels 
at the instrument. The constrained scattering modelling technique determines a three-
dimensional molecular structure that best accounts for the observed scattering curve 
through trial-and-error searches that rule out structures that are incompatible with the 
observed scattering curves. By fixing the analyses to what is already known about 
the macromolecule, namely the carbohydrate rings, and varying only the flexible 
regions, namely the Φ and Ψ angles of each glycosidic linker, significantly fewer 
modelling variables are involved in the scattering fits. Through the variation of these 
Φ and Ψ angles, the analysis of 5,000-8,000 models provided sufficient statistical 
detail to result in clear V-shaped graphs of R-factor vs. RG and R-factor vs. RXS 
values. The best-fit models were identified by the lowest R-factor values, and these 
were verified by the agreement of the modelled and experimental RG and RXS values 
at this point. The quality of the HS dp6-dp16 scattering fits was similar to those of 
the heparin dp18-dp36 fits (Chapter 4: section 4.2.3). Interestingly, no good fits 
could be obtained for the HS dp18 and dp24 structures. Even though the 
monodispersity of these two fragments had been established by the single peaks seen 
in the ultracentrifugation c(s) analyses (Figure 5.4), it is possible that residual sample 
heterogeneity contribute to the lack of fit. It is more likely that flexibility, i.e. the 
accumulation of conformational variability at 17 and 23 glycosidic linkages in HS 
dp18 and dp24, compared to the variability between 5 to 15 linkages in HS dp6-
dp16, has resulted in the appearance of multiple conformations for HS dp18 and 
dp24 that precluded the ability to fit one single conformation to these two scattering 
curves. This modelling outcome is distinct from that for heparin dp6-dp36 when 
good fits could be obtained for all six structures. This outcome suggested that the 
heparin structures show greater rigidity than the HS fragments. 
The solution structures of the HS dp6-dp16 fragments exhibited a degree of 
bending (Figures 5.11 and 5.12a).  In addition the HS structures are longer for reason 
of alterations in the glycosidic Φ and Ψ angles (Figure 5.13). The physical basis of 
these changes in HS is likely to arise from the GlcA-GlcNAc sequence (as opposed 
to the IdoA-GlcNS sequence in heparin), together with less repulsion between 
sulphate-sulphate, sulphate-carboxylate, and carboxylate-carboxylate groups in HS.  
This study has provided fresh insight into potential HS-protein interactions 





structures has been discussed previously (Chapter 4: section 4.2.4). In distinction, 
only one protein-HS crystal structure is known (Shaya et al., 2010). It was of interest 
that the Φ and Ψ angles for this are in the similar range to those seen in the 19 
heparin-protein crystal structures (Table 5.2). Several studies of heparan sulphate-
protein interaction have noted that SAS sequences, in which two short S-domains are 
separated by an NA sequence, are preferred for optimum binding (Kreuger et al., 
2006). This is particularly true for oligomeric proteins such as, for example, MIP-1α 
(Stringer et al., 2002) or platelet factor 4 (Stringer and Gallagher, 1997). In these 
cases the multiple heparin binding sites on the oligomer are not always arranged in a 
linear way, so that a single long S-domain cannot readily bind to more than one site 
on the same multimer. It has been reasonable to suppose that NA-domains, composed 
of alternating α-(1-4) and β-(1-4) linked hexopyranoses, would be more flexible than 
the unusually stiff heparin structure of S-domains, allowing SAS sequences to bend in 
order to present two S-domains to heparin binding sites on opposite sides of a protein 
complex. The conclusion that can be drawn from our study of heparan sulphate NA 
fragments supports this intuitive reasoning. 
 
(5.4) Materials and methods 
(5.4.1) Purification of HS fragments 
HS oligosaccharide fragments were prepared in collaboration with Dr. 
Barbara Mulloy (see page 117) according to a similar method to that previously used 
for heparin oligosaccharides (Khan et al., 2010; Pellegrini et al., 2000; Mulloy et al., 
1997; Rice et al., 1985). Exhaustive heparinase digestion was used to minimise the 
content of fully sulphated sequences. About 100 mg of HS (prepared from a crude 
glycosaminoglycan mixture, the kind gift of Laboratori Derivati Organici, Italy: a 
mixture of HS-I and HS-II as described in (Casu et al., 1983) was weighed out and 
dissolved in about 2 ml phosphate buffer pH 7. An aliquot of 200 µl heparinase I 
stock solution was added and left to digest at room temperature for at least 2 hours, 
long enough for the reaction to run to completion. The reaction mixture was 
evaporated to dryness, using a rotary evaporator at 50°C. 
To isolate the HS fragments, the dried digest was dissolved in 1.5 ml of 2% 
ammonium bicarbonate solution, and filtered through a 0.45 micron syringe filter 





was then applied to a preparative gel permeation chromatography (GPC) column 
(100 × 1.6 cm; packed with Biogel P10) (Bio-Rad, UK). The HS fragments were 
eluted using 2% ammonium bicarbonate at a flow rate of 0.2 ml/min in 2 ml 
fractions. The absorbance of the fractions was measured at 234 nm and the top 
fractions corresponding to each individual resolved peak were pooled. The HS 
oligosaccharides larger than dp20 were not completely resolved to baseline 
resolution (Figure 5.2). The pooled fractions were evaporated under reduced pressure 
and lyophilised before assessment of their sizes by analytical GPC (Mulloy et al., 
1997). Like heparin, GPC was carried out using two columns (TSK G3000 SW-XL, 
30 cm; TSK G2000 SW-XL, 30 cm; Anachem, UK) connected in series. The eluant 
was 0.1M ammonium acetate solution at a flow rate of 0.5 ml/min, and HS was 
detected with a refractive index detector (RI-1530, Jasco, UK). The chromatography 
system was calibrated using the First International Reference Reagent Low 
Molecular Weight Heparin for Molecular Weight Calibration (NIBSC 90/686). HS 
quantisation was achieved by integration of the area under each refractive index peak 
and comparison with a standard curve prepared using known concentrations of low 
molecular weight heparin. An absorption coefficient of 5500 M-1 cm-1 was used for 
HS experiments (Powell et al., 2010).    
 
(5.4.2) PAGE of HS fragments 
The HS fragments were analysed by PAGE to determine the level of purity of 
each one according to a previously described method (Turnbull & Gallagher, 1988; 
Vives et al., 2001). Each HS fragment (5 µg) was mixed with 20% glycerol up to a 
maximum volume of 10-15 µl, and then loaded into separate wells (Figure 5.2, inset). 
Phenol red in 20% glycerol in a maximum volume of 10 µl was also applied to a 
separate well as a marker. Initially samples were run through a stacking gel (5% 
acrylamide/0.5% bisacrylamide) at 150 V for 20-30 min until the phenol red started 
to enter the resolving gel. In the resolving gel (25% acrylamide/1% bisacrylamide), 
samples were run at a constant current of 18 mA until the phenol red reached the 
bottom of the gel. The discontinuous buffer system of Laemmli (Laemmli, 1970) 
consisted of 0.125 M Tris/HCL, pH 6.8 in the stacking gel and 0.375 M Tris/HCL, 
pH 8.8 in the resolving gel. The gel running buffer was 25 mM Tris/0.192 M glycine, 





bands. The gel was then destained in water to remove excess dye and clear the gel 
background. 
 
(5.4.3) Analytical ultracentrifugation of HS fragments  
Sedimentation velocity data for eight HS fragments (dp6, dp8, dp10, dp12, 
dp14, dp16, dp18 and dp24) were obtained on two Beckman XL-I analytical 
ultracentrifuges (Beckman-Coulter Inc, Palo Alto, CA) using both absorbance and 
interference optics. Experiments with the dp6-dp24 fragments were performed at 
concentrations of 0.5 mg/ml in 10 mM HEPES and 137 mM NaCl (pH 7.4). The 
buffer density was measured at 20oC using an Anton-Paar DMA5000 density meter 
to be 1.00480 g/ml. A partial specific volume of 0.467 ml/g determined for heparin 
(Pavlov et al., 2003) was used for HS. An alternative higher value of 0.55 ml/g for 
HS has been reported elsewhere, and was used for data processing only when 
required to confirm that the partial specific volume has no effect on the outcome of 
this study (Fujiwara et al., 1984). Analytical ultracentrifugation runs were carried out 
in an eight hole AnTi50 rotor with standard double-sector cells with column heights 
of 12 mm at 20ºC using absorbance optics at 234 nm and interference optics. 
Sedimentation velocity data were collected at 40,000, 50,000 and 60,000 rpm using 
absorbance optics and interference optics. The continuous c(s) analysis method was 
used to determine the sedimentation coefficients s20,w of the eight HS fragments 
using SEDFIT software (version 9.4) (Dam & Schuck, 2004; Schuck, 2000). The c(s) 
analysis directly fits the experimental sedimentation boundaries using the Lamm 
equation, the algorithm for which assumes that all species have the same frictional 
ratio f/fo in each fit. The final SEDFIT analyses used a fixed resolution of 200, and 
optimised the c(s) fit by floating the meniscus and cell bottom when required, and 
holding the f/fo value, baseline and cell bottom fixed until the overall root mean 
square deviations and visual appearance of the fits were satisfactory (Figure 5.4). 
The individual f/fo values calculated previously for the heparin fragments were used 
for the equivalent HS fragments (Chapter 4: section 4.2.2).   
 
(5.4.4) Synchrotron X-ray scattering of HS fragments  
  X-ray solution scattering of the above eight HS fragments dp6-dp24 were 





(ESRF) at Grenoble, France in two sessions with a ring energy of 6.0 GeV 
(Narayanan et al., 2001). In the first session, data were collected for six HS 
fragments in 16-bunch mode using beam currents from 63 mA to 89 mA. In the 
second session, data were collected for all eight HS fragments in 16-bunch mode 
using beam currents from 65 mA to 78 mA. Data were acquired using an improved 
fibre optically-coupled high sensitivity and dynamic range CCD detector (FReLoN) 
with a smaller beamstop. The sample-to-detector distance was 3.0 m. Experiments 
used the same HS concentrations of 0.5 mg/ml and buffers used in the sedimentation 
velocity experiments. For each HS fragment, samples were measured in a flow cell 
which moved the sample continuously during beam exposure in 10 time frames with 
different exposure times of 0.1 s, 0.25 s, 0.5 s and 1 s to check for the absence of 
radiation damage effects. This exposure was optimised using on-line checks for the 
absence of radiation damage to show that this was not detectable. 
Guinier analyses give the radius of gyration, RG, which measures the degree 
of structural elongation in solution if the internal inhomogeneity of scattering within 
the macromolecules has no effect. Guinier plot at low Q values (where Q = 4 π sin 
θ/λ; 2θ is the scattering angle and λ is the wavelength) gives the RG and the forward 
scattering at zero angle I(0): (Glatter & Kratky, 1982) 
 
ln I(Q) = ln I(0) - RG2 Q2/3 
 
This expression is valid in a Q.RG range up to 1.5. If the macromolecular structure is 
sufficiently elongated (i.e. rod-shaped), the radius of gyration of the cross-sectional 
structure RXS and the mean cross-sectional intensity at zero angle [I(Q).Q]Q→0 
parameters are obtained from fits in a higher Q range:  
 
ln [I(Q).Q] = ln [I(Q).Q]Q→ 0  - RXS2 Q2/2 
 
The RG and RXS analyses were performed using an interactive PERL script program 
SCTPL7 (J. T. Eaton and S. J. Perkins, unpublished software) on Silicon Graphics 
O2 Workstations. Indirect Fourier transformation of the full scattering curve I(Q) in 





yields the maximum dimension of the macromolecule L and its most commonly 
occurring distance vector M in real space:  
 







The transformation was carried out using GNOM software (Semenyuk & Svergun, 
1991). For dp6, the full X-ray I(Q) curves contained 318 data points in the Q range 
between 0.40 nm-1 and 1.80 nm-1. For dp8 and dp10, 332 data points each were used 
in the Q range between 0.34 nm-1 and 1.80 nm-1. For dp12, 298 data points were used 
in the Q range between 0.30 nm-1 and 1.60 nm-1. For dp14, 295 data points were used 
in the Q range between 0.30 nm-1 and 1.59 nm-1. For dp16, 343 data points were used 
in the Q range between 0.29 nm-1 and 1.80 nm-1.  
 
(5.4.5) Molecular modelling of HS fragments  
Linear HS models were created using the crystal structure of the HS 
tetrasaccharide (dp4) observed in its complex with heparinase II (PDB code: 3E7J), 
and using Discovery Studio (version 2.5) molecular graphics software (Accelrys, San 
Diego, CA). The residues in HS dp4 were N-acetyl-D-glucosamine (NAG), D-
glucuronic acid (GCU) and 4,5-dehydro-D-glucuronic acid (GCD) in the order NAG-
GCU-NAG-GCD (PDB three-letter nomenclature). The NAG-GCU disaccharide was 
taken to be the base structure, and these disaccharide units (NAG-GCU) were joined 
by glycosydic bonds to generate a fully extended linear HS dp30 structure. In this, 
the phi (Φ) and psi (Ψ) angles were maintained at similar values observed in the 
starting dp4 structure. Linear HS dp6-dp24 models were created from this extended 
dp30 starting model by the removal of non-required disaccharides. Totals of 5,000 
conformationally-randomised models for each of dp6, dp8, dp10 and dp12, and 8,000 
similar models for each of dp14 and dp16 were created starting from each linear 
model. In the original HS dp4 structure, the Φ and Ψ angles were -90° and 124° 
respectively for the GlcA-GlcNAc (GCU-NAG) disaccharide and 85° and 95° 
respectively for the GlcNAc-GlcA (NAG-GCU) disaccharide. These Φ and Ψ angles 
were randomised to take any value in a maximum range of ±45° from their starting 





ExtractAngle.pl script provided with the Discovery Studio software. For example, in 
the case of dp16, a total of eight Φ and Ψ angles for GlcA-GlcNAc and seven Φ and 
Ψ angles for GlcNAc-GlcA were randomised in this way. To avoid steric clashes 
between the dp16 atoms in each randomised structure, a constant force field termed 
Dreiding minimization provided in Discovery Studio was used to correct this. 
Dreiding minimization was useful in generating structures by providing accurate 
geometries and reasonably accurate steric barrier for organic, biological and main 
group inorganic molecules (Chapter 3: section 3.4.2). 
 
(5.4.6) Constrained scattering and sedimentation coefficient modelling  
Each HS model was used to calculate the X-ray scattering curve for 
comparison with the experimental curve using Debye sphere models (Okemefuna et 
al., 2009; Furtado et al., 2008; Gilbert et al., 2006). A cube side length of 0.520 nm 
in combination with a cutoff of 4 atoms was used to create the spheres for the HS 
dp6-dp16 models. The hydration shell corresponding to 0.3 g/ g H2O was created by 
adding spheres to the unhydrated sphere models using HYPRO (Ashton et al., 1997), 
where the optimal total of hydrated spheres is listed in Table 1. The X-ray scattering 
curve I(Q) was calculated using the Debye equation as adapted to spheres and 
assuming a uniform scattering density for the spheres: (Perkins & Weiss, 1983). 
 
where g(Q) is the squared form factor for the sphere of radius r, n is the number of 
spheres filling the body, Aj is the number of distances rj for that value of j, rj is the 
distance between the spheres, and m is the number of different distances rj. Other 
details are given elsewhere (Perkins, 2001; Okemefuna et al., 2009; Furtado et al., 
2008; Gilbert et al., 2006). X-ray curves were calculated without instrumental 
corrections as these were considered to be negligible for the pinhole optics used in 










∑ n2 + n( g(Q) = I(0)I(Q) 2-1-  





hydrated models after grid transformation was used to assess steric overlap between 
the HS disaccharides, where models showing less than 95% of the optimal totals 
(Table 5.1) were discarded. This procedure was found to be insensitive to steric 
overlap in the case of oligosaccharides, and was discontinued in favour of the 
Dreiding minimization procedure (above). Next, the models were assessed by 
calculation of the X-ray RG values from Guinier fits of the modelled curves using the 
same Q ranges used for the experimental Guinier fits in order to allow for any 
approximations inherent in the use of the Q.RG range up to 1.5. Models that passed 
the N and RG and RXS filters were then ranked using a goodness-of-fit R-factor in 
order to identify the best-fit eight models for each HS fragment. 
Sedimentation coefficients s020,w for the best fit scattering models were 
calculated directly from molecular structures using the HYDROPRO shell modelling 
program (Chapter 3: section 3.4.6). The default value of 0.31 nm for the atomic 
element radius for all atoms was used to represent the hydration shell surrounding 
HS.  
 
(5.4.7) Protein Data Bank accession number 
 The best-fit dp6-dp16 models were deposited in the Protein Data Bank 
http://www.rcsb.org/pdb/ with accession codes of 3QHG (dp6), 3QHH (dp8), 3QHI 




















Complement Factor H possesses multiple independent binding sites for heparin 






The alternative pathway, one of the three activation pathways of the 
complement system of innate immunity, is a natural defence system for the 
recognition and destruction of foreign pathogens in vertebrate tissues (Pillemer et al., 
1954; Pangburn & Muller-Eberhard, 1984; Muller-Eberhard, 1988; Joiner, 1988). 
The activation of C3, the central component of complement system, to C3b through 
the removal of the small anaphylatoxin C3a from C3 by cleavage initiates the 
alternative pathway. Complement Factor H (FH), a 154 kDa plasma glycoprotein, is 
the major regulator of the alternative pathway and enables host and non-host surfaces 
to be distinguished by inhibiting C3 activation on host cells. FH performs this 
regulatory function by acting on C3b in three ways. FH acts as a cofactor in the 
factor I-mediated proteolytic inactivation of C3b into iC3b (Weiler et al., 1976; 
Pangburn et al., 1977), accelerates the spontaneous decay of C3 convertase of the 
alternative pathway (Whaley & Ruddy, 1976), and displaces factor B from the C3 
convertase (C3bBb) (Whaley & Ruddy, 1976).  
FH consists of 20 short complement regulator (SCR) domains, each of which 
contains about 61 residues. The SCR domains constitute the most abundant domain 
type in complement, and are also known as short consensus repeats or complement 
control protein domains (Soares & Barlow, 2005).  FH has three binding sites for 
C3b, where SCR-1/4 binds to intact C3b, SCR-6/10 binds to the C3c region of C3b, 
and  SCR-16/20 binds to the C3d region of C3b (Sharma & Pangburn, 1996; 
Jokiranta et al., 1998). FH inhibits surface-bound C3b activity on host cell surfaces 
by recognising polyanionic structures such as sialic acid, heparan sulphate (HS) and 
dermatan sulphate, all of which are found on host cell surfaces (Kazatchkine et al., 
1979; Carreno et al., 1989). Heparin has been often used as a model for such 
interactions for reason of its ready availability, sometimes being considered as an 
analogue of HS. FH has two major binding sites for heparin within SCR-7 and SCR-
20. A third binding site for heparin was originally located at SCR-13, but this was 
reassigned to SCR-9, then this SCR-9 site has been questioned (Blackmore et al., 
1996, 1998; Ormsby et al., 2006; Schmidt et al., 2008). FH was the first protein to be 
genetically linked to age-related macular degeneration (AMD), a common disease 
leading to blindness in the elderly. A Tyr402His polymorphism at SCR-7 in FH has 
been associated with many cases of AMD (Klein et al., 2005; Haines et al., 2005; 




appear between the retinal pigment epithelium and Bruch’s membrane, and are a 
biological indicator for the development of AMD (Bird et al., 1995). Drusen contain 
oxidized lipids and aggregated proteins including FH (Hageman et al., 2001). 
Glycosaminoglycans are also present in drusen (Kliffen et al., 2001).  
To date, our studies of full-length FH and heparin and HS fragments have 
resulted in molecular structures at medium resolution. Although crystal structures of 
small FH fragments have been reported to date, the large size, glycosylation and 
interdomain flexibility of full-length FH have precluded its crystallisation to date. 
Constrained solution scattering modelling showed that FH has a folded-back SCR 
structure (Figure 6.1a) (Aslam & Perkins, 2001; Okemefuna et al., 2009). Analytical 
ultracentrifugation showed that FH is about 85% monomeric, together with dimeric, 
trimeric and higher species up to nonamers in a combination of reversible and 
irreversible equilibria (Okemefuna et al., 2009; Nan et al., 2008). The solution study 
of six heparin fragments dp6-dp36 showed that these have extended and semi-rigid 
structures that are pre-formed in a conformation that is ready to interact with proteins 
such as FH, and molecular structures were determined (Figure 6.1b) (Chapter 4: 
Figure 4.11d). The solution structures of HS dp6-dp16 fragments (in which the 
heparin-like highly-sulphated regions have been removed by digests) showed that 
these were longer and more bent than the corresponding heparin fragments (Figure 
6.1c) ( Chapter 5: Figure 5.10f). A single molecule of heparin dp36 or HS dp24 is not 
able to bind simultaneously to the two major binding sites in FH unless the FH 
domain structure becomes significantly more compact (Figure 6.1). Because the 
interactions of FH with heparin and HS fragments have not yet been characterised, 
we describe in this study the conformational and oligomeric properties of FH in the 
presence of heparin and HS fragments. Previously tetramer formation in FH in the 
presence of dextran sulphate and high molecular weight unfractionated heparin has 
been reported using gel filtration chromatography and analytical ultracentrifugation 
(Pangburn et al., 2009). Here analytical ultracentrifugation and X-ray scattering are 
used to examine the FH complexes with heparin and HS fragments, together with 
molecular modelling (Perkins et al., 2008, 2009). The results provided new insight 
into these FH complexes, most notably that the two major heparin sites exist 
independently of each other in an inflexible FH structure that is not able to bend into 
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strong binding. The implications of these findings for the regulatory function of FH 
and their importance for AMD are discussed. 
 
(6.2) Results and discussion 
(6.2.1) X-ray scattering data for FH mixtures with heparin  
For X-ray scattering and analytical ultracentrifugation studies, full-length 
native FH was purified from the same pooled plasma stock used previously 
(Okemefuna et al., 2009; Nan et al., 2008a, 2008b). This gave a homogenous peak in 
gel-filtration chromatography and a single clean band on SDS-PAGE (Figure 6.2). 
All experiments were carried out at FH concentrations of 0.45-1.08 mg/ml which is 
comparable with physiological FH concentrations in plasma between 0.235-0.81 
mg/ml (Saunders et al., 2006). Given the ionic nature of the FH-heparin interactions, 
all experiments were performed in buffers with 137 mM NaCl in order to correspond 
to near-physiological conditions in plasma. 
Solution scattering is a diffraction technique that studies the overall structure 
of biological macromolecules in solution (Perkins et al., 2008). In order to determine 
the conformational and self-association properties of FH in the presence of six 
heparin fragments (dp6, dp12, dp18, dp24, dp30 and dp36), mixtures of FH (0.47 
mg/ml) with 1:1 molar ratios of each heparin fragment were characterized by 
synchrotron X-ray scattering. FH concentrations of 0.47 mg/ml were advantageous in 
reducing the effect of large FH oligomers compared to 1 mg/ml. The experiments 
result in the scattering curve intensities I(Q) measured as a function of the scattering 
vector Q. Given the small sizes of dp6-dp36 (1.88-11.30 kDa in mass) compared to 
FH (154 kDa), the Guinier analyses of the I(Q) data at low Q values will primarily 
observe structural and associative changes in FH when studied in the presence of 
heparin. These Guinier plots of In I(Q) versus Q2 gives the radius of gyration RG, 
which measures the degree of macromolecular elongation. The Q range of 0.06 to 
0.13 nm-1 gave the requisite linear RG analyses for FH and its heparin mixtures 
(Figure 6.3a). The mean observed RG values obtained for the FH mixture with dp6 
and dp12 were 8.4 ± 0.5 nm and 7.3 ± 0.4 nm respectively (Table 6.1). These RG 
values were slightly smaller than that of 8.9 ± 0.3 nm observed for FH alone. The RG 
values increased significantly when heparin dp18-dp36 was added to FH (Figures 
6.3a and 6.4a). The mean RG values were observed to be 10.4 ± 0.3 nm, 9.9 ± 0.4 nm, 
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Table 6.1. X-ray scattering and sedimentation coefficient data for the FH complexes with six heparin fragments dp6-dp36, and the 
sedimentation coefficient modelling fits for the FH oligomers complexed with heparin dp36  












Experimental          
FH   8.9 ± 0.3 2.93 ± 0.03 1.82 ± 0.01 34 5.5 ± 0.1 7.6 ± 0.2 8.5 9.4 ± 0.5 10.5  
FH + dp6   8.4 ± 0.5 2.80 ± 0.01 1.79 ± 0.02 35 5.6 ± 0.1 7.4 8.3 ± 0.5 9.3 ± 0.6 10.4 
FH + dp12   7.3 ± 0.4 3.08 ± 0.04 1.81 ± 0.06 32 5.6 ± 0.1 7.8 8.1 ± 0.1 9.6 ± 0.5 10.3 ± 0.2 
FH + dp18 10.4 ± 0.3 3.31 ± 0.07 1.82 ± 0.05 38 5.7 ± 0.1 7.1 ± 0.2 8.3 ± 0.4 9.4 ± 0.5 10.8 ± 0.1 
FH + dp24   9.9 ± 0.4 4.49 ± 0.04 1.80 ± 0.02 36 5.6 ± 0.1 7.1 ± 0.2 8.5 9.1 ± 0. 1 10.4 ± 0.5 
FH + dp30 10.8 ± 0.3  4.53 ± 0.04 1.80 ± 0.06 38 5.8 ± 0.1 7.2 ± 0.1 8.6 ± 0.2 9.5 ± 0.6 10.6 ± 0.3 
FH + dp36 11.7 ± 0.9 5.11 ± 0.02 1.83 ± 0.02 40 5.7 ± 0.1 7.0 ± 0.2 8.2 ± 0.3 9.1 ± 0.1 10.6 ± 0.3 
Modelling *          
FH + dp36 
(Okemefuna et 
al., 2009)   
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(Table 6.1). The Guinier I(0)/c value is proportional to molecular weight and this 
decreased slightly after mixture with dp6 and dp12 (Figure 6.4b). This indicated that 
dp6 and dp12 decreased the proportion of 8-10% of oligomers seen for free FH 
(Okemefuna et al., 2009; Nan et al., 2008), suggesting that these blocked the FH 
self-association sites. The I(0)/c values increased significantly with the larger heparin 
fragments (Figure 6.4b). That I(0)/c was more than doubled for the dp36 mixture 
compared to FH alone showed that FH oligomer formation had been strongly 
induced by heparin. Because the scattering curve is an average of the species present 
in the sample, it was not possible to state whether a single complex or multiple 
oligomeric species had been formed, nor was it possible to say whether 
conformational changes had taken place in FH on interaction with heparin.  
The two cross-sectional Guinier analyses (Figure 6.3) monitor the structural 
proximity relationships between non-neighbouring (RXS-1) and neighbouring (RXS-2) 
SCR domains (Aslam & Perkins, 2001). The overall folded-back SCR domain 
structure of FH leads to the RXS-1 value, while the localised extended structural 
arrangement of SCR domains leads to the RXS-2 value. When no heparin was present, 
the RXS-1 value of FH was 2.93 ± 0.03 nm, which is in agreement with the previous 
value of 2.7 ± 0.1 nm for free FH (Table 6.1) (Nan et al., 2008). The RXS-1 values 
were almost unchanged at 2.80 ± 0.05 nm for the FH-heparin dp6 mixture and 3.08 ± 
0.04 nm for the FH-heparin dp12 mixture. The RXS-1 values increased significantly 
with heparin size for dp18-dp36 (Figure 6.4c). Thus the RXS-1 values of 3.31 ± 0.07 
nm, 4.49 ± 0.04 nm, 4.53 ± 0.04 and 5.11 ± 0.02 nm for the complexes of FH with 
dp18, dp24, dp30 and dp36 respectively were seen, indicating that new proximity 
relationships between non-interacting SCR domains had occurred in these mixtures. 
When no heparin was present, the RXS-2 was 1.82 ± 0.01 nm, in good agreement with 
the previously reported RXS-2 value of 1.79 ± 0.03 nm (Nan et al., 2008). When 
heparin fragments were added, no significant changes in the RXS-2 values were 
observed (Figure 6.4(d)), all of which remained within the same range of 1.79 nm to 
1.83 nm (Table 6.1). The RXS-2 values indicated that the linear extended arrangement 
of neighbouring SCR domains remained unchanged in FH-heparin mixtures.  
The distance distribution function P(r) represents the summation of all the 
distances r between every pair of atoms within the macromolecule. The P(r) curve, 
calculated from the full I(Q) curve (Materials & Methods), gives the RG and I(0) 
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from the P(r) analyses were in good agreement with the Guinier analyses (Figure 
6.4a,b). The intensity of the P(r) curve increased significantly in the presence of 
large size of the heparin fragment. The maximum length L is measured when the P(r) 
curve reaches zero at large r value. In the absence of heparin, the L value of FH was 
34 nm, in good agreement with the previously reported L value of 33 nm (Nan et al., 
2008). The maximum, M, in the P(r) curve corresponds to the most frequently 
occurring interatomic distance within the structures. For free FH, the main peak M1 
and a sub-maximum peak M2 were observed at r values of 5.8 nm and 11.6 nm 
respectively. When dp6 was added, the L, M1 and M2 values were unchanged at 35 
nm, 6.0 nm and 11.7 nm respectively (Figure 6.5a). When dp12 was added, the L, 
M1 and M2 values were again unchanged at 32 nm, 6.7 nm and 11.6 nm, although 
there was a small increase in the size of the M2 peak. Starting with dp18, larger 
changes were observed in which the L values were increased with heparin sizes, the 
M1 peak disappeared, and the M2 peak became more prominent. With dp18, dp24, 
dp30 and dp36, the L values increased to 38 nm, 36 nm, 38 nm and 40 nm 
respectively, indicating an increase in FH oligomer formation. There was also a large 
increase in the size of the P(r) curve for the FH mixtures with dp24, dp30 and dp36 
(Figure 6.5b). The P(r) curves thus show that large FH oligomer had formed in the 
presence of 1:1 molar ratios of heparin dp24-dp36.  
 
(6.2.2) X-ray scattering data for FH mixtures with HS  
Mixtures of FH with eight HS fragments in 1:1 molar ratios that correspond 
to depleted sulphate contents (i.e. its NA-domain (Chapter 5: section 5.4.1) were 
studied in order to compare the effect of heparin and HS on FH. The same FH 
concentrations and buffer was used. In the Guinier analyses (Figure 6.6a), the RG 
values measured for FH mixtures with HS dp6 and HS dp8 were 7.8 ± 0.1 nm and 
7.8 ± 0.1 nm respectively, in agreement within that for free FH of 7.9 ± 0.1 nm. With 
HS dp10, FH showed a slightly smaller RG value of 7.6 ± 0.1 nm. With HS dp12, HS 
dp14, HS dp16, HS dp18 and HS dp24, the RG values of these mixtures with FH 
showed small increases to 8.0 ± 0.1 nm, 8.1 ± 0.1 nm, 8.1 ± 0.1 nm, 8.2 ± 0.1 nm and 
8.3 ± 0.1 nm respectively (Figure 6.7a). The Guinier I(0)/c values also showed small 
increases with increased HS size (Figure 6.7b). The small increases in the RG and 
I(0)/c values for FH-HS mixtures were generally smaller (with only one exception) 
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The cross-sectional radii of gyration RXS-1 and RXS-2 for the eight FH-HS 
mixtures were also analysed (Figure 6.6b). Compared to the RXS-1 value of 2.7 ± 0.1 
nm for free FH, the RXS-1 values for the first six FH-HS mixtures were slightly 
smaller (Figure 6.7c). The RXS-1 values were 2.64 ± 0.06 nm, 2.60 ± 0.10 nm, 2.53 ± 
0.04 nm, 2.50 ± 0.03 nm, 2.66 nm and 2.52 ± 0.01 nm for the mixtures with dp6, 
dp8, dp10, dp12, dp14 and dp16 respectively. For dp18 and dp24, the RXS-1 values 
were slightly increased at 2.87 ± 0.04 nm and 2.74 ± 0.04 nm respectively. 
Compared to the RXS-2 value of 1.79 ± 0.03 for free FH, no significant changes in the 
RXS-2 values in FH-HS mixtures were observed (Figure 6.7d).  
The distance distribution function P(r) curves was calculated for the FH 
mixtures with HS dp6, dp12, dp18 and dp24. Interactions between FH and HS were 
observed in all four cases, as shown by the increased intensity of the P(r) curves in 
all four cases, especially in the case of FH dp24 (Figure 6.8b). The lengths L were 30 
nm for the dp6 and dp12 mixtures, similar to that for free FH (Figure 6.8a). The L 
values were increased to 32 nm and 31 nm for dp18 and dp24 respectively. The 
maximum M1 and sub-maximum M2 peaks were observed at r values of 4.8 nm and 
10.2 nm for free FH. For the dp6, dp12, dp18 and dp24 mixtures, the M1 peak was 
unchanged in position in a range between 4.2 nm to 5.1 nm. The M2 peak was 
likewise also unchanged between 7.8 nm to 10.5 nm. While the M2 peak first became 
visible for heparin dp12 and dp18, this change first became visible for HS only when 
the dp24 fragment was used (Figure 6.8a). 
Compared to the effects of heparin on FH, the HS fragments showed similar 
effects but these were reduced in their magnitude. Thus, while interactions between 
FH and HS were detectable, the reduced number of sulphate groups in the HS 
fragments compared to those in heparin appeared to be responsible for the smaller 
observed effects. 
 
 (6.2.3) Sedimentation velocity data for FH mixtures with heparin  
Analytical ultracentrifugation (AUC) provides structural information on 
macromolecules in solution by following their sedimentation behaviour under a high 
centrifugal force (Cole et al., 2008). In order to complement the X-ray scattering data 
for FH-heparin mixtures, sedimentation velocity data were collected for native FH at 
1.08 mg/ml in the presence of six heparin fragments (dp6-dp36) in 1:1 ratios in the 
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advantageous in making more visible the peaks that arise from its oligomers (see 
below). The velocity data were analysed using SEDFIT fits based on the interference 
optics to generate the size distribution analyses c(s) of the FH-heparin mixtures. 
Three rotor speeds of 40,000 rpm, 50,000 rpm and 60,000 rpm were used in order to 
evaluate potential reaction boundaries. Reaction boundaries are concentration-
dependent and rotor speed-dependent peaks that correspond to the co-sedimentation 
of two different species if there is an equilibrium between themselves during 
sedimentation. They exhibit well-defined s20,w values and masses that are 
intermediate between the actual s20,w values and masses of the two different species, 
and are distinct from undisturbed boundaries which correspond to the actual 
sedimentation species themselves (Okemefuna et al., 2010; Li et al., 2010). 
The analyses of interference scans showed that FH behaves differently in the 
presence of different fragments of heparin (Figures 6.9A, 6.9B and 6.9C). Because 
the s20,w values of free heparin dp6-dp36 sediment at 1.2 S to 1.9 S (Chapter 4: 
Figure 4.7), peak overlap of the FH peaks between 5 S to 22 S with the heparin peaks 
does not occur. In all the FH-heparin mixtures, the c(s) plots showed that monomeric 
FH was observed to sediment at an s20,w value of  5.66 ± 0.09 S, in good agreement 
with an s20,w value of 5.5 ± 0.1 S for free FH at 0.87 mg/ml. In the mass distribution 
analyses c(M), this peak corresponded to a molecular mass value of 132 ± 4 kDa in 
the FH-heparin mixtures, compared to one of 134 ± 4 kDa for free FH at 0.87 mg/ml. 
These values were in good agreement with the previously reported s20,w value of 5.65 
± 0.05 S and c(M) value of 142 ± 2 kDa for free FH at concentration between 0.17 to 
5.92 mg/ml (Nan et al., 2008). 
About 12-15% of FH oligomers were previously reported for free FH at 
different pH and salt concentrations (Okemefuna et al., 2009; Nan et al., 2008). 
These were seen as small peaks numbered 2 to 10 in the c(s) plots (Figures 6.9A, 
6.9B and 6.9C). No significant changes were observed in the presence of small size 
of heparin dp6 and dp12. Thus the FH-heparin dp6 mixture showed the same 
oligomeric peaks ranging from dimer to heptamers at s20,w values of  7.95 S, 9.77 S, 
11.39 S, 14.09 S, 16.63 S and 19.60 S at 50,000 rpm (Figure 6.9Bd). Similar peaks 
were seen for the FH-heparin dp12 mixture at s20,w  values of  8.07 S, 9.96 S, 11.86 S, 
13.44 S, 16.09 S and 19.50 S (Figure 6.9Bd). The mean proportion of all the 
oligomers at 40,000 rpm, 50,000 rpm and 60,000 rpm were 9 ± 3% and 9 ± 2% in the 
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for free FH (Figure 6.10a). Ultracentrifugation indicated that slight decrease in the 
oligomerisation of FH occurred in the presence of heparin dp6 and dp12 in 1:1 ratios, 
and this complements the observation of small reductions in the RG values seen by X-
ray scattering. Accordingly, heparin dp6 slightly inhibit FH oligomer formation.  
In distinction, the FH mixtures with the larger heparin fragments (dp18-dp36) 
showed major increases in the oligomer peak intensities between s20,w values of 7 S 
to 22 S (Figures 6.9Bd and 6.10a). These oligomers amounted to 42 ± 2 %, 29 ± 1 %, 
61 ± 2 %, and 63 ± 4% of FH in the dp18, dp24, dp30 and dp36 mixtures 
respectively (Figure 6.10a). A greater FH oligomerization in the presence of heparin 
dp30 and dp36 was shown by the exceptional increase in size of peak 8 at an s20,w 
value of 18.6 S and 18.0 S, which accounted for 49% and 28% of the FH oligomers 
(Figure 6.9Bd).  Peak 8 correspond to higher molecular masses of around 765 kDa 
and 714 kDa respectively in the c(M) plots for FH-dp30 and FH-dp36, although this 
calculation assumes that the frictional ratio has not changed, which is unlikely for 
this large FH oligomer. Moreover, the proportion of dimer also increased with 
increase in heparin size. In the presence of dp6 and dp12, the dimer proportion was 4 
± 1 % and 5 ± 2 % respectively, which is similar to the free FH value of 4 ± 1 %. 
With the larger heparin fragments, the proportion of dimer was increased to 11 ± 2 % 
(dp18), 7 ± 1 % (dp24), 9 ± 1 % (dp30) and 14 ± 1% (dp36) (Figure 6.10a). In 
summary, these results suggest that heparin dp6 and dp12 are not large enough to 
crosslink FH, but may inhibit the formation of those observed in free FH. Starting 
with dp18, heparin becomes long enough to crosslink FH molecules to form a 
different set of large oligomers.  
A further examination of the c(s) analyses extended these conclusions. The 
FH monomer peak was found at the same position for all the FH-heparin mixtures 
(Figure 6.9Bd; Table 6.1), which is as expected because the FH monomer will be 
almost unaffected by the binding of a single heparin molecule (1.88-11.30 kDa in 
mass, compared to 154 kDa for FH). The lack of change in the S values shows that 
no major conformational change occurs when heparin binds to monomeric FH. The 
FH dimer peaks in the dp18-dp36 complexes shifted towards lower S values by about 
0.7 S compared to the peaks seen with dp6 and dp12 (Figure 6.9Bd; Table 6.1). This 
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more extended conformation than that for the free FH dimer. The comparison of 
three rotor speeds (Figures 6.9A, 6.9B and 6.9C) showed no change in the peak 
positions, although there was significant oligomer peak broadening at 40,000 rpm 
and peak narrowing at 60,000 rpm. The absence of peak shifts between Figures 6.9A, 
6.9B and 6.9C indicate that the FH-heparin complexes showed slow association and 
dissociation rates compared to sedimentation rates, i.e. those reaction boundaries do 
not appear to be present.   
Sedimentation velocity experiments for FH-heparin dp6 mixtures at 50,000 
rpm were performed in order to assess whether dp6 was bound to FH. These 
employed molar ratios that ranged from 1:0.5 to 1:8 at a FH concentration of 1.12 
mg/ml, and using the same buffer (Figure 6.11). In the c(s) analyses, peaks 1 and 2 at 
5.5 S and 7.5 S correspond to the FH monomer and dimer, while peak A at 1.1 S 
correspond to unbound dp6. For the molar ratios of 1:0.5 to 1:4, no unbound dp6 
peak was observed at s20,w values of  1.02 S to 1.1 S, indicating that dp6 was fully 
bound to FH and was incorporated within peak 1. The unbound heparin dp6 peak 
only appeared at the high molar ratios of 1:6 and 1:8, indicating that there were 
multiple binding sites for heparin dp6 within FH. Because two major heparin binding 
sites are known at SCR-7 and SCR-20 in FH, this would explain the absence of the 
dp6 peak A at low molar ratios of 1:2. The absence of the dp6 peak at molar ratios of 
1:3 and 1:4 also indicate an interaction between dp6 and monomeric FH. Here, the 
two small peaks B and C that become visible at high molar ratios may correspond to 
reaction boundaries that involve the formation of 1:1 and 1:2 complexes of FH with 
dp6. This interpretation is complicated by the appearance of peaks B and C in free 
FH, suggesting that they originate from the presence of unknown buffer components. 
Integration of the c(s) plots showed no changes in the proportions of monomer, 
dimer and oligomers proportions at all the FH-dp6 ratios (Figure 6.10b). In 
conclusion, even though no increased FH oligomer formation took place, the changes 
in the heparin peaks A, B and C are consistent with a FH-heparin dp6 interaction.  
Similar sedimentation velocity experiments for FH-heparin dp12 mixtures at 
50,000 rpm were performed in order to assess whether an interaction between FH 
and dp12 was detectable. These used the same range of molar ratios used for dp6 
above, based on a FH concentration of 1.0 mg/ml. In distinction to the dp6 
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increase in the dp12 molar ratios (Figure 6.12). Integration showed that no changes 
were observed for the 1:0.5 and 1:1 ratios, while increased FH oligomerization was 
observed for the higher ratios up to 28 ± 2 % and 28 ± 1 %  for the 1:6 and 1:8 ratios 
respectively (Figure 6.10c).  Interestingly, the proportion of the FH dimer and trimer 
was increased for the 1:6 and 1:8 ratios, being 10 ± 1 % and 9 ± 1 %  of dimer, and 7 
± 1 % and 7 ± 1 % of trimer respectively (Figure 6.10c). In comparison, these 
proportions were more than halved in free FH, being 4 ± 1 % and 2 ± 1 % 
respectively. These results indicate that heparin dp12 interacts with FH in a 
concentration-dependent manner.  
Sedimentation velocity experiments for FH-heparin dp36 showed the extent 
of the peak shifts that occur with increased oligomer formation (Figure 6.13). Figure 
6.13 is derived from the FH-dp36 c(s) analyses shown in Figures 6.9A, 6.9B and 
6.9C. The significant peak broadening at 40,000 rpm and peak narrowing at 60,000 
rpm for the FH-dp36 mixture was already noted above. The increased number of 
peaks seen at 60,000 rpm compared to 40,000 rpm suggested that more than one type 
of FH-heparin oligomer may be structurally formed for each FH-heparin oligomer.  
 
(6.2.4) Sedimentation velocity data for FH mixtures with HS  
To evaluate the FH-HS interaction, sedimentation velocity experiments were 
also performed for 1:1 FH mixtures with HS dp6, dp12, dp18 and dp24 at two rotor 
speeds of 40,000 rpm and 50,000 rpm in HEPES buffer. The FH concentration was 
0.45 mg/ml. In all the FH-HS mixtures at 50,000 rpm, monomeric FH gave an s20,w 
value of  5.52 ± 0.04 S and a molecular mass of 132 ± 4 kDa (Figure 6.14). This is in 
good agreement with the monomer s20,w value of 5.48 ± 0.02 S and mass of 134 ± 4 
kDa for free FH at 0.87 mg/ml, and a monomer s20,w value of  5.67 ± 0.07 S and mass 
of 132 ± 4 kDa observed for the FH-heparin complexes. Even though the FH 
concentration was halved compared to that used with heparin (above), the oligomer 
peaks remained visible in the c(s) plots. In the presence of HS dp6, five oligomeric 
species were observed at s20,w values of 8.0 S, 9.8 S, 12.4 S, 14.9 S and 18.5 S for 
dimer to pentamer respectively (Figure 6.14).  In the presence of HS dp12, six 
oligomer peaks were observed at slightly altered s20,w values of 7.7 S, 9.2 S, 10.5 S, 
12.7 S, 14.8 S and 17.4 S. The proportion of the FH oligomers in the presence of HS 
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lower than the 12% proportion of oligomers in free FH (Figure 6.15). However the 
oligomer proportion of FH in the presence of HS dp18 and dp24 was higher at 21% 
and 14% respectively. As for the FH-heparin mixtures, these results suggest that the 
small HS fragments dp6 and dp12 slightly inhibit FH oligomerisation, while the 
larger HS fragments increase FH oligomerisation (Figure 6.15). Given that the 
proportion of FH oligomer in the presence of heparin dp18 was larger than that for 
FH-heparin dp24 (Figure 6.10), it was of interest that the same has occurred with HS 
dp18 and HS dp24 (Figure 6.15). For both FH-heparin and FH-HS, the dimer peak is 
more pronounced in the mixtures of FH with dp18/dp24 and less so for dp6/dp12 
(Figures 6.9 and 6.14). As for the FH-heparin mixtures, the FH oligomers in the 
presence of HS dp18 and HS dp24 were also shifted towards lower s20,w values, 
indicating changes in the oligomer shapes to more extended conformations when 
these incorporated the larger HS fragments (Figures 6.13 and 6.14). In summary, 
similar results were obtained for FH-HS mixtures when these were compared to 
those for FH-heparin mixtures, although the magnitudes of the oligomerisation 
changes were reduced for HS when these were compared with heparin (Figures 6.10 
and 6.15). 
 
(6.2.5) Modelling of FH-heparin dp36 complexes  
Molecular modelling of the scattering and ultracentrifugation data provides a 
validation of the experimental data and their interpretation (Perkins et al., 2008, 
2009). In this instance, scattering modelling for the FH-heparin and FH-HS mixtures 
were not feasible because of insufficient monodispersity in the samples that were 
mixtures of free and complexed protein, the latter of which formed a series of 
oligomers. Ultracentrifugation modelling of the experimental s20,w values had 
previously explained the peaks 2-7 to arise from dimeric to heptameric forms of FH, 
starting from the 2001 X-ray scattering solution structure (Aslam & Perkins, 2001; 
Nan et al., 2008). Here, the SCR-7 and SCR-20 domains in FH were joined up with 
heparin dp36 to create models for dimeric, trimeric, tetrameric and pentameric 
oligomeric complexes (Figure 6.16). It should be noted that scattering modelling was 
not able to identify specific SCR domain arrangements; only that the SCR domains 
are folded back. Accordingly the relative locations of SCR-7 and SCR-20 are 
putative only. While ring-like structures were readily modelled, alternative dimeric 
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from a recent FH model based on fitting the 20 SCR domains with 19 flexible linkers 
between the domains (PDB code 3GAV) (Okemefuna et al., 2009) in combination 
with the heparin dp36 model (PDB code 3IRL) (Chapter 4: Figure 4.11d), the FH-
heparin complexes were created manually from the best-fit solution structures of FH 
and dp36 using Discovery Studio molecular graphics. In this FH model, the SCR-7 
and SCR-20 domains were separated by 27 nm.  
The outcome of the modelling is summarised: 
(a) The predicted s020,w value for an antiparallel dimer model created from 
two dp36 and two FH molecules was 7.5 S. This agreed well with the observed 
values of 7.0-7.2 S for dp18-dp36, given that the method is accurate to ± 0.21 S 
(Perkins et al., 2009) (Figures 6.16a and 6.17a; Table 6.1). A parallel dimer model 
that was created using these four molecules was more compact in its shape and gave 
a larger predicted s020,w value of 8.1 S (Figures 6.16b and 6.17b, Table 6.1). An 
antiparallel dimer was favoured by this calculation. 
(b) The predicted s020,w values for the trimeric, tetrameric and pentameric 
ring-like complexes were 8.8 S, 9.5 S and 10.6 S, in good agreement with the 
experimental peaks observed at 8.2-8.6 S, 9.1-9.5 S and 10.4-10.8 S for dp18-dp36 
(Figures 6.16(c-e) and 6.17(c-e); Table 6.1). In distinction to this agreement, the 
more compact crossed-over tetrameric and pentameric gave predicted s020,w values of 
11.3 S and 12.4 S that were almost 2 S higher than the experimental values (Figures 
6.16(f,g) and 6.17(f,g); Table 6.1). 
(c) Control calculations were performed using other scattering best-fit FH 
models. One was derived from X-ray scattering curve fits for homozygous FH, based 
on fitting five rigid SCR fragments with four flexible linkers between the domains 
(PDB code 3N8O) (A. I. Okemefuna & S. J. Perkins, unpublished modelling). Here 
SCR-7 and SCR-20 were positioned more closely together with a separation of 10 
nm. The other was derived from X-ray scattering curve fits for homozygous FH, 
based on fitting the 20 SCR domains with 19 flexible linkers between the domains 
(PDB code 3N0J) (Nan, et al., 2010). Here SCR-7 and SCR-20 were separated by 13 
nm. Similar FH-heparin models were created (Figures 6.18 and 6.19). The outcome 
of the modelling (Table 6.1) showed that the predicted s020,w values were higher by 
about 1 S compared with the 2009 model. This difference is attributed to the closer 
separations of 10 nm and 13 nm between SCR-7 and SCR-20 in these two extra FH 
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compact to explain the experimental s20,w values. 
 
(6.3) Conclusions  
Heparin and HS interact with a wide range of proteins that are involved in 
biological and physiological processes (Capila & Linhardt, 2002). The most 
prominent type of interaction between heparin or HS and proteins is ionic, being 
provided by the sulphate and carboxyl groups (Capila & Linhardt, 2002). FH 
performs its regulatory function by recognising polyanionic molecules present on the 
host cell surfaces that are absent on bacterial surfaces, thereby positioning itself for 
the control of activated C3b that would otherwise damage the host. Despite the 
biological importance of FH, there has been no structural understanding up to now of 
how full-length FH interacts with heparin and HS fragments. Polyanionic molecules 
such as HS and sialic acids on the host cell surface enhance the regulatory 
effectiveness of FH by 10-fold through its inhibition of complement activation 
(Pangburn, 2000; Meri & Pangburn, 1990; Pangburn & Müller-Eberhard, 1978). In 
this study, we have studied the heparin and HS interactions with FH as a function of 
oligosaccharide size. Our results provide four novel insights into the FH interaction 
with heparin and HS in near-physiological salt by showing that (i) both polyanionic 
oligosaccharides promote strong FH oligomer formation; (ii) at least two heparin 
binding sites on FH are involved; (iii) little structural changes in FH occur after 
heparin or HS binding; and (iv) the higher sulphation of heparin leads to 
strengthened FH binding when compared to HS.   
FH is a major complement regulator found in plasma at concentrations of 
0.235 mg/ml to 0.81 mg/ml (Saunders et al., 2006). Free FH self associates to form 
12% oligomers at physiological concentrations (Nan et al., 2008), and these 
oligomers persist over a range of salt concentrations and pH (Okemefuna et al., 
2009). The SCR domains responsible for FH self-association sites are not yet known, 
but are found within at least the SCR-6/8 and SCR-16/20 domains, both of which 
also bind to heparin (Fernando et al., 2007; Okemefuna et al., 2008). An 
understanding of FH oligomers was central to interpret the interaction between FH 
and C-reactive protein, given that C-reactive protein inhibited FH oligomer 
formation (Okemefuna et al., 2010). Here, our solution scattering and analytical 
ultracentrifugation data showed that small fragments of heparin dp6 and dp12 




decrease in the proportion of the FH oligomers seen in the c(s) plots (Figure 6.10). 
The small HS fragments dp6 and dp12 also resulted in slight decreases in FH 
oligomer formation. Even though these changes were at the level of experimental 
error, they were consistently seen in all four cases. Further experiments with higher 
molar ratios of heparin dp6 and dp12 showed that both interacted with FH (Figures 
6.11 and 6.12). This was corroborated by comparative ultracentrifugation 
experiments with the SCR-6/8 fragment in the presence of 1:0.3 and 1:2 molar ratios 
of heparin dp10 that showed these interacted (Fernando et al., 2007). Overall, these 
data demonstrate that the small fragments of heparin/HS in 1:1 molar ratios were not 
long enough to cross-link FH molecules to promote FH oligomer formation, and that 
the FH oligomer sites within SCR-6/8 and SCR-16/20 may overlap with heparin/HS 
binding sites. 
Here, in the presence of large heparin and HS oligosaccharides, different set 
of FH oligomers were identified that were strongly promoted by the use of 1:1 molar 
ratios of heparin dp18-dp36 and HS dp18-dp24 (Figures 6.4, 6.7, 6.10 and 6.15). 
These are consistent with the reports of FH dimer and tetramer formed in the 
presence of dextran sulphate and high molecular weight unfractionated heparin (12-
14 kDa; approximately dp38-dp46) (Pangburn, et al., 2009). That 2009 study was 
based on sedimentation equilibrium data, which averages the ultracentrifugation 
data; this approach was less informative that our present use of c(s) analyses in 
sedimentation velocity experiments which directly observed FH-heparin oligomers 
as individual peaks ranging from dimer to octamer.  The higher FH-heparin and FH-
HS oligomers are distinct from those seen with FH and >10 µM zinc, when large 
polydisperse FH oligomers were formed through the presence of weak zinc binding 
sites on the surface of FH that cross-link FH monomers (Nan et al., 2008; 2011). No 
discrete FH-zinc oligomers were observed, unlike those seen for FH-heparin and FH-
HS (Figures 6.9 and 6.14), suggesting that the interaction between FH and 
heparin/HS is a well defined one at the molecular level. This is explained by the 
occurrence of two separate heparin binding sites within SCR-7 and SCR-19/20 
(Pangburn et al., 1991; Blackmore et al., 1996, 1998). Provided that the heparin 
structure is long enough (Figure 6.1), these two sites can be joined together by single 
heparin molecules in order to form cross-linked oligomers (Figure 6.17; Table 6.1). 
The larger heparin fragments dp18-dp36 (5.65-11.30 kDa) resulted in a dramatic 




29-63% (Figure 6.10), which is as much as a five-fold increase in FH oligomerisation 
observed with heparin dp36 compared to the 12% of oligomers observed for free FH. 
In addition to FH oligomer formation, the movement of the c(s) peak positions 
towards lower S values showed that the FH oligomers became more extended in their 
shapes. The scattering data also showed that the larger heparin fragments increase 
FH oligomer formation dramatically (Figure 6.4).  
The formation of large FH oligomers by heparin and HS provides new insight 
into the structural properties of FH. Even though there are two heparin binding sites 
in FH, there were no indications that heparin dp18-dp36 caused a large 
conformational change in FH to bring these two sites together and result in a 1:1 
complex of FH and heparin. The spatial separation of the SCR-7 and SCR-19/20 
sites would need to be about 6-12 nm apart for such a 1: 1 complex to form with 
dp18-dp36. Such a conformational change to a more compact FH structure would 
have caused visible increases in the s20,w values of the FH monomer peak. These 
were never observed in the c(s) analyses (Figures 6.9 and 6.14; Table 6.1). The 
molecular modelling of FH oligomer structures confirmed this reasoning. Good 
agreements between the experimental and predicted s20,w values for the FH-heparin 
dimer to pentamer were obtained when the heparin dp36 models were combined with 
FH models in which the SCR-7 and SCR-20 domains were separated by 26 nm 
(Figures 6.1 and 6.17; Table 6.1). If the SCR-7 and SCR-20 domains were positioned 
closer together at 10-13 nm, the predicted s20,w values of the FH-heparin oligomers 
became about 1-2 S larger than the experimental values (Figures 6.18 and 6.19; 
Table 6.1). This outcome indicates that the inter-SCR domain linkers in the FH SCR 
domain structure are much less flexible than anticipated in earlier structural studies, 
where its folded-back structure shows little variation as a function of salt, pH or 
heparin ligand (Okemefuna et al., 2009). If the two heparin binding sites in FH are 
independent of each other, this implies that the role of the heavily glycosylated and 
smaller SCR-12/15 domains at the centre of FH is to maintain the functional 
independence of the N-terminal and C-terminal ends of FH.  
The comparative use of heparin and HS in the study of FH oligomers clarifies 
the binding of anionic oligosaccharides to FH. Constrained scattering modelling for 
the heparin fragments showed semi-rigid and partially bent structures, and this 
becomes more evident when the heparin sizes increase beyond dp18 (Chapter 4: 




dp36, and kinks have also been seen in protein crystal structures such as those 
between FGF1-FGFR2 and heparin dp10 (Pelligrini et al., 2000). The kink in heparin 
provided optimal electrostatic and hydrogen-bond contacts with the protein (Raman 
et al., 2003), and these kinks may facilitate optimal contact formation between FH 
and heparin in their complexes. By ultracentrifugation, it was of interest that the 
oligomer peak 8 was much increased in size with heparin dp30 and dp36 (Figure 6.9 
and 6.13). Given the existence of an inflexible FH domain structure and a semi-rigid 
heparin structure, it follows that some oligomer arrangements with heparin dp30 and 
dp36 may be energetically more favoured and their relative proportions will increase. 
In distinction to heparin, the HS fragments used in the present study corresponds to 
the long NA-domains with GlcA and GlcNAc residues, in which the highly-sulphated 
S-domains with IdoA2S and GlcNS residues have been removed by heparinase I 
digests. For HS, constrained scattering modelling for dp6-dp16 showed a less rigid 
structure that was longer and more bent than that of heparin, and such a structure 
became more evident for the largest HS dp18 and dp24 fragments which could not be 
modelled as a single structure using the X-ray scattering curve (Chapter 5). The 
scattering and ultracentrifugation data for the FH-HS mixtures are fully consistent 
with the FH-heparin data in terms of FH oligomer formation. Two major differences 
from the FH-heparin complexes were observed. Firstly, HS caused reduced levels of 
FH oligomers to form (Figures 6.10 and 6.15). This is attributed to the reduced 
number of sulphate groups in HS compared to those in heparin. Secondly, the 
relative proportions of the peak intensities for the individual FH-HS oligomers 
decreased uniformly with increased size of the HS fragment (Figure 6.14), compared 
to the less uniform decrease observed with the heparin fragments (Figure 6.9). This is 
attributed to the greater flexibility of the HS fragments, which are better able to 
optimise their conformations to match those presented by the SCR-7 and SCR-20 
sites in a comparatively inflexible FH SCR domain structure.   
The identification of at least two independently-binding heparin sites on FH 
by the observation of FH-heparin oligomers has functional implications. The need 
for heparin binding to two different FH sites will confer a greater selectivity of FH 
for host cells that have a high enough density of heparin-like or HS-like surface 
oligosaccharides, unlike that found at bacterial surfaces. Two separate weak binding 
events with µM affinities will become an overall interaction with a high affinity of 




1981). This has implications for disease. Common polymorphisms contribute to 
genetic disease in a manner that is distinct from rare mutations. Disease-risk 
polymorphisms will exert their effect over a period of decades, while disease-causing 
mutations will show a much earlier effect in life. Mechanisms for FH-mediated 
disease involve either the aggregation of FH to form pathogenic deposits or the 
reduced control of inflammatory events by FH (Perkins et al., 2010). Age-related 
macular degeneration is common in the aged population, being responsible for over 
50% of blindness in the elderly in the Western world (Bird, 2010), while atypical 
haemolytic uraemic syndrome affects young individuals, typically after an 
immunological insult to the kidney (Goodship & Kavanagh, 2010). FH is found in 
the drusen deposits of the retina that are a hall-mark of age-related macular 
degeneration (Hageman et al., 2005). A single FH polymorphism at Tyr402His in 
SCR-7 has been associated with many cases of age-related macular degeneration 
(Klein et al., 2005; Haines et al., 2005; Edwards et al., 2005; Hageman et al., 2005). 
An investigation of glycosaminoglycans within Bruch’s membrane found little 
evidence of chondroitin sulphate and HS in drusen, and the size and structure of 
glycosaminoglycans in drusen is not yet known (Kliffen et al., 1996). If the drusen 
deposits contains glycosaminoglycans of size dp18 or larger, their presence would 
enable FH to aggregate continuously to form larger aggregates resembling those seen 
when zinc was added to intact FH (Nan et al., 2008). It is alternatively possible that 
the weaker binding of the Tyr402His FH allotype to host cell surfaces may trigger a 
higher level of immune attack and inflammation if the His402 allotype binds more 
weakly to heparin or HS. The evidence for this is currently mixed, where some 
studies state that there is weaker heparin and HS binding with His402, while others 
state that there is no difference (Clark et al., 2006, 2010). The loss of either the SCR-
7 or the SCR-19/20 heparin binding function in FH will compromise its regulatory 
function, and will lead to disease. The present ultracentrifugation and scattering 
studies now open the way for more detailed studies of the FH-heparin and FH-HS 
interactions that will enable these molecular mechanisms to be deciphered.  
 
(6.4) Materials and methods 
(6.4.1) Purification of FH and the heparin/HS fragments 
Native FH was purified in collaboration with Dr. Ruodan Nan (Department of 




monoclonal affinity chromatography with MRC-OX23 column (Sim et al., 1993). To 
prevent FH from proteolytic cleavage, 5 mM EDTA and 0.5 mM protease inhibitor 
Pefabloc-SC70 were added into 50 ml of this anonymised human plasma. The mixed 
plasma was then dialysed against Tris buffer (25 mM Tris-HCl, 140 mM NaCl, 0.5 
mM EDTA, pH 7.4). After dialysis, the plasma was centrifuged at 10,000 rpm at 4ºC. 
In order to remove IgG binding proteins, the plasma was passed through a column of 
non-immune IgG immobilized on Sepharose. The plasma was then passed through a 
lysine-sepharose column to remove plasminogen/plasmin. After that, the plasma was 
passed through MRC-OX23-Sepharose, a monoclonal antibody column specific for 
FH, at a rate less than 1 ml/min. Bound FH was eluted with 3 M MgCl2, pH 6.9. To 
remove Mg2+, the eluant was dialysed against 4 litres of HEPES buffer (10 mM 
HEPES, 137 mM NaCl, pH 7.4) with 0.5 mM EDTA and then with 4 litres of 
HEPES buffer without EDTA. After dialysis the plasma was passed through a Hitrap 
Protein G HP column to remove contaminant IgG. The volume of purified FH was 
reduced using Amicon® Ultra-15 centrifugal filter with a molecular weight cut-off of 
50 kDa at 2,000 rpm. Non-specific aggregates and human serum albumin were 
removed using SuperoseTM 6 gel-filtration column in HEPES buffer at flow rate of 1 
ml/min (Figure 6.2(a)). Fractions corresponding to the major FH peak were pooled. 
The purified sample was reconcentrated by centrifugation. The purity of FH was 
checked by sodium dodecyl sulphate polyacrylamide gel elctrophorsis (SDS-PAGE) 
(Figure 6.2(b)). SDS-PAGE was performed by using NuPAGE® Novex 3-8% Tris-
Acetate mini gel and the standard protocol. The FH concentration was determined 
from an absorption coefficient (1%, 1 cm) of 16.7 (Okemefuna et al., 2009). FH was 
dialysed into HEPES buffer for scattering and ultracentrifugation experiments, and 
its integrity was routinely checked by SDS-PAGE before and after experiments.   
The dp6-dp36 fragments of heparin were prepared from bovine lung heparin 
as described in Chapter 4: section 4.4.1. In summary, about 80 mg of heparinase-I-
digested heparin was subjected to chromatography in order to isolate the dp2-dp16 
fragments as well-resolved peaks and the dp18-dp36 fragments as slightly less well-
resolved species. The high monodispersity of the six dp6-dp36 fragments was shown 
by the single peaks observed by analytical ultracentrifugation c(s) size distribution 
analyses (Chapter 4: Figures 4.4, 4.5 and 4.6). Heparin concentrations were 
measured by weighing the lyophilised product after evaporation of 2% ammonium 




HS is comprised of short S-domains (IdoA2S and GlcNS residues), long NA-
domains with GlcA and GlcNAc residues, and mixed domain regions at the junctions 
between the S-domains and NA-domains (Capila & Linhardt, 2002; Coombe & Kett, 
2005). The dp4-dp24 fragments of HS were prepared following exhaustive 
heparinase I digestion of 100 mg of a HS stock to leave only the NA-domains by 
minimizing the presence of fully sulphated S-domain sequences (Chapter 5: section 
5.4.1). The four dp6-dp12 fragments were eluted as well-resolved peaks, while the 
four larger fragments dp14-dp18 and dp24 were slightly less well resolved. 
Monodispersity was demonstrated by PAGE and c(s) analyses (Chapter 5: Figures 
5.2 and 5.4). HS concentrations were measured using an absorption coefficient of 
5500 M-1 cm-1 (Powell et al., 2010).  
 
(6.4.2) X-ray scattering data for FH mixtures with heparin and HS  
X-ray scattering data for mixtures of FH with either six heparin or four HS 
fragments were fully acquired in one of two sessions on the ID02 beamline at the 
European Synchrotron Radiation Facility (ESRF) at Grenoble, France, operating in 
four-bunch mode with a ring energy of 6.0 GeV (Narayanan et al., 2001). These two 
sessions provided the final data presented here, and followed trial experiments 
performed in three earlier sessions with 0.4-1.95 mg/ml FH concentrations and fewer 
heparin fragments. Storage ring currents ranged from 40 mA to 43 mA (heparin) and 
from 69 mA to 76 mA (HS). Data were acquired using an improved fibre optically-
coupled high-sensitivity and dynamic-range CCD detector (FReLoN) with a smaller 
beamstop. The sample-to-detector distance was 2 m. Data were collected for FH in 
mixtures with a 1:1 molar ratio of heparin or HS in 10 mM HEPES buffer and 137 
mM NaCl (pH 7.4). The FH concentration was 0.47 mg/ml (heparin mixtures) and 
0.45 mg/ml (HS mixtures). Samples were measured in a flow cell which moved the 
sample continuously during beam exposure in 10 time frames with different exposure 
times between 0.1 sec to 0.5 sec to avoid radiation damage effects. Exposure times 
were optimised using on-line checks during acquisitions to verify the absence of 
radiation damage, after which the frames were averaged.  
Guinier analyses give the radius of gyration, RG, which characterizes the 
degree of structural elongation in solution if the internal inhomogeneity of scattering 




π sin θ/λ; 2θ  is the scattering angle; λ is the wavelength) gives the RG and the 
forward scattering at zero angle I(0): (Glatter & Kratky, 1982) 
 
ln I(Q) = ln I(0) - RG2 Q2/3 
 
This expression is valid in a Q.RG range up to 1.5. If the structure is elongated (i.e. 
rod-shaped), the radius of gyration of the cross-sectional structure RXS and the mean 
cross-sectional intensity at zero angle [I(Q).Q]Q→0 parameters are obtained from:  
 
ln [I(Q).Q] = ln [I(Q).Q]Q→ 0  - RXS 2 Q2/2 
 
The RG and RXS analyses were performed using an interactive PERL script program 
SCTPL7 (J. T. Eaton and S. J. Perkins, unpublished software) on Silicon Graphics 
OCTANE workstations. Indirect Fourier transformation of the full scattering curve 
I(Q) in reciprocal space gives the distance distribution function P(r) in real space. 
This yields the maximum dimension of the macromolecule L and its most commonly 
occurring distance vector M in real space:  
 







The transformation was carried out using GNOM software (Semenyuk & Svergun, 
1982). For this, the X-ray curves contained 192-215 intensity data points in the Q 
range between 0.08 nm-1 extending up to between 1.34 nm-1 and 2.15 nm-1 for the FH 
mixtures with heparin dp6-dp36. Similar X-ray curves were used for the FH mixtures 
with HS dp6-dp24.  
 
(6.4.3) Sedimentation velocity data for FH mixtures with heparin and HS 
Sedimentation velocity data were obtained using two Beckman XL-I 
analytical ultracentrifuges (Beckman-Coulter Inc, Palo Alto, CA, U.S.A.) equipped 
with both absorbance and interference optics (Cole et al., 2008). Experiments were 
carried out in an eight-hole AnTi50 rotor with standard double-sector cells with 




data were collected with rotor speeds of 40,000 rpm, 50,000 rpm and 60,000 rpm 
using interference optics. Experiments with FH and six 1:1 mixtures with heparin 
dp6-dp36 were performed at 1.08 mg/ml FH in 10 mM HEPES, 137 mM NaCl, pH 
7.4. Experiments with FH mixtures were performed with heparin dp6 and dp12 in 
molar ratios that ranged from 1:0.5 to 1:8 at 1.0-1.12 mg/ml FH. The buffer density 
of 1.00480 g/ml was measured at 20 oC using an Anton-Paar DMA5000 density 
meter. Partial specific volumes were calculated for FH and its 1:1 heparin mixtures 
to be 0.717 ml/g for FH, 0.714 ml/g for FH and dp6, 0.711 ml/g for FH and dp12, 
0.708 ml/g for FH and dp18, 0.705 ml/g for FH and dp24, 0.702 ml/g for FH and 
dp30 and 0.699 ml/g for FH and dp36 (Perkins, 1986). The continuous c(s) analysis 
method was used to determine the sedimentation coefficients s20,w using SEDFIT 
software (version 9.4) (Dam & Schuck, 2004; Schuck, 2000). In the c(s) analysis, the 
sedimentation boundaries are fitted using the Lamm equation, the algorithm for 
which assumes that all species have the same frictional ratio f/fo in each fit. The final 
SEDFIT analyses used a fixed resolution of 200 and a fixed frictional ratio f/fo, of 
1.78 for FH and all the heparin mixtures. The c(s) fits were optimised by floating the 
meniscus and cell bottom when required, and the baseline and cell bottom fixed until 
the overall root mean square deviations and visual appearance of the fits were 
satisfactory. The percentage of FH oligomers was derived using the c(s) integration 
function.  
The sedimentation velocity data for four 1:1 FH-HS mixtures were performed 
as above, using 0.45 mg/ml FH. The partial specific volumes for the 1:1 HS mixtures 
were 0.716 ml/g for FH and dp6, 0.715 ml/g for FH and dp12, 0.714 ml/g for FH and 
dp18, and 0.705 ml/g for FH and dp24 (Perkins, 1986). 
 
(6.4.4) FH-heparin dp36 oligomer modelling 
Models to account for the s20,w of the FH oligomers formed with heparin dp36 
were created using the best-fit X-ray solution scattering model for FH (PDB code: 
3GAV) and heparin dp36 (PDB code: 3IRL) (Okemefuna et al., 2009; Khan et al., 
2010). To check for consistency, two other best-fit FH structures were used that were 
based on alternative X-ray scattering modelling (R. Nan, A. I. Okemefuna and S. J. 
Perkins, unpublished work). Using the Discovery Studio molecular graphics software 
(version 2.1) (Accelrys, San Diego, CA, U.S.A.), FH-heparin models were created 




in the first FH structure and the other end of the dp36 structure close to FH SCR-7 or 
SCR-20 in the next FH structure. This procedure was used to create FH-heparin dp36 
structures based on FH dimer, trimer, tetramer and pentamer. The sedimentation 
coefficients s020,w for these oligomeric models were calculated directly from the 
molecular structures using the HYDROPRO shell modelling program (Garcia de la 
Torre et al, 2000). The default value of 0.31 nm for the atomic element radius for all 







































FH is a major regulatory protein of the alternative complement pathway and 
is able to discriminate host from pathogen cell surfaces by recognising 
glycosaminoglycans, heparan sulphate (HS) and dermatan sulphate (DS), on the host 
and thus inhibits complement activation (Clark et al., 2006). FH was the first protein 
to be genetically linked to AMD, which further underlines its importance to the host 
innate immune response. A single polymorphism in FH at position 402 (Tyr402His) 
in SCR-7 domain increases the risk of AMD (Hageman et al., 2005; Haines et al., 
2005; Klein et al., 2005). FH has two major binding sites for heparin/HS in domains 
SCR-6/8 and SCR-19/20. The extent and degree of the effects of heparin/HS 
fragments on the native FH and the potential relevance of these interactions to AMD 
had not been elucidated prior to this thesis. Prior to performing interaction studies of 
FH with heparin/HS fragments, it was necessary to determine the molecular 
structures of a range of heparin and HS fragments in solution. Heparin is readily 
available and is often used as an analogue for HS. Up to now, molecular structures 
for heparin had been determined only for small fragments. For free heparin, solution 
structures by NMR spectroscopy were available for heparin dodecasaccharide (dp12) 
and synthetic pentasaccharides (dp5). Unlike heparin, no structural data were 
currently available for free HS fragments except for a crystal structure in which HS 
dp4 was complexed with heparinase II. This thesis presents the molecular structures 
of a range of heparin and HS fragments and their effects on native FH in solution. A 
multidisciplinary approach involving X-ray scattering, AUC and constrained 
modelling was used to determine the molecular structures of heparin and HS 
fragments, and their effects on native FH.  
 
(7.2) Solution structure of Heparin 
Prior to this thesis, no molecular structures had been reported for larger 
heparin fragments. In this thesis, the molecular structures of large heparin fragments 
in solution were determined by the joint use of X-ray solution scattering, AUC and 
constrained scattering modelling. AUC revealed that purified heparin fragments of 
sizes dp6-dp36 were monodisperse from the single peaks seen in c(s) analyses and 
analytical size exclusion chromatography. The sedimentation coefficients s20,w 
increased linearly from 1.09 S to 1.84 S with heparin size. The corresponding 
scattering studies on the same fragments resulted in RG values that also increased 
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with heparin size from 1.33 nm to 3.12 nm and maximum lengths L that increased 
from 3.0 nm to 12.3 nm. The greater sensitivity of the RG values to the conformation 
revealed that the heparin solution structures became progressively more bent with 
increased size. The constrained modelling of 5,000 randomised heparin conformers 
starting from the NMR structure resulted in best-fit structures for dp18, dp24, dp30 
and dp36 that indicated moderate flexibility in mildly bent structures (Chapter 4: 
section 4.2.3). The comparison of these solution structures with the 19 crystal 
structures of heparin-protein complexes revealed similar angular orientations 
between the iduronate and glucosamine rings, both in the solution and the crystal 
states. It was concluded that heparin has a semi-rigid and extended conformation that 
is preformed in a conformation that is well defined for binding to proteins such as FH 
without major conformational changes (chapter 4: section 4.3). 
 
(7.3) Solution structure of HS 
Prior to this study, no molecular structures had been reported for free HS 
fragments.  In this study, the molecular structures of purified HS fragments ranged 
from dp6 to dp24 in solution were determined following the same method used 
above for the heparin structure determinations. AUC, analytical size exclusion 
chromatography and PAGE revealed that the HS fragments were monodisperse from 
the single peaks seen in c(s) analyses, the observation of single sharp peaks in 
analytical size exclusion chromatography, and single bands by PAGE analysis. The 
s20,w values increased from 0.82 S to 1.26 S and 1.05 S to 1.35 S for dp6 to dp24 
using absorbance and interference optics respectively (Chapter 5; Table 5.1). The X-
ray scattering studies on the same fragments showed that the RG values increased 
from 1.03 nm to 2.82 nm, the cross-sectional radii of gyration RXS ranged from 0.30 
nm to 0.65 nm and the maximum lengths L ranged from 3.0 nm to 10.0 nm (Chapter 
5; Table 5.1). Deviations of these RG, RXS and L values from linearity revealed that 
the HS solution structures became more bent with increased size. This bending was 
confirmed by constrained molecular modelling of 5,000-8,000 randomised HS 
conformers that resulted in 8 best fit structures for each of dp6 to dp16. Like heparin, 
this bending is revealed by the appearance of kinks in the HS structure at a few 
positions. Comparisons of these solution structures with the solution structures of 
heparin fragments revealed that HS structures exhibit a more bent conformation than 
heparin. The physical basis of greater bending in HS is likely to arise from the GlcA-
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GlcNAc sequence (as opposed to the IdoA-GlcNS sequence in heparin), together 
with the absence or reduction of repulsion between sulphate-sulphate, sulphate-
carboxylate, and carboxylate-carboxylate groups in HS. Thus it was concluded that 
HS exhibits more flexibility around the glycosidic linkages than the semi-rigid 
structures of heparin.  
 
(7.4) Effects of heparin and HS fragments on the native FH structure 
  Prior to this study, the effects of heparin and HS fragments on the native FH 
were not known. This thesis provides a novel comparative insight into the 
interactions of these two anionic polysaccharides with their protein ligands. 
Oligomer formation and the conformational properties of FH in the presence of a 
range of heparin and HS fragments were studied by X-ray solution scattering and 
AUC. The AUC data showed that the small heparin fragments (dp6, dp12) slightly 
decreased the tendency of FH to form a series of oligomers, while the large heparin 
fragments from dp18 to dp36 showed a dramatic increase in the oligomerisation of 
FH up to between 42% to 63%. These results revealed that small heparin fragments 
dp6-dp12 were not long enough to cross-link the FH molecules, while the large 
fragments dp18-dp36 were long enough to cross-link the FH to form higher 
oligomers. X-ray scattering data for FH in the presence of large heparin fragments 
(dp18-dp36) also revealed a dramatic increase in the RG values that ranged from 11.4 
to 11.73 nm, RXS values from 3.31 to 5.11 nm, I(0)/c values from 0.044 to 0.092 and 
maximum length L from 35 to 40 nm, indicating higher oligomers formation as well 
as conformational changes in FH. Binding studies of the dp6 molecules to FH in 
various ratios demonstrated at least two heparin binding sites on the FH molecule. 
Like heparin, the effects of HS fragments (dp6-dp24) on the native FH were 
also studied. Both X-ray and AUC data for FH titrated with small HS fragments 
revealed slight decreases in the oligomerization of FH. In the presence of larger HS 
fragments (dp14-dp24), FH showed increases in the RG values from 8.05 to 8.27 nm 
and I(0)/c values from 0.042 to 0.073. Only slight changes in the RXS values were 
observed. An increase in the maximum length L of FH was seen only in the presence 
of dp18 and dp24. Like heparin, AUC data for FH in the presence of large HS 
fragments revealed increase in the oligomerisation of FH up to between 16% to 24%. 
As for heparin, these results also suggested that the smaller HS fragments slightly 
inhibit the tendency of FH to form oligomers, while the larger HS fragments increase 
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oligomerisation in FH. The overall effects of HS fragments on the structure of FH is 
less than observed with heparin fragments, and this is attributed to the reduced 
degree of sulphation of HS fragments. 
The results from this thesis provided four novel insights into the FH 
interaction with heparin and HS in near-physiological salt conditions. First, both 
polyanionic oligosaccharides promote strong FH oligomer formation. At least two 
independent heparin binding sites on FH were involved in these interactions. Little 
structural changes in FH were observed after heparin or HS binding. Finally the 
higher sulphation of heparin leads to strengthened FH binding when compared to HS. 
Taken together, the identification of at least two independent heparin/HS sites on FH 
through the observation of FH-heparin oligomers has functional implications. The 
principal one is that the weakening of the FH interaction at either of the two 
heparin/HS sites on host cell surfaces through the genetic alteration of FH at either 
site provides an avenue for higher levels of inflammatory attack, given that FH will 
not bind so well to host cells and will be less able to protect them. This thesis opens 
the way for more detailed studies of the FH-heparin and FH-HS interactions to 
enable these molecular mechanisms to be deciphered in more detail.  
 
Future Work:  To improve further the understanding of the solution structures of 
the HS fragments and their effects on intact FH, the HS parent material will be 
digested with heparinase III. Such heparinase III digests will produce sulphated HS 
fragments in distinction to heparinase I digests which produce HS fragments with a 
few sulphate groups at its reducing and non-reducing ends. For structural studies of 
these different sulphated HS fragments, the same techniques used for heparin and 
less-sulphated HS fragments will be used. Following solution structural 
determinations of these fragments, the effects of these fragments on intact FH will be 
studied for comparison with our previous results. By the same token, the solution 
structures of two other classes of glycosaminoglycans, namely dermatan sulphate and 
chondroitin sulphate, will be studied using the same techniques used in this thesis. 
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